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Abstract 
Dry powder inhalers (DPIs) are breath actuated devices relying on the inhalation effort 
generated by the patients during the inhalation manoeuvre to de-aggregate and disperse the 
powder formulation and release the dose for lung deposition. The aerodynamic dose emission 
characteristics vary among patients depending on the maximum inhalation flow (MIF), the 
inhalation volume (Vin) and the initial acceleration of the inhalation manoeuvre (ACIM). The 
compendial method for in-vitro testing of DPIs uses a vacuum pump to represent the patient’s 
inhalation manoeuvre. Furthermore, the pharmacopoeia recommended the use of a MIF 
corresponding to 4 kPa pressure drop with a Vin of 4 L. The vacuum pump square wave 
profile cannot be replicated by humans, and it is by no mean representing the actual patient’s 
inhalation manoeuvre. Additionally, most of the patients and even healthy volunteer are 
unable to achieve the pharmacopoeia recommended inhalation parameters of MIF and Vin 
when inhaling through different DPIs. 
In this thesis, a wide range of MIFs and Vins were used to investigate the dose emission and 
aerodynamic characteristics of formoterol and indacaterol using the in-vitro methodology. 
Furthermore, an ex-vivo methodology using COPD patients’ inhalation profiles and simulated 
patients’ inhalation profiles was used instead of a vacuum pump to study the performance of 
the indacaterol Breezhaler®.  The aim of the study was to initially investigate the effect of 
MIF and Vin on the dose emission and the aerodynamic dose emission of indacaterol (Onbrez 
Breezhaler® and formoterol (Aerolizer® and Easyhaler®) over a MIF range of 28.3, 60, 90 and 
120 L/min and a Vin range of  0.5, 0.75, 1, 1.5 and 2 L. Secondly, to assess the effect of all 
three inspiratory parameters MIF, Vin and ACIM on the aerodynamic dose emission of 
indacaterol Breezhaler® using the ex-vivo methodology with both COPD patients’ inhalation 
profiles and simulated patient’s inhalation profiles. The formoterol dose emitted after the first 
inhalation (ED1) from the Aerolizer® significantly increased (p < 0.05) with increasing the 
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MIF and the Vin. Conversely, the dose emitted after the second inhalation (ED2) and the 
residual amount (RA) decreased significantly (p < 0.05) with increasing the MIF and Vin. The 
ED1 and RA (% of the nominal dose) at low MIF of 28.3 L/min and Vin 0.5 L were 45.91%, 
34%. At high MIF 120 L/min and a Vin of 2 L, the ED1 and RA were 70.75%, 22.91%. The 
formoterol dose emission from Easyhaler® showed that increasing the Vin and MIF resulted 
in a significant (p < 0.05) increase in the total emitted dose (TED), the fine particle dose 
(FPD) and a significant decrease in the Mass median aerodynamic diameter (MMAD) over a 
MIF range of 28.3, 60 and 90 L/min with a Vin range of 240, 750, 1500, 2000 mL. The 
increase in the Vin above 750 mL showed no improvement in the aerodynamic characteristics 
of formoterol from Easyhaler®. Similarly, the dose emission of indacaterol from Breezhaler® 
showed that the ED1 significantly increased (p < 0.05) with increasing the MIF, while both 
the ED2 and RA decreased.  At a low MIF of 28.3 L/min and a Vin of 0.5 L, the ED1 and RA 
(% of the nominal dose) were 66.5% and 20.4%. In contrast, at a high MIF of 120 L/min and 
a Vin of 2 L, the ED1 and RA were 95.2% and 4.1% respectively. The dose strength study of 
indacaterol 150 µg and 300 µg showed that despite the difference observed in the carrier 
particle size, size distribution (SEM) and drug to carrier ratio yet both formulations produced 
a good drug content uniformity with a % CV < 1.8% and 100% dose recovery. The results of 
the dose emission and the aerodynamic characteristics followed the same trend for both dose 
strengths. The increase in the MIF and Vin resulted in an improvement in the aerodynamic 
characteristics of both formulations. The Breezhaler® device was able to generate particles 
within the extrafine range (≤ 3 µm) when a MIF of 60 L/min and above was used. 
Secondly, the performance of 150µg indacaterol Breezhaler®  was evaluated using an ex-vivo 
method with COPD patients’ inhalation profiles. The results showed the importance of 
increasing the MIF on the dose emission characteristics of indacaterol dose emitted from 
Onbrez Breezhaler®. At a low MIF of 28.3 L/min, the TED and FPD were 92.0 µg ± 4.2 and 
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28.7 µg ±1.6 while at a high MIF of 87.8 L/min the TED and FPD were 125.1 µg ± 1.4 and 
45.6 µg ± 0.8. The impact of the Vin and ACIM was difficult to be determined using COPD 
patients’ profiles. Therefore, simulated inhalation profiles (changing one parameter at a time) 
were used to identify the extent of each parameter. The results of the study showed that 
increasing both the Vin and the ACIM showed an impact on the dose emission characteristics 
of indacaterol. An increase in the Vin from 1 L to 3 L resulted in an increase in the TED and 
FPD with less impact on the MMAD. Similarly, increasing the ACIM from 2 L/s2 to 8 L/s2 
increased the TED, FPD and more observed effect of the MMAD than the Vin. The results of 
in-vitro studies showed that a MIF of 30 L/min and a Vin of 750 mL were sufficient to de-
aggregate the formoterol dose from a reservoir based Easyhaler®. The dose emission from 
capsule based inhalers Breezhaler® and Aerolizer® require a higher MIF > 60 L/min and 
patients are recommended to inhale twice in order to empty the capsule especially those with 
limited lung capacity. The use of an ex-vivo methodology is important for identifying the 
effect of all inhalation manoeuvre parameters. Although the MIF is the dominant factor in the 
dose emission from DPIs, increasing both ACIM and Vin resulted in an improvement in the 
aerodynamic characteristics of indacaterol Breezhaler® that explains the recommendations of 
forceful, deep and prolonged inhalation manoeuvre for patients using DPIs. 
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Thesis structure  
This thesis comprises of 8 chapters: 
Chapter 1: Presents a general introduction with an emphasis on the importance of the 
pulmonary route, types of inhaler delivery devices for drug administration, factors affecting 
the dose de-aggregation and lung deposition, common methods for determining the dose 
emission and APSD of inhaled products.  
Chapter 2: Provides a review of the respiratory systems, respiratory diseases, types of inhaler 
devices, factors affecting dose emission from the inhalers, factors affecting dose deposition in 
the lungs, DPI resistance, and using the literature to highlight the importance of different 
inspiratory parameters. We also discussed recent modifications in the Pharmacopeia methods 
to study the APSD of inhaled products. 
Chapter 3: Provides a list of laboratory materials and instrumentation that were used in the 
experimental in-vitro and ex-vivo studies. It also provides a detailed explanation of the HPLC 
method development and validation for the quantification of indacaterol and formoterol. 
Chapter 4: Presents the in-vitro dose emission performance of both formoterol Aerolizer® 
and indacaterol Breezhaler®  after two separate  inhalations using different MIFs of (28.3 
L/min, 60 L/min, 90 L/min and 120 L/min), and  different Vins of (0.5 L, 0.75 L, 1 L, 1.5 L, 
and 2 L).  
Chapter 5: Outlines the in-vitro assessment of formoterol aerodynamic dose emission 
characteristics from an Easyhaler® using dose unit sampling apparatus (DUSA) and ACI at 
different MIFs and Vins. 
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Chapter 6: Presents the in-vitro assessment of dose strength indacaterol 150 µg and 300 µg 
dose emission using DUSA after two inhalations and investigation of the aerodynamic 
characteristics using ACI at different MIFs and Vins. 
Chapter 7: Discusses the use of the ex-vivo methodology to determine the effect of real life 
recorded and simulated COPD patients’ IPs on the aerodynamic dose emission characteristics 
of indacaterol Breezhaler®.  
Chapter 8: Presents a general discussion and conclusion to the study carried out in this thesis 
as a whole, and finally making some recommendations for future research. 
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 Introduction 
The inhalation route of drug delivery is considered as one of the most efficient routes of drug 
administration because this route has been widely accepted for localised treatment of 
respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) 
(Bisgaard et al., 2001). For local  effect, the orally inhaled drugs are delivered directly to the 
site of action to provide rapid onset of action while using small doses, thus providing fewer 
systemic side effects (Rau, 2006). The lung has also been used as a portal for systemic 
delivery due to its large alveolar epithelial absorption area, rich blood supply, and low 
enzymatic activity when compared to the  oral route of drug administration (Patton et al., 
2004). 
The main types of inhaler available for treating lung diseases can be classified into three main 
categories: nebulisers, pressurised metered dose inhalers (pMDIs), dry powder inhalers 
(DPIs), and recently, soft mist inhalers (SMIs). Nebulisers are not true competitors to pMDIs 
and DPIs for outpatient use as they are bulky non-portable, a large amount of medication is 
wasted, and treatment times are long (Grossman, 1994, Islam and Gladki, 2008). 
The pMDI was the first inhaler device to deliver bronchodilators with a multi-dose capability 
and consistent and reproducible dosing characteristics, and it was relatively inexpensive 
(Boyd, 1995, Vaswani and Creticos, 1998). Although pMDIs are popular and the most 
commonly used inhalers in delivering therapies for asthma and COPD, they have some major 
drawbacks, such as poor coordination between dose actuation and patient inhalation. 
Furthermore, the fast-moving plume aerosol results in more dose  being deposited in the 
oropharynx even with good inhalation technique (Crompton, 1981, Purewal and Grant, 1997, 
Dolovich, 1999, Lavorini and Corbetta, 2008, Roche et al., 2013). 
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Higher lung deposition and lower oropharyngeal deposition were achieved with some new 
formulations using a drug solution in hydrofluoroalkane (HFA) HFA-134a propellant 
compared to a drug suspension. An example of a drug solution is beclomethasone 
dipropionate-HFA-134a, ethanol (Qvar, TEVA). The high vapour pressure of HFA coupled 
with the small droplet size from the pMDI solution is the driving force to enhance peripheral 
and total lung deposition. The correct pMDI technique involves firing the pMDI while 
breathing in deeply and slowly and then following inhalation with a breath-holding pause to 
allow particles to sediment on the airway surfaces (Newman, 2005, Gibaldi, 2007, Usmani, 
2015). 
The complexity associated with pMDI formulations (e.g., poor solubility of surfactants in 
HFA propellants, the use of co-solvent, partial solubility of some drugs in HFA, stability 
issues for fragile molecules, a small amount of the drug can be delivered due to the small 
volume of the metering chamber), the cold Freon effect, the misuse of pMDIs, poor 
understanding of how to use a pMDI, and some minor greenhouse effects associated with 
HFAs may become an issue in the future. All these factors have pushed the inhalation 
scientists to think about a safe and viable alternative to deliver a wider range of drugs for both 
local and systemic effects while still delivering a large dose of drugs such as tobramycin. 
DPIs have the potential to overcome all the above problems. All currently marketed DPIs are 
breath-activated and do not require propellants to generate the aerosol. It is the interaction of 
the patient’s inspiratory flow with the resistance of the inhaler device that causes de-
aggregation of the powder formulation to deliver the drug to the lungs (Clark and 
Hollingworth, 1993, Chrystyn, 2003, Telko and Hickey, 2005). Each DPI has its unique 
internal resistance; the difference in their resistance is due to the internal design of DPIs 
(Steckel et al., 1997, Chrystyn, 2003). DPIs can be classified into three main categories: low, 
medium, and high resistance according to the pressure drop generated across the inhaler 
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device when inhaling through a DPI. The turbulent energy inside the inhaler is represented by 
the pressure drop (∆p) that occurs during the inhalation manoeuvre. The relationship between 
the intrinsic resistance and the inhalation flow has been defined as √∆𝐏 = Q*R, where the 
pressure drop is directly proportional to both the flow rate (Q) and the intrinsic resistance (R) 
(Clark and Hollingworth, 1993, Dal Negro, 2015).  The flow rate required for a set inspiratory 
effort through a low resistance device will be faster when compared to a high resistance 
device. The fast inhalation flow will result in high turbulent energy, and this will result in an 
improvement in the quality of the emitted dose. All commonly used DPIs show flow rate 
dependency of dose emission, and the extent of flow rate dependency varies from device to 
device (Chrystyn, 2009).  
In fact, high resistance devices show less flow rate dependency than low resistance devices. 
The former was developed to provide consistent dosing irrespective of the inhalation flow and 
to limit the oropharyngeal deposition caused by the high velocity of the inhaled particles and 
its associated side effects, especially with some inhaled drugs such as corticosteroids. Each 
DPI requires a minimum threshold inspiratory effort to de-aggregate the formulation and to 
achieve particles within the respirable range ≤ 5 µm. High resistance devices such as 
Handihaler® and Easyhaler® would require less flow than low resistance devices such as 
Breezhaler® and Aerolizer® (Pedersen et al., 1990, Assi and Chrystyn, 2000, Al-Showair et 
al., 2007b, Azouz et al., 2015b, Price and Chrystyn, 2015). ERS/ISAM task force state that 
“patients using DPIs should inhale as long, deep and for as long as they can in order to 
maximise the dose emission and lung deposition”(Laube et al., 2011). The forceful inhalation 
from the start of the inhalation manoeuvre (fast acceleration) was found to be important for 
the promotion of the dose de-aggregation and therefore in increasing the benefits from every 
single dose (Everard et al., 1997, Chrystyn and Price, 2009). 
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Patients’ failure to use their DPI device correctly can result in a reduction in the dose reaching 
the lungs. Studies have shown that approximately 40% ± 20 of patients with asthma and 
COPD have experienced a problem in using their inhalers correctly (Rau, 2006, Bartolo et al., 
2017, Chrystyn et al., 2017). Regardless of the inhaler device used, patient misuse is common, 
and more errors are observed with DPIs than with pMDIs. For good airway disease 
management, it is very important for patients to use their device correctly, as failure to do so 
will result in poor asthma and COPD control (Lavorini et al., 2008, Noyce, 2017). The 
inhaled dose efficacy depends on the aerodynamic characteristics of the emitted dose; the 
latter is dependent on the inter-relation between the formulation, the inhaler device used, the 
inter- and intrapatient variability, and the inhalation technique (Bonini and Usmani, 2015, 
Ibrahim et al., 2015). 
In the Pharmacopoeia method for the in-vitro dose emission testing of DPIs, a vacuum pump 
is used to generate an inhalation flow with a constant MIF that corresponds to a 4 kPa 
pressure drop with an inhaled volume of either 2 L (FDA, 1998) or 4 L (USP, 2014). The 
airflow square wave profile generated by the vacuum pump cannot be replicated by a human 
and is not representative of the bell-shaped patient inhalation profiles (IPs) in real-life use 
(Copley et al., 2014, Azouz et al., 2015b). 
A clinical study showed that the majority of patients with asthma and COPD could neither 
achieve the required flow rate corresponding to a pressure drop of 4 kPa across the inhaler nor 
achieve the 4 L Vin (Azouz et al., 2015a, Chrystyn et al., 2015). In the routine use of the 
inhalers, patients’ inspiratory parameters vary due to different factors caused by the size of the 
lungs, which in turn are related to the age and gender in addition to the degree of obstruction 
in the airways (Stocks, 1995, Al-Showair et al., 2007b). Not all patients inhale in the same 
manner, and each patient will achieve different respiratory parameters depending on the 
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education they receive on how to use their inhaler properly and their lung capacity. For 
instance, patients with COPD and asthma are unable to achieve a 4 L inhaled volume across 
the device. It has been reported that patients with asthma and COPD inhaling through DPIs 
were able to achieve an average inhaled volume of 2 L (Hawksworth et al., 2000). 
The IPs differ according to the DPI in use. For example, a study of blister- and reservoir-
based DPIs showed that dose de-aggregation occurs immediately at the start of the inhalation 
manoeuvre, whereas capsule-based devices required a greater inhalation time to empty the 
dose effectively (Chrystyn and Price, 2009).  For DPIs, three important inhalation manoeuvre 
parameters were identified to be important for drug aerosolisation and deposition to the lungs, 
namely MIF, Vin and ACIM  (Laube et al., 2011, Bagherisadeghi et al., 2017). Although the 
impact of the MIF has been extensively studied since the emergence of DPIs, researchers have 
only recently realised the importance of the Vin and ACIM, especially with the technical 
advances in the inhalation science with patients’ inhalation recording and the breath 
simulators. Recently, several studies have highlighted the importance of the Vin and ACIM in 
the overall aerodynamic dose emission from DPIs (Yakubu et al., 2013, Chrystyn et al., 2015, 
Buttini et al., 2016a, Bagherisadeghi et al., 2017). The studies showed that increasing the Vin 
and ACIM resulted in high fine particle dose (FPD) and a reduction in the mass median 
aerodynamic diameter (MMAD) of the inhaled particles.  
The use of a vacuum pump does not replicate the patient’s IP in real life, which results in a 
poor in-vitro in-vivo correlation. Researchers have recently introduced a new in-vitro method 
that is more representative of a patient’s real-life use. Breath simulator-based methods (BRS) 
have been introduced recently to study the aerodynamic characteristics of the inhaled products 
using previously recorded patient IPs (Copley et al., 2014). This was termed ex-vivo 
methodology, as the profiles are generated in-vivo and replayed in-vitro using the breath 
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simulator.The BRS is connected to the Andersen cascade impactor (ACI) by using a mixing 
inlet (MI) between the Alberta idealised throat (AIT) and the ACI. Such ex-vivo methodology 
is becoming popular for testing the performance of orally inhaled products (OIPs). The use of 
real patient IPs measured during routine operation of the DPI has therefore enhanced the 
investigation of the aerodynamic characteristics of the emitted dose from different marketed 
DPIs (Nadarassan et al., 2010, Olsson et al., 2013, Chrystyn et al., 2015, Bagherisadeghi et 
al., 2017).  
In this thesis, in-vitro and ex-vivo methodologies were used to assess the effect of MIF, Vin, 
and ACIM on the dose emission and the aerodynamic characteristics of an emitted dose of 
formoterol and indacaterol. Three commercial DPI devices were used, namely, Onbrez 
Breezhaler® two strengths (150 µg and 300 µg indacaterol), Easyhaler® (12 µg formoterol), 
and Foradil Aerolizer® (12 µg formoterol). Patient IPs and simulated IPs were used in this 
thesis to study aerodynamic dose emission characteristics from 150 µg indacaterol 
Breezhaler®. 
 Aims and objectives  
1.2.1 Aims 
The aims of this study were: 
 To investigate the effect of MIF and Vin on the dose emission and the aerodynamic 
characteristics of the emitted dose of both formoterol and indacaterol from Aerolizer®, 
Easyhaler®, and Onbrez Breezhaler® using in-vitro methods  
 To assess the effect of the three main inhalation manoeuvre parameters in the patient 
IPs (MIF, Vin, and ACIM) on the aerodynamic characteristics of the emitted dose of 
indacaterol from Onbrez Breezhaler® using COPD patients’ IPs and simulated COPD 
patients’ IPs. 
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1.2.2 Objectives  
The objectives of this study were: 
 To measure the dose emission and dose delivery uniformity (n=16) of formoterol from 
a Foradil Aerolizer® powder formulation at different MIFs (28.3, 60, 90, and 120 
L/min) and Vins (500, 750, 1000, 1500, and 2000 mL) after one and two inhalations. 
 To evaluate the effect of MIF and Vin on the dose emission and aerodynamic particle 
size distribution (APSD) of formoterol emitted from an Easyhaler® using different 
MIFs and Vins. 
 To measure the dose emission and dose delivery uniformity (n=16) of indacaterol 
from an Onbrez Breezhaler® at different MIFs (28.3, 60, 90, and 120 L/min) and Vins 
(500, 750, 1000, 1500, and 2000 mL) after one and two inhalations. 
 To assess the effect of dose strength (150 µg and 300 µg) on the dose emission and 
APSD of indacaterol using different MIFs and Vins after one and two inhalations. 
 To determine the amount of indacaterol delivered from an Onbrez Breezhaler® using 
COPD patients’ IPs using ex-vivo methodology. 
 To use ex-vivo methodology with simulated patients’ IPs to identify the effect of each 
inspiratory parameter (MIF, Vin, and ACIM) on the aerodynamic dose emission 
characteristics of indacaterol Breezhaler®. 
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 Respiratory system 
The respiratory system of a human being consists of a branching system, whereas 23 
bifurcations of air channels comprised the whole system, starting from the mouth to the tiny 
clusters of alveoli. It is responsible for the supply of oxygen to the blood through inspiration. 
Therefore, it will be distributed to various parts of the body, and in the process of oxygen 
supply carbon dioxide is removed by the reverse mechanism of expiration, the gaseous 
exchange is taking place in the alveoli (Bisgaard et al., 2001).  
2.1.1 The Lungs 
The lungs are the main organ of the respiratory system. It has a spongy texture with a cone-
like structure. The lungs are different in the structure, whereas the left lung is comprised of 
only two lobes comparing to three lobes to the right lung. Moreover, the left lung is smaller 
due to the presence of the heart (Waldron, 2007).  
 
Figure 2.1: Lungs inhalation and exhalation mechanism (Marieb and Hoehn, 2007) 
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The base of the lungs located on the diaphragm on a side, while the top is located in the root 
of the neck. Each lung is covered by a membrane called pleura. The pleura is divided into two 
membranes, the one who is covering the external surface of the lungs known as the visceral 
pleura, and the lining membrane of the thoracic cavity and it is known as parietal pleura. The 
intrapleural fluid which acts as a lubricant to reduce the friction between layers during 
breathing fills the space between the two membrane layers. The lungs have a unique 
elasticity, whereas the lungs inflate during the inspiration and a reverse mechanism of 
exhalation deflate the lungs. This elastic  features of the lungs due to the elastic fibres and 
collagen which form the lungs tissue (Marieb and Hoehn, 2007, Ward et al., 2010).  
The contraction and the relaxation of the lung tissue, a diaphragm and chest rib during the 
inhalation and exhalation is  shown in Figure 2.1. The mechanism of the inhalation is taken 
place due to subsequent contractions in the diaphragm, then it moves downward, and finally, 
the muscles between the ribs which are known as the inter-costal contract, which leads to the 
ribcage is being pulled outwards. The air is then drawn into the lungs by the negative intra-
thoracic pressure as result of the thoracic cavity volume is increased. During the expiration 
mechanism, the reverse mechanism is taken place, whereas, the inter-costal muscle relax, the 
diaphragm return to its original anatomical position, therefore, pulling the ribcage down and 
leading to the lungs to be contracted. These actions subsequently reduce the volume of the 
thoracic cavity, and that enforce the air to be exhaled out of the lungs (Waldron, 2007, 
Rogers, 2010, West, 2012).  
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2.1.2 The respiratory airways  
Respiratory organs and tissues are responsible for gaseous exchange; however, air from 
outside the body passes through those organs, and subsequently, oxygen and carbon dioxide 
exchange takes place (Figure 2.2). These organs and tissues are called the respiratory system 
to generate energy and perform metabolic functions; the human body requires oxygen, which 
can be breathed into the body during inspiration. Carbon dioxide, which is a waste gas 
produced due to chemical reactions within cells during the energy production process, can be 
removed or cleared from the body during expiration. CO2 in high percentage is harmful to the 
cells (Bisgaard et al., 2001). 
 
Figure 2.2: Schematic diagram of upper and lower respiratory tract (Bisgaard et al., 2001) 
The respiratory system can be classified according to its function into the upper and lower 
respiratory tract. The upper respiratory tract includes nasal passages, pharynx and larynx, 
which are lined by respiratory ciliated epithelium, and secrete mucus, whereby cilia clear 
breath from unwanted particles or dust from airways and mucus secretion are propelled to the 
pharynx and can then be swallowed or coughed up. 
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The main functions of the upper respiratory tract are moistening, heating and filtering of the 
air entering the respiratory system. The condition of atmospheric air is normally 20 oC and ~ 
50% moisture, when inspired the air is heated to the desired temperature of 37oC and 
humidity of 99% in the upper respiratory tract (Waldron, 2007). The lower region of the 
respiratory tract starts from the trachea a rigid tube that consists of cartridge mainly to the 
alveoli is responsible for the gaseous exchange and respiration (Bisgaard et al., 2001, Hickey, 
2003). 
2.1.3 Conducting airways 
It controls the exchange of atmospheric air in and out on a regular basis into the respiratory 
organs and tissues. The conducting airways are like an inverted tree in shape and form very 
complex tubes and branches. Moreover, these branches and tubes are narrower, thinner and 
more in number as they penetrate deeper into the lungs. The upper part of conducting airways, 
the trachea and larynx, carry air to and from the lower parts, whereas by the middle of the 
thorax it splits into right and left main bronchi, each of which controls the air feed to one of 
the lungs. Anatomically, the trachea (windpipe) is a muscular tube that is supported by a C-
shaped cartilage ring that protects it and prevents it from collapse (Hickey A, 2005, Ward et 
al., 2010). A bronchial wall become thinner with the subdivision, and by level 16 of 
branching respiratory zone starts, and gaseous exchange takes place (Figure 2.3). On the other 
hand, airways from the trachea and the terminal bronchioles down to branch 16 are all known 
as a conducting zone of airways. It is called a conducting zone, as no gaseous exchange 
occurs within these branches due to lack of alveoli; this area is often anatomically known as 
dead space. 
The conducting airways have two main functions; firstly, the delicate structure of the alveoli 
is protected by warming and humidifying inhaled air to avoid excessive exposure to dry cold 
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air, and secondly, to allow inhaled air to reach the more distal region where gas exchange 
occurs. Terminal bronchioles, which are down to distal parts of respiratory airways, branch 
into bronchioles, which in turn branch to tiny bronchioles. These ultimately become alveolar 
ducts, thin-walled sacs called alveoli, which are responsible for the respiratory gaseous 
exchange. Thus the zone from respiratory bronchioles down to alveoli is known as the 
respiratory zone (Weinberger et al., 2008). The lung airways branching system undergoes 23 
bifurcations, whereas the airways surface area is less than the enormous surface area of the 
alveoli, which allows the efficient gas exchange to take place. In contrast, the surface area of 
human airways is approximately 2.5 m2, while it is approximately 80 and 140 m2 for the 
Alveoli and Alveolar wall respectively (Widdicombe and Wine, 2015). 
Table 2-1: The respiratory airways’ branching and dimensions (Weinberger et al., 2008) 
Airways number and dimension 
Name of airway Number Diameter (mm) Cross-sectional area 
(cm2) 
Trachea  
1 
25 5 
Main bronchi  
2 
11-19 3.2 
Lobar bronchi  
5 
4.5-13.5 2.7 
Segmental bronchi  
19 
4.5-6.5 3.2 
Subsegmental bronchi  
38 
3-6 6.6 
Terminal bronchi  
1000 
1 7.9 
Terminal bronchioles  
35000 
0.65 116 
Terminal respiratory 
bronchioles 
 
630.000 
0.45 1000 
Alveolar ducts and sacs  
4 x 106 
0.4 17.100 
alveoli 300 x 106 
 
0.25-0.30 700.000 
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The most popular model that describes the branching system of the respiratory airways ( see 
Figure 2.3) is known as Weibel model (Weibel, 1963).  It has been shown to help describe the 
branching and zones in the human respiratory system. It illustrates the branching of lungs and 
respiratory airways, which are divided into two regions or zones. Firstly, the conducting 
airways zone is down to branch 16 bifurcation, and the respiratory zone goes from branches 
16 to 23. The transitional zone is the region that connects the two zones or regions; it consists 
of generation 17 through to 19 generation of the branching (Muttil et al., 2009). Muscles and 
receptors that are responsible for the bronchodilator are found in the conducting zone of 
airways; nevertheless, a respiratory airway inflammation is predominate in the conducting 
zone and is also present in parts of the respiratory zone. 
 
Figure 2.3: Schematic diagram of airways Branching Model (Weibel, 1963)  
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 Lung function indices, volume and capacity  
The data of the inspired and expired lung volume measured for the patients using a spirometry 
can be a useful tool to determine the severity of the pulmonary disorder the patients have, then 
it can also be characterised and quantified (Quanjer et al., 1993, Wanger et al., 2005, Hickey, 
2006). The inhaled and exhaled volume is only forming part of the total lung volume during 
the normal breathing pattern.  
 
Figure 2.4: Static lung volumes and capacities based on volume – time spirogram (Wanger et al., 
2005) 
The pathophysiological status of the patient’s lung can be determined using the lung volume 
and capacities information.  The spirometry is used for the measurement of the air inhaled and 
exhaled which can be characterised by tidal volume (TV), inspiratory reserve volume (IRV), 
expiratory reserve volume (ERV), vital capacity (VC) and the inspiratory capacity (IC). The 
definition of these parameters is given below. 
The volume of air remaining in the lungs, which are known as residual volume (RV) and 
functional residual volume (FRV) after expiration, can be estimated using both gas dilution 
methods and body plethysmography.  The volume of the air that can be processed by the 
respiratory system of a healthy adult is approximately 10 to 20 m3.  The forceful vital capacity 
manoeuvre measurement provides important information and data. These data are the forced 
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vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and the peak expiratory 
flow rate (PEFR). The area at which gaseous exchange in the lungs takes place is 
approximately 120 – 160 m2; it is supplied with 2000 km of blood capillaries. For each breath 
at rest, a volume of 500 mL tidal air is inspired and expired from the lungs. However, this 
number will increase during heavy work. Also, the number of breaths of an adult during 
heavy work is a triplicate to the number of breath at rest which is 12 times every minute 
(Hickey, 1996, Hinds, 2012). The definition of the different lung volume parameter was 
deduced from the lung capacity measurement shown in Figure 2.4. These parameters are as 
follow:  
 Tidal volume (TV): during a normal breath cycle, it is the volume of air that is inhaled 
and exhaled of the respiratory tract. 
 Inspiratory reserve volume (IRV): after normal tidal inspiration, the IRV is the 
maximum volume that can be inspired at the end of normal inspiration or tidal 
inspiration. 
 Expiratory reserve volume (ERV): is the additional maximum volume that can be 
exhaled out of the lungs at the end of tidal expiration. 
 Inspiratory Capacity(IC): The maximum inspired volume of air after normal tidal 
expiration [IC= TV+IRV] 
 Residual volume (RV): is defined as the remaining air in the lungs after a maximum 
expiratory effort  
 Functional residual capacity (FRC):  FRC is the air volume retained in the lungs after 
a normal tidal expiration [FRC= ERV +RV] 
 Vital capacity (VC): is defined as the volume of the air that can be exhaled from the 
lungs after maximum inspiration [VC= IRV + TV +ERV]  
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 Total lung capacity (TLC): after an inspiratory effort, TLC is the air volume in the 
lungs, it can be calculated from the volumes as follow [TLC= IRV+TV+ERV+RV] 
Pulmonary function tests (PFTs) are considered a useful tool to the clinicians to determine 
whether the obstructive or restrictive illness is present and identify the defect location. It 
comprises of three different tests including spirometry, lung volume and diffusion capacity. 
The spirometry is used to determine the presence and the obstructive severity defect in the 
airways. The scooped pattern flow volume loop is a main marker (Figure 2.5), then using 
numerical values FEV1 and FVC. The ratio of FEV1/ FVC < 80% indicate an obstructive 
defect, in addition, obstruction severity can be determined when compared to predicated lung 
volumes (Pellegrino et al., 2005). 
 
Figure 2.5: a, b). Examples of obstructive pulmonary defect characterised with low FEV1. c). 
typical restrictive defect characterised with low TLC. d). obstructive and restrictive defect low 
TLC and FEV1 (Pellegrino et al., 2005). 
Diffusion capacity (DCLO) test is used to determine the gas transfer function of the lungs. It 
might be falsely decreased with patients have severe restrictive and obstructive diseases. It 
can be seen with intrinsic restrictive conditions such as Sarcoidosis and Amyloidosis, and 
extrinsic restrictive conditions such as obesity and neuromuscular disease. Factors such as 
obesity and race affect PFT parameters reading (Al Ghobain, 2012, Belacy et al., 2014). 
19 
 
 Respiratory clearance mechanism, impact on dose absorption 
The respiratory tract fundamental function is to filter the inhaled air before reaching the 
delicate compartments of the respiratory system. There are different mechanisms to clean the 
air inhaled. The clearance mechanism of the mucociliary layer is one of the important 
mechanisms to remove mucus and foreign particles deposited in the respiratory airways 
(Figure 2.6). Its mechanism involves the transporting of the mucus with deposited particles 
with the help of the ciliated cells in the pulmonary epithelium. The particles trapped in the 
mucus will be either swallowed or coughed up following the proximal transportation by the 
cilia (Stahlhofen et al., 1990, Olsson et al., 2011). 
The goblet cells are responsible for the secretion of mucus, which consists of both watery, and 
gel phases (which contain mucin and glycoproteins). The production of mucus in healthy 
individuals is approximately 10 to 20 mL per day. However, in patients with chronic 
bronchitis, this volume can be increased up to 10 times, which thereby causes damage to the 
cilia lining of the airways (Toremalm, 1960).  
 
Figure 2.6: Schematic diagram shows the different clearance mechanism of the inhaled particles 
within the respiratory airways (Hussain et al., 2011)  
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The respiratory defence mechanism acts to prevent foreign particles entering the respiratory 
system. Similarly, inhaled aerosol particles are eliminated from the respiratory system by the 
defence mechanism to avoid the interaction with lung cells, that leading to poor respiratory 
disease control and therapy failure (Labiris and Dolovich, 2003, El-Sherbiny et al., 2015).  
Inhaled particles clearance mechanism depends on the deposition site of the particles within 
the lungs. The mucociliary escalator acts to eliminate particles in the tracheobronchial tree, in 
contrast, particles in the lower alveolar region cleared by the mean of phagocytosis process of 
the macrophages (El-Sherbiny et al., 2011). It has been reported that particles in the range of 
1.5 to 3µm reach the alveolar region are engulfed by the macrophages (El-Sherbiny et al., 
2015). Furthermore, large porous particles will reach the alveolar region of the lungs due to 
their aerodynamic size; however, the clearance of these particles is reduced due to their large 
geometric diameter (Edwards et al., 1997, Olsson et al., 2011). Mucociliary clearance (MCC) 
rate found to be affected by different factors such as age, airways diseases (asthma and 
COPD) and smoking (Vastag et al., 1986, Messina et al., 1991, Olsson et al., 2011).  
The inhaled drug particles (≤ 5µm) should be able to pass through the defence system of the 
airways to reach the airways and  have a therapeutic effect (Tena and Clarà, 2012). Smaller 
particles will have more velocity to escape through the mucus and reach the peripheral region 
of the airways (Stahlhofen et al., 1990, El-Sherbiny et al., 2015). It is reasonable to assume 
that total lung deposition between healthy volunteer and patients with common asthma and 
COPD does not contrast to a clinically significant degree for any available product in the 
market. Nevertheless, the difference will be in the regional distribution of the total lung dose, 
whereas in a patient with the mentioned condition the cross-sectional area will be smaller and 
therefore, the inhaled drug particles will deposit more in proximal regions of the lungs 
(Thorsson et al., 1998).  
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 Respiratory diseases 
The respiratory system common diseases are asthma and the chronic obstructive pulmonary 
disease (COPD). The causes of these disorders vary from genetic factors, infections and 
irritating pollutants particles. The inhalation therapy is considered effective in the treatment of 
some local respiratory disorders; these treatments are very effective at low doses with less 
systemic side effects when compared to another route of drug administration (Nokhodchi and 
Martin, 2015).  
2.4.1 Asthma  
It is a chronic disorder occurs due to inflammation of the lungs airways, which causes the 
constriction of the pulmonary airways and becomes more sensitive to certain triggers such as 
dust, pollen and viral infections. This inflammation causes the lungs airways to spasm and 
narrowing, then excessive production of mucus, which results in the symptoms that 
accompanied asthma. Many cells and cellular element play a role, specifically, T-
lymphocytes, macrophages, neutrophils and mast cells, etc. it is characterised by recurrent 
wheezing, breathing difficulties, chest tightness and coughing which normally happen in the 
early morning or at night. These symptoms are combined with a different degree of airflow 
obstruction which depends on the severity of the inflammation; this obstruction is reversible 
by using treatment and sometimes spontaneously (Masoli et al., 2004, Waldron, 2007, GINA, 
2016). A chronic pathological condition affects people all over the world. It has been shown 
that 334 million people have asthma and in the next 20 years; this number is predicted to 
increase by 1/3 (~ 100 million), children are the most prevalence category (Lavorini and 
Corbetta, 2008, GINA, 2016). In the UK, asthma patients are around 5.4 million people, who 
are currently receiving treatment for the disease. Also, 1 in 11 children (1.1 million) in the UK 
has asthma, compared to 1 in 12 adults (4.3 million). In the recent data published by the NHS 
in 2014, 1216 people died from the complications of asthma. The National Health Service 
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(NHS) is spending a total of 1billion sterling pounds per year to cover the cost of emergency 
room visits, treatments and hospitalisation (AsthmaUK, 2016). 
 Causes of asthma 
It can be inherited due to a genetic problem, or passed from the parents on their genes; some 
patients who have asthma have no family history of the disease. The fundamental causes that 
lead to asthma are not well known yet. However, the genetic disposition to atopy which 
stimulates the immune system to generate an immunoglobin IgE antibody to a certain element 
in the environment is considered as risk factor for the developing of asthma disorder 
(Schieken, 2002, Holgate, 2010). 
In a patient with asthma, lungs airways are more sensitive to irritation than normal. The 
irritation of the airways can happen by exposure to triggers such as pollen, grass, mould, dust 
mites and trees, etc. This type of asthma is affecting both adult and children, but it is more 
common in children. These allergens can cause sneezing, wheezing, itchy eyes and a runny 
nose. 
The viral infections and recurrent sinus inflammation can cause asthma. The well known rule 
of thumb is that environment where people live can determine whether they have asthma or 
not. The risk factors that are associated with the environment are: 
 The exposure to fume from the exhaust system of cars, trucks, etc. 
 Smoking during pregnancy or infancy 
 Viral infections during infancy 
 Exposure to inflammation triggers particles such as pollen, food preservatives and 
drugs, paint odour, cleaning product and temperature and weather changes, etc. ( 
American Thoracic Society (American Thoracic Society, 2013).  
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 Asthma pathogenesis 
Asthma can be classified into two main types depending on the causes and the pathogenesis 
of each type. The main two types are the extrinsic (atopic) and intrinsic (non-atopic), whereas 
as atopic asthma occurs when the lungs are exposed to an external factor or allergen which 
trigger the inflammation in the lungs such as dust, pollen, etc. In non-atopic asthma, no 
external factors associated affecting the lungs (Holgate, 2008, Holgate, 2010, Nakagome and 
Nagata, 2011). 
Atopic asthma normally associated with childhood and it is related to specific triggers that 
lead to an inflammation of the lung airways. Moreover, family history, eczema, and rhinitis 
are associated with this type of asthma. The pathogenesis of atopic asthma can be described as 
a sequence of pathways following the trigger of the lungs smooth muscles by an external 
factor such as an allergen, or known as environmental stimuli as shown in Figure 2.7. The 
release of immunoglobulin E (IgE) from the B-lymphocyte upon the exposure to a trigger, 
lead to series of inflammatory responses. The binding of the IgE to inflammatory cells to 
release chemical mediators. The main inflammatory cells are mast cells, esinophils and T-
lymphocyte (Holgate, 2010).  
The above mentioned chemical inflammatory mediators cause bronchoconstriction effect to 
the airways of the lungs, spams and mucus secretion, in response symptoms of asthma 
become more pronounced (Currie et al., 2005, Ward et al., 2010). Non-atopic asthma 
normally occurs due to viral respiratory infection or few triggers, which are not external. This 
type is associated with adulthood and IgE has no role in the pathogenesis of the disease. The 
symptoms of this type of asthma can be very severe and persistent (Lambrecht and Hammad, 
2003, Ward et al., 2010)  
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Figure 2.7: Demonstrate the inflammatory response of lungs smooth muscle in atopic asthma 
(Lambrecht and Hammad, 2003)  
 Symptoms of asthma  
The symptoms of asthma differ between patients in term of severity and frequency. Moreover, 
the asthma symptoms may happen during the physical activity or at night . Some patients 
have an asthma attack symptoms more than one time a day, while others may have one in a 
week or so (Masoli et al., 2004, Holgate, 2010). The symptoms of the asthma characterisation 
can be used for the diagnosis purposes whether it is happened due to allergic or non-allergic 
environmental stimuli. The most common symptoms of asthma are as follow (GINA, 2016): 
 Wheezing sound: During the inhalation, high wheezing sound can be heard. 
 Breathlessness: inability to breath for seconds, or unable to do physical activity. 
 Tightness: due to the lungs airways constriction patients feel chest tightness. 
 Coughing: the inflammatory response to expel mucus for the airways. 
In the asthmatic patients, different airways are affected such as trachea, bronchi and 
bronchioles. The symptoms of asthma can be worse during the exacerbations, whereas the 
25 
 
increase in the mucus secretion leads to a further constriction of the airways and some cases 
complete airways blockage. Asthma is associated with a decrease in both peak expiratory 
flow (PEF) and forced expiratory volume in one second (FEV1) (Barnes, 1996, Bradding et 
al., 2006, Holgate, 2010). 
 Classification of asthma 
Asthma can be classified into four main groups depending on three main factors. Firstly, the 
prevalence of the symptoms during the daytime, symptoms during night time and the overall 
lung function as shown in Table 2.2. 
Table 2-2: Classification of Asthma (Busse et al., 2015, GINA, 2016)  
Severity level 
Symptoms frequency FEV1 or 
PEF (% 
predicted) 
FEV1 or PEF (% 
variability) 
Diurnal Nocturnal 
Intermittent ≤ 2 /week ≤ 2/month ≥ 80 < 20 
Mild 
persistent 
> 2/week but < 
1/day 
< 2/month 
 
≥ 80 
 
20-30 
 
Moderate 
Persistent 
Daily 
 
> 1/week 
 
> 60 - < 80 
 
> 30 
 
Severe 
Persistent 
Continuous 
 
Frequent 
 
≤ 60 
 
> 30 
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2.4.2 Chronic obstructive pulmonary disease (COPD) 
It is a progressive pulmonary disease characterised by an obstruction in the airflow through 
the respiratory airways, the symptoms of the disease are not fully reversible. Upon the 
exposure to harmful and noxious gases and particles, the lungs airways progress an 
inflammatory response. COPD is considered as one of the common respiratory diseases; it 
affects 65 million people worldwide in the range of moderate to a severe state of COPD. It 
caused the death of 3 million people worldwide in 2010. In the UK an average of 1.2 million 
people are diagnosed with COPD in overall, and it is more prevalence in the age of 40 years 
and older. In 2012, the UK was in the top 20 countries with high mortality rate due to COPD. 
The disease is common in men than in women, but recent data showed that the number of  
women diagnosed with COPD increased significantly in the last ten years (British Lung 
Foundation, 2017). The main cause of the COPD condition is smoking which contributes to 
90% of the cases according to the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD, 2016). 
In COPD patients, two main conditions may comprise the disease; these conditions are 
chronic bronchitis and emphysema (Figure 2.8). Both can be characterised by different 
features as follow: 
 Bronchitis is an inflammatory condition, which affects the bronchi causing an excess 
formation of mucus and thickening the lining of the bronchi walls. As a result of this 
condition the airways and the cilia are damaged which make it harder to breathe and 
slow the clearance of the mucus due to the lack of cilia. 
 Emphysema is the other condition that comprises the COPD with bronchitis. It affects 
the small airways and the alveoli in the lungs. It will cause malformation of the air 
sacs as it becomes loose, which in turn leads to a bigger but fewer air sacs, which 
ultimately affect the gaseous exchange. 
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Figure 2.8: The difference in the airways obstruction between Emphysema and Bronchitis 
(American Thoracic Society, 2013) 
 Causes of COPD 
The main causes of the COPD condition are cigarette smoke, infection of the bronchi and air 
pollution (Jensen et al., 2000, GOLD, 2016). The bronchitis is caused by the impairment in 
the ventilation because of the bronchi diameter decrease, which happens when the irritant 
persists to trigger the inflammatory cells. In some patients, chronic bronchitis can occur by 
the excess production of mucus in the patient lungs. In contrast, the emphysema causes the 
inability of exhaling the air out of the lungs as result of Alveolar wall damage. Air trapping is 
a common feature in patients with COPD (Morenz et al., 2012).  
There are different causes and risk factors associated with the occurrence of COPD such as: 
 Exposure to cigarette smoke: Long-term smoking is the most common cause of COPD 
 Genetic:  In some cases, the deficiency in Alpha-1 antitrypsin causes COPD. 
 Nature of occupation: long-term exposure to dust or chemical irritant in the workplace is 
also a significant factor for COPD. 
 Exposure to fume and fuel emission: the quality of life is an important factor. In 
developing countries, people are at high risk, due to the lack of good ventilated houses  
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 Dietary, Age and respiratory disease history (Mannino and Buist, 2007, GOLD, 2016). 
The genetic factor between people affects the suitability disregard if the patient was a smoker 
or not. For some reasons, which are not identified yet, some smokers are not at risk, and 
others who are not smokers have COPD. The possible explanation is that patient who 
develops COPD has a deficiency in Alpha-1 antitrypsin which decreases the level of protease 
inhibitor (Barnes 2000, Barnes, 2004).  
 Pathogenesis of COPD  
The pathophysiological process that causes the COPD is a complex process, which involves 
different inflammatory cells in the body. The main cells involved in the process are 
neutrophils and CD8+ Lymphocyte (Figure 2.9). These cells counteract each other, which 
results in various destructive changes in the epithelium of the smooth muscle in the lungs 
(Barnes 2000). The analysis of the inflammatory cells activity during the early stage can help 
the diagnosis of the disease. The increase in the inflammatory cells such as macrophage, T-
lymphocytes, B- lymphocytes, and neutrophils which occur as a consequence of the destructive 
inflammation process in the small airways and the alveoli, this can be used when cell profile 
analysis is performed (Retamales et al., 2001, Barnes, 2004). Upon the exposure to the trigger 
factors such as noxious particles and harmful gaseous lead to an activation of these 
inflammatory cells and mediators. Furthermore, the oxidative stress as well as the imbalance 
between both protective and aggressive defence system in the lungs and respiratory airways 
considered as another possible process in the pathogenesis of the COPD (Barnes 2000). In 
people who smoke cigarettes, the increase in the oxidants compounds can result in serious 
damages to the protein and lipids and ultimately cause tissue damage. These oxidants also 
inhibit the anti-proteases enzymes (α1 antitrypsin, AAT) that lead to further damage in the 
balance between the protease and the anti-proteases (Carr et al., 2016). 
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Figure 2.9: Pathophysiology and the inflammatory process in COPD (Barnes, 2010) 
 Symptoms of COPD 
The signs and symptoms accompanied by COPD disorder can vary from mild to very severe 
symptoms. Normally, the symptoms start mild in the early stages. The early signs are 
persistent or a phlegmy cough, and in other cases, the symptoms start with short of breath in 
the early stages (American Thoracic Society, 2013, GOLD, 2016). The common signs and 
symptoms of COPD vary between patients and include:  
 Phlegmy or a persistent cough , dyspnoea, breathlessness                             
  Wheezing and nocturnal breathlessness  
 Weight loss and Tiredness  
According to (American Thoracic Society, 2013)‘‘Many people with COPD develop most, if 
not all, of these signs and symptoms.'' 
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 Classification of COPD 
In COPD, both the peak expiratory flow (PEF) and forced expiratory volume in one second 
(FEV1) decreased in all patients. It has been classified into four groups (mild, moderate, 
severe and very severe) depending on the degree of the airflow obstruction or in other words, 
the disease severity (BTS, 2016, GOLD, 2016). These criteria can be measured using 
spirometry, hence, help in the diagnosis of the COPD as shown in Table 2.3. 
Table 2-3: Classification of COPD according to the disease severity (GOLD, 2016).  
COPD stage Spirometric criteria Signs and symptoms 
Mild 
 FEV1/FVC < 0.7 
 FEV1≥ 80% predicated 
Smoker’s cough, no sign of abnormal 
lung function. 
Moderate 
 FEV1/FVC < 0.7 
 50% ≤ FEV1< 80% 
predicated 
Progressive stage, symptoms are more 
pronounced, i.e., shortness of breath. 
Severe 
 FEV1/FVC < 0.7 
 30% ≤ FEV1< 50% 
predicated 
Exacerbation stage limits physical 
activity, shortness of breath become 
worse at this stage 
Very severe 
 FEV1/FVC < 0.7 
 FEV1< 30% predicated/ 
< 50% with chronic 
respiratory failure 
Impairment in the life quality, life 
threatening exacerbation attacks more 
common at this stage 
Despite the fact that COPD is an irreversible disorder, some test can be carried out such as 
reversibility testing to assess the COPD prognosis and therefore, determine the appropriate 
treatment to help manage the symptoms (BTS/NICE, 2016). 
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2.4.3 Asthma and COPD differences 
Asthma and COPD have some similar characteristics in the signs and the symptoms such as 
the coughing and wheezing. However, they are two different respiratory conditions in 
different features such as the disease onset, symptoms frequency and the reversibility of the 
obstructive airways (Table 2.4).  
 The disease onset: In asthma, the disease onset is common in the childhood, while in 
COPD, more common in the age category of the mid-50s in smokers and ex-smokers 
(Hogg et al., 2004, BTS, 2016). 
 Exacerbations: asthma is characterised by chest tightness, shortness of breath and cough, 
which normally occur due to an allergen, exercise and viral infection. In contrast, the 
respiratory tract infections are considered as the main cause of COPD exacerbation 
(Pauwels, 2001) 
 Prognosis: The treatment of asthma aims to reverse the symptoms and are almost 
symptoms free between the exacerbation attacks. In COPD, airways obstruction reverse 
partially, but symptoms are persistent almost every day (BTS/NICE, 2016) 
 Pathogenesis: The number of eosinophils and neutrophils in the inflammatory response 
vary between COPD and asthma. Whereas, the percentage of eosinophils is more in 
asthmatic patients when compared to COPD patients. The percentage of neutrophils is 
much higher in COPD patient than asthma patient (Carr et al., 2016).  
 Treatment and maintenance therapy: Inhaled corticosteroids are effective in relieving 
eosinophils mediated inflammation in Asthmatic patients, while neutrophils mediated 
inflammation is more resistant to these agents (George and Brightling, 2016). In COPD 
smoking cessation is helpful to reduce the progression of lung function as well as 
shortness of breath, then bronchodilators can be used (BTS, 2016). 
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The difference in the maintenance therapy can be seen from the usage of corticosteroids and 
bronchodilators, whereas, the first line treatment in the asthmatic patient is corticosteroid to 
control the inflammation caused by the trigger factors, then bronchodilator can be used to 
control the symptoms. In COPD, the opposite is true for the treatment of COPD conditions. 
Where  Bronchodilator is the first line of the drug of choice in the maintenance treatment and 
corticosteroid can be used only in some cases where bronchodilators are not effective to 
control the symptoms in a patient with moderate to severe conditions along with frequent 
exacerbation (Barnes 2000, BTS/NICE, 2016). 
Table 2-4: Common differences between Asthma and COPD, including common differential 
diagnostic symptoms (Yawn, 2009).  
Patient history Asthma COPD 
Smoker / non-Smoker Possibly Nearly all 
Symptoms < 45 years Frequent Less frequent 
Chronic cough symptoms Infrequent Common 
Nocturnal wheezing and breathlessness Common Uncommon 
Extent breathlessness Variable Persistent 
Variability in symptoms day to day Common Uncommon 
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2.4.4 Treatment and Management of Asthma  
Asthma is known as a multi-factorial disorder. Therefore, the complete cure of the disease is 
difficult. The first treatment of the asthmatic patient can be done by avoiding the trigger or 
stimulus factor that cause inflammation and the airways obstruction, reduce the usage of the 
drug therapy, tackle the cause of possible exacerbation and ultimately achieve the normal 
lungs function on daily activity (GINA, 2016). 
The main components of asthma disorder are the inflammation and the airways constriction. 
Thereby, treatments that minimise these two components are considered as the effective 
asthma treatment regimens. Inhaled corticosteroids (ICSs) such as fluticasone, budesonide 
and beclomethasone, leukotriene inhibitors, xanthines (theophylline) muscarinic antagonist 
(e.g., long-acting tiotropium and short-acting ipratropium) and mast cell stabiliser, which 
inhibits the release of chemical mediators, act with medication mentioned above to reduce the 
airways inflammation. Bronchodilator, which can be classified into short-acting β-2 agonist 
(SABA) such as salbutamol and long-acting β-2 agonists (LABA) such as formoterol and 
salmeterol, can be used to dilate the lung airways and reduce bronchoconstrictions. The 
combinations of LABA with ICS have been found to have a synergistic effect and help 
asthma control (Barnes and Godfrey, 1998). Another agent can be used for the management 
of the asthma symptoms such as anti-allergic non-steroidal agents (cromoglycate). The 
guidelines in the management of asthma have illustrated that ICS are the standard of asthma 
control (Suissa et al., 2000, Murphy, 2007). The management of asthma can be summarised in 
5-steps approach designed by the British Thoracic Society (BTS, 2016). These steps were 
based on the use of SABA (e.g., salbutamol and terbutaline) as first line relievers, then 
followed by the use of ICS (e.g., budesonide and fluticasone) as preventers. The final step 
involves the use of LABA (e.g., salmeterol) and an oral corticosteroid for short courses in the 
very severe cases and the exacerbation. 
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Step 1: SABA such as salbutamol used as a reliever, it has a quick onset of action (peak at 
approximately 15mins) which ensure a quick relief from the symptoms. This medication can 
be inhaled as required by the patient. However, the use of more usage might indicate the poor 
control of asthma such as using 2 or more canisters per month or more than ten puffs per day. 
SABA is a recommended bronchodilator therapy on daily basis use.  
 
Figure 2.10: Stepwise plan for the management of asthma symptoms (BTS, 2016) 
Step 2: In this step, the use of inhaled corticosteroid becomes an option, depending on how 
the symptoms have improved using the SABA. The dose use should be within an acceptable 
safety range to improve lung function and prevent exacerbation. Early use of ICS lead to an 
improvement in the asthma management and less use of other medication (O'byrne et al., 
2001, Bernstein, 2008, Corrigan et al., 2009).  
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Step 3: In patients with severe symptoms, the increase of ICS use may lead to unwanted side 
effects. Therefore, BTS, 2007 recommended before increasing the dose of ICS, a combination 
of LABA such as salmeterol, formoterol with  ICS should be used to improve the lungs 
function. Thereby reduce the probability of exacerbation of symptoms (Kips and Pauwels, 
2001a, Kips and Pauwels, 2001b, Pauwels et al., 2003, Shepherd et al., 2008). 
Step 4: If a moderate dose of ICS is not effective, and there is a response to the use of LABA, 
but the asthma control is still poor, in this case, the dose of ICS should be increased, while 
LABA remains constant. If this does not improve the lungs function, then the use of 
leukotriene receptor antagonist, theophylline or slow release tablets of β-2 agonist is 
recommended. LABA should not be given alone; it always has to be given in combination 
with ICS for asthma treatment (Currie et al., 2005, Tee et al., 2007).  
Step 5: In this step, the use of oral steroids is recommended in the lowest dose possible that 
help control asthma symptoms. At this stage, the patient will experience severe symptoms and 
exacerbation. Therefore they should be referred to specialist care (Waldron, 2008). These 
receptors have to be available for the medication to activate the β-2 adrenergic receptors. The 
epithelium of the airways starting from the large bronchi downward to the terminal 
bronchioles have a high density of these receptors (Carstairs et al., 1985).The use of 
bronchodilators in an asthmatic patient were found to enhance the clearance mechanism in the 
pulmonary airways (Hasani et al., 2005).  
The dose of ICS should be used in the minimum dose possible to relief symptoms and reduce 
the unwanted side effects such as cataracts and increased risk of infections. The use of ICS 
reduces the hospitalisation and death cases due to asthma (Kips and Pauwels, 2001b).  
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2.4.5 Treatment and management of COPD 
Patient with suspected symptoms of COPD should be examined by undergoing different 
pulmonary function capability testing such as post-bronchodilator spirometry and pulmonary 
function test. These procedures are aimed to examine the degree of airways obstruction, the 
extent of condition severity and the probability of reversibility. A chest radiograph can be 
used to confirm the condition and exclude any thought of other overlapping respiratory 
condition. The diagnostic tests that should be done are forced expiratory volume in a second 
(FEV1) in addition to the volume of  air exhaled using fast and forceful exhalation (FVC).In 
patient with COPD, these two parameters reduce as well as the ratio  FEV1/ FVC which is 
considered as a diagnostic marker for the obstruction in the pulmonary airways. An FEV1/ 
FVC  ≥ 0.7 suggests no obstruction in the airways (Pauwels et al., 2003, GOLD, 2016). 
The aim of COPD management can be summarised into main points such as: 
 To ensure the diagnosis of the disease in early stages accurately. 
 It helps control the common symptoms associated with the condition. 
 Prevent complications by reducing the number of exacerbation incidence.  
 Improve the patient’s quality of life. 
The treatment of COPD is required to improve the breathing pattern of the patient, and that 
can be achieved by improving the patient FEV1 profile. The drugs used for the treatment of 
COPD have been investigated to which extent this medication capable of retrieving or 
improve the FEV1 (López-Encuentra et al., 2005).  
COPD Management involves two main strategies to control the disease and help the patient 
on a daily basis. These strategies are non-pharmacological management and pharmacological 
management (Figure 2.11). 
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 Non-pharmacological management  
 Smoking cessation: In the early stages of COPD, stopping smoking is considered a key 
factor. The patient history of smoking can help during the diagnosis as well as the 
management of the disease. Therefore, these data should be obtained from the patients 
to know the number of year’s patient have been smoking cigarettes for as well as the 
number of packs per day/week etc.    
 Vaccination: pneumococcal and influenza vaccine annually. 
 Pulmonary Rehabilitation: Patient with recurrent exacerbation, it includes 
physiotherapy, disease education, exercise and nutritional support. 
 Travel advice: patient with low FEV1 % and having a long-term oxygen therapy 
should be informed that air travel might increase the risk of pneumothorax (Achilleos 
and Powrie, 2011) 
 Pharmacological management  
The pharmacological management of COPD comprises of different lines and each of this 
medication has to be given under certain conditions to improve the lung function and help the 
patient with daily life (Hasani et al., 2005). This medication can be classified as follow: 
 Bronchodilators  
The patient with COPD condition should take an inhaled bronchodilator medication to help 
with the symptoms. If the inhalation of bronchodilators showed signs of improvement in the 
lung function and improve exercise tolerance, it is preferable to continue prescribing the 
treatment (Celli et al., 2004, Hasani et al., 2005, Achilleos and Powrie, 2011). Cazzola and 
Page (2014) stated “Bronchodilators are central to the treatment of chronic obstructive 
pulmonary disease (COPD) because they alleviate bronchial obstruction and airflow 
limitation, reduce hyperinflation and improve emptying of the lung and exercise 
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performance”. For this reason, ‘‘all guidelines highlight that inhaled bronchodilators are the 
mainstay of the current management of all stages of COPD’’ (Cazzola and Page, 2014). 
The first choice is using the short acting β-2 agonist SABA (salbutamol and terbutaline), these 
treatments described due to their rapid onset of action, in addition to the relief the symptoms 
(BTS/NICE, 2016). Inhaled long-acting muscarinic antagonist LAMA, e.g., ipratropium 
bromide (Atrovent®) is as effective as SABA as it targets M1 and M3 receptors; the only 
disadvantage is that in some cases, the slower acting mechanism of this treatment(Achilleos 
and Powrie, 2011). The long-acting β-2 agonist LABA such as salmeterol and formoterol 
should be considered if the SABA treatment (four times daily) did not improve the symptoms 
and enhance the lung function. These treatments have a long acting mechanism approximately 
12-14 hours. Additionally, some studies have shown the importance of using LABA over the 
use of SABA as the first line in the management of stable COPD (Van Noord et al., 2000, 
Cazzola et al., 2004). The use of LABA in COPD patients inhibit the mast cells mediator 
release and thereby reduce the nerve activation (Nials et al., 1994). The combination 
treatment of LABA and LAMA are found to provide a synergistic effect, which will provide 
an improvement in the lung function and maintain the effect overnight, compared to daytime 
improvement when single treatment administered. The reason for that is LAMA will decrease 
the vagal tone that happens in COPD, therefore, airways relaxation when the receptor 
activated by LABA, e.g., a combination of formoterol and tiotropium (Duova Rotacap®) 
(Cazzola and Tashkin, 2009).  
 Inhaled corticosteroid (ICS) 
The use of ICS in the treatment of COPD has not understood the reason is that during the 
COPD the inflammation is caused by neutrophils. The use of ICS is controversial in the 
management of stable COPD (Keatings et al., 1996, Barnes, 2010). In patients with FEV1 < 
50% experiencing an exacerbation twice a year despite the use of LABA, the use of ICS with 
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high dose should be considered. The combinations of ICS with LABA such as 
Beclomethasone dipropionate / Formoterol fumarate was found to decrease the chance of 
exacerbation by approximately 25% when compared to the effect of LABA alone in reducing 
the risk of exacerbation (Nannini et al., 2007, Barnes et al., 2013). 
 
Figure 2.11: Strategies for the management of stable COPD (Achilleos and Powrie, 2011)  
Guidelines have been changed and patients with FEV1 less than 60% were approved to use a 
combination of ICs and LABA (Seretide Accuhaler®) (Calverley et al., 2003, Roche et al., 
2014). The short course use of oral corticosteroid is considered during an exacerbation. 
However, patient must not use this treatment for maintenance therapy due to their serious 
unwanted side effects (Achilleos and Powrie, 2011). 
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The study showed that formoterol has an effect in the treatment of COPD, due to its ciliary 
enhancement mechanism and bronchodilation, whereas the mucociliary clearance 
significantly improved when formoterol used for a week (Melloni and Germouty, 1992).  
Formoterol lipophilicity properties give it the ability to entrain within the membrane, which 
means activation last for a longer period (Anderson, 1993). The mucolytic agent usages in the 
management of COPD for a patient with a chronic cough, nonetheless, no evidence shown 
improving symptoms in a patient with exacerbation or reduce the frequency of the 
exacerbation. When these treatment used for more than two months, meta-analysis data 
showed that the exacerbation reduced by 29% when compared to placebo (Poole and Black, 
2001).  
 Theophylline for COPD patients  
The use of theophylline in COPD, even though it has side effects when used in bronchodilator 
doses, however, there is increasing evidence showing that it has a role in controlling the 
inflammation in COPD patients. It’s anti-inflammatory response occur at low plasma 
concentration, the role that theophylline plays is pronounced at low concentration by 
activating the histone deacetylases, and thereby improving the anti-inflammatory effect of 
ICS (Barnes, 2006). Theophylline should be used in patients who are not able to use the 
inhaled therapy, or it can be used after bronchodilators SABA and LABA (Achilleos and 
Powrie, 2011).The mechanism of theophylline was found to be enhanced when combined 
with oxidative stress (Barnes, 2005). In addition to the use of theophylline as bronchodilator, 
it has a significant cardiovascular effect in COPD patients, whereas study by Matthay, 1987 
state that ‘‘Administered to COPD patients orally as a sustained-action preparation or 
intravenously as aminophylline, theophylline enhances both right and left heart systolic pump 
function and lowers both pulmonary artery pressure and pulmonary vascular resistance’’ 
(Matthay, 1987). 
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 Supplemental long-term oxygen therapy (LTOT) 
The use of LTOT in COPD patients should be assessed if the patient shows the following 
criteria (BTS/NICE, 2016): 
 Severe status of airways obstruction  
 Patient show signs of Cor pulmonale  
 Patient with hypoxaemia (Sa02≤ 90%, threshold of ≤ 88%) 
 Cyanosis  
 Polycythaemia  
This step is introduced to improve the patient survival, daily exercise, sleep and cognitive 
performance in a patient with hypoxaemia (GOLD, 2016). The oxygen determination in 
patients is needed; arterial oxygen saturation can be measured using the pulse oximetry 
(SpO2), in addition to the physiological indication for oxygen supply such as oxygen tension 
(PaO2) < 7.2 kPa (54mmHg). The target is to maintain the SpO2 level above 90% during the 
patient's rest and sleep to prevent of tissue hypoxia. In some cases, when CO2 retention 
occurs, signs of patient acidemia should be monitored, if acidemia occurred, then mechanical 
ventilation is essential for patient survival (BTS, 2016).  
2.4.6 Summary of COPD and asthma treatment 
The guidelines data produced by the (BTS, 2016, GOLD, 2016) demonstrated that inhaled 
bronchodilators, as well as inhaled corticosteroid, are the main choice in the treatment of 
asthma and COPD. Therefore, it is crucial to ensure successful dose emission from the 
marketed inhaler devices, also, to ensure that the emitted dose from the device has the 
tendency for distal respiratory airways deposition during the inhalation manoeuvre.  
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 Pulmonary route of drug administration  
The pulmonary route of administration was used over many years. The history of the origin of 
inhaled therapies was established 4000 years ago in India by smoking the leaves of the Atropa 
belladonna plant to treat coughs. During the 19th and early 20th centuries, asthmatic patients 
smoked cigarettes that contained stramonium powder mixed with tobacco to treat their disease 
symptoms (Bisgaard et al., 2001, O'Callaghan et al., 2001, Ashish et al., 2012). Inhalation 
devices that have been developed recently can be classified into three main categories - the 
improvement of nebulisers and the production of two types of compact inhalation devices: 
pMDIs and DPIs (Grossman, 1994, Labiris and Dolovich, 2003).  
 Pulmonary drug delivery is considered as one of the most efficient routes for drug 
administration. The inhalation route of administration was used to deliver the drug to the site 
of action in different forms such as vapour of aromatic plants and myrrh, whereas by the 19th-
century liquid nebulisers were coming into use for treatment via the pulmonary drug delivery 
route. It has been used mainly to treat respiratory tract diseases such as asthma and chronic 
obstructive pulmonary disease (COPD) over the last few decades (Bisgaard et al., 2001, 
O'Callaghan et al., 2001, Ashish et al., 2012). Recently, it has been used for other purposes 
than treating lung disease, whereas it is used in the treatment of diabetes, for vaccination and 
also gene therapy (Laube, 2014). The use of pulmonary route to deliver medication to the 
lungs epithelium directly is more efficient and reduce the chance of potential side effects that 
caused by the use of another route of drug administration. It has some significant advantage, 
despite the fact that the bioavailability of drug through inhalation route depends on the proper 
technique of device use and the particle size following the formulation dispersion inside the 
device (Chege and Chrystyn, 1994, Chrystyn, 2007, Vincken et al., 2010).  
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The common advantages of using inhalation route are listed below (Chrystyn, 2006).: 
 High local concentration and targeting  
 The low doses of drug used (for instance, salbutamol is 200µg, when compared to an 
oral dose of 4 mg of salbutamol). 
 Low local and systemic concentration, thus reducing the toxicity  
 Efficacy and rapid onset of action  
 Bypass the first pass metabolism 
 It is needle-free pulmonary route delivery 
 Low enzymatic activity when compared to the liver 
 Huge specific surface area, making this route suitable for protein and peptides.  
Therefore, the inhalation route of drug administration is the favoured route for the treatment 
of different diseases especially respiratory conditions such as asthma and COPD. The local 
and systematic efficiency of drug delivery to the lungs depends on three major parameters 
including the patient inhalation manouvere, the inhaler device and the formulation (Chrystyn, 
2006, Ibrahim et al., 2015). 
2.5.1  Mechanism of inhaled particle deposition 
Particles deposition in the respiratory tract can be defined as particles with a mass median 
aerodynamic diameter of ≤ 5µm and are more likely to enter the lungs and make deposits in 
different regions of the airways according to their particle size (Chrystyn, 1999). The 
deposition of the particles to the lung airways occurs via three major mechanisms: inertial 
impaction, gravitational sedimentation and Brownian diffusion (Figure 2.12). Velocity as well 
as the size of particles, affects the particle deposition. Particles can also be deposited on the 
surface of the pulmonary tract by other mechanisms such as interception and electrostatic 
precipitation (Heyder et al., 1986, Gonda, 1990, Heyder, 2004, Lindström, 2004). 
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Figure 2.12: Mechanisms that control inhaled particles deposition in the respiratory airways 
(Hussain et al., 2011) 
 Inertial impaction  
Particles with a large diameter and high intensity tend to follow the impaction mechanism 
when it is travelling at high velocity in the air stream. The change of airways direction makes 
it difficult for the large particles to follow the airstream. The deposition of the particles by the 
inertial impaction will take place at the bifurcation of the large airways, larynx, trachea and 
mouth. Particles with diameter > 10μm are deposited by the impaction mechanism (Hickey A, 
2005, Tena and Clarà, 2012) 
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 Gravitational sedimentation  
This mechanism occurs with smaller particles (0.5-5μm), whereas particles that move down 
the airways will be affected by the slow flow of the air velocity due to the opposing resistive 
forces of the air and tends to be deposited due to the gravitational force. The gravitational 
sedimentation mechanism will take place as a result of breath holding after the inhalation 
manoeuvre. Uniform particles distribution throughout the respiratory airways can be achieved 
by sedimentation, which in turn could be enhanced by slow, deep breaths and holding the 
breath after inhalation (Tena and Clarà, 2012). 
 Brownian diffusion  
The diffusion mechanism occurs with particles size smaller than 0.5μm; furthermore, the 
diffusion mechanism of particle deposition increases as the particles size decreases. Particles 
tend to diffuse to the surrounding surface due to the residence time of particles being long in 
addition to the short travelling distance to reach the airways. The diffusion mechanism is 
enhanced by holding the breath after inhalation. The diffusion mechanism is inversely 
proportional to particle size and relates directly to the residence time of the particles in the 
airways (Gonda, 1990). 
 Other mechanisms Electrostatic charge effect and interception 
Electrostatic precipitation occurs when charges of opposite sign are induced by charged 
particles onto the walls of respiratory airways that electrically conduct when normally 
uncharged. Consequently, the electrostatic force attracts the charged particles to the surface of 
the airways. For that reason, charged particle deposition will be greater than the neutral 
particles. The interception mechanism of the deposition takes place when the particles 
dimensions are similar to that of the airways the particles are passing through; for example, 
the small airways and alveoli (Stuart, 1984, Hillery et al., 2002). 
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 Inhaler devices for pulmonary drug delivery 
The successful management of lung disease can be affected by the adequate use of the 
inhalers and thereby the delivery of the drug to the lungs. The availability of the inhaler that is 
easy to use, able to deliver the medication to the lungs in a reproducible and cost-effective 
manner is crucial for successfully inhaled treatment (Selroos et al., 1996, Pedersen et al., 
2010, Vincken et al., 2010). There are different criteria that the ideal inhaler device should 
include: 
 Firstly generating an aerosol bolus with an optimum particle size in the range of 0.5 
to 5μm 
  Dose delivery uniformity over the course of treatment 
  Easy to use 
 Patient preference and robustness  
 Finally, portable and inexpensive (O’Connor, 2004, Brand, 2005, Chrystyn, 2007, 
Ibrahim et al., 2015). The DPIs and MDIs are the most commonly prescribed inhaler 
devices, nebulisers are used in certain situation depending on the patient’s status. 
The criteria of the ideal inhalers (Figure 2.13) do not exist in inhaler devices in the market 
nowadays, nonetheless, prescribing the right inhaler for the right patient can maximise the 
benefits of the inhaler use.The effectiveness of the inhaler device is found to be affected by 
the correct choice of the device and the proper inhalation technique (Barnes and Godfrey, 
1998, Haughney et al., 2010, Scichilone, 2015).  Different parameters should be taken into 
consideration to choose the right inhalers such as tolerability, ease of use by the patient and 
preference (Newman, 2005). 
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Figure 2.13: Criteria of an ideal inhaler device (Chrystyn, 2007)  
2.6.1 Nebulisers 
The nebulisers are the first inhalation devices to be developed and used for the treatment of 
different respiratory disorders. They have been developed over years, however the first 
nebuliser was only invented in1849, followed by portable nebuliser in 1858, after that the 
glass bulb nebuliser was introduced in the 1930s and the plastic bulb nebuliser in 1940 
(Grossman, 1994, Anderson, 2005). The first compressed nebuliser was designed and 
introduced in Germany in 1930s, which was known as Pneumostat®. Both solutions and 
suspension formulated active pharmaceutical ingredients (API) can be aerosolised from this 
device. The solvents used are usually either water alone or water in combination with co-
solvents such as ethanol and propylene glycol (Clarke and Newman, 1984).  
The minimal inspiratory effort required for aerosol delivery from a nebuliser is 6 to 8 L/min 
(Newhouse et al., 1976, Lavorini, 2013). The patient data suggest the effectiveness range of 
the nebuliser vary from 10 - 50% of the delivered dose (Clark, 1995). The nebulisers operate 
by converting the drug solution or suspension into fine aerosol droplets for inhalation. It can 
be used for patients who cannot use the pMDIs or DPIs correctly, including patients with an 
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acute exacerbation who require a high therapeutic dose such as antibiotics (e.g., Tobrmycin 
Inhalation solution 300mg/ 5mL, TOBI®) such a high dose can not be delivered using pMDIs 
or DPIs. The nebulised medication can be breathed in using a mouth piece or face mask (Fink, 
2000, Boe et al., 2001, VanDevanter and Geller, 2011). 
There is medication wastage up to 50% of the medication nominal dose retained in the dead 
space of the chamber or exhaled during the exhalation manoeuvre using nebulisers. In 
addition to the oropharyngeal deposition caused by large droplets size which are unable to 
reach the peripheral airways (Smaldone and LeSouef, 2001). The nebulisers can be classified 
depending on the design and the mechanism of dose release into three main types: Jet 
nebuliser, Mesh and Ultrasonic nebulisers as shown in Figure 2.14. 
 
Figure 2.14: Schematic diagrams of a). Air- jet nebuliser b) Ultrasonic nebuliser and c) Mesh 
nebuliser (Ghazanfari et al., 2007, Ari, 2014)  
Jet nebuliser converts the drug solution into a fine mist for inhalation using compressed gas, 
oxygen cylinder or electrical compressor (Dhand, 2003, Ari, 2014). Ultrasonic nebuliser has 
a piezoelectric crystal vibrating at high frequency (1-3 MHz). It is unsuitable for high 
viscous solutions/ or suspension, heat sensitive material (e.g., proteins) and large residual 
volume post inhalation (Ari and Fink, 2011, Ari, 2014). Mesh nebuliser uses multiple 
apertures in a mesh or aperture plate; the medication solution is forced by the mean of 
micro-pump through this aperture to generate the aerosol (Ari, 2014).  The nebulisers are 
used for some patients, but they are not as popular as the MDIs and DPIs for the delivery of 
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medication into the lungs (Clark, 1995). There are different reasons for that such as their 
bulky nature although there are some portable patient nebulisers, difficult to clean, time - 
consuming (Dolovich et al., 2005).  
2.6.2 Metered dose inhalers (MDIs) 
MDIs were firstly introduced in 1956. They remain the most prescibed inhalers (Vaswani and 
Creticos, 1998). They represent about 80% of the inhaler products on the market (O’Connor, 
2004). There are different reasons for the popularity of these devices as they are inexpensive, 
simple to manufacture and available with different drug formulations (Chrystyn, 2007). 
pMDIs are used in the delivery of a wide range of active pharmaceutical ingredients (APIs) 
including bronchodilators, anti-cholinergic, anti-inflammatory and corticosteroids. APIs form 
1% or upper limit of 2% w/w of the formulation to reduce the chance of valve clogging 
(Smyth, 2003). When used effectively pMDIs are as effective as other pulmonary drug 
delivery systems (Fink, 2000). There are four main functional components of pMDIs:  The 
canister, metering valve, actuator and mouthpiece as shown in Figure 2.15. The propellants 
are the driving force to expel the drug formulation from the canister. The propellant forms at 
least 80% w/w of the formulation, reducing the amount of the propellant has been shown to 
affect the spray characteristics of the inhaled aerosol (Fink, 2000, Ju et al., 2010). In addition 
to the drug substance, pMDIs may contain other substances such as surfactant and co-solvent 
mixture to improve the stability of the formulation and spray characteristics of the inhaled 
aerosol. 
The pMDIs are either suspension or solution based formulation of drug in propellants. For 
decades, chlorofluorocarbons (CFC)  have been used as propellant in pMDIs formulation. In 
1987 the Montreal Protocol banned the use of the CFC propellants due to their depletion 
effect on the ozone layer. The hydroflouroalkanes (HFAs) such as HFA134a and HFA227 are 
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used as alternative in the formulation of pMDIs (Hou et al., 2015). The solution pMDIs have 
been shown to be more efficient than suspension pMDIs in maximising the drug delivery to 
the lungs (Clay and Clarke, 1987, Hickey, 2006, Gibaldi, 2007). The deposition of the aerosol 
in the lungs improved with HFA- pMDIs due to the reduction in the oropharyngeal 
deposition, which occurs due to forcful blast of CFCs propellant (Dolovich, 1999, Gibaldi, 
2007, Usmani, 2015). 
 
Figure 2.15: Schematic diagram showing the components of pMDIs  
Many problems have been identified with MDIs in term of the effectiveness of the devices 
and the usability. The patient inhalation technique is one of the most concerns, some studies 
reported that up to 94% of the patients have a poor inhalation technique (Brocklebank et al., 
2001, Crompton et al., 2006, Lavorini et al., 2008, Roche et al., 2013). Patient training  on 
how to use the device correctly did not completely solve the problem of the coordination 
51 
 
between patient inhalation and dose actuation. Many patients were unable to use the device 
correctly after training (Crompton, 2004, Al-Showair et al., 2007a, Hardwell et al., 2011, 
Gowrishankar, 2013).The problem with poor coordination is that the medication is either 
emitted too early or too late in the inhalation manoeuvre cycle (Crompton, 1981, Donnell, 
2001). The patient failure in achieving a slow inspiration technique was one of the main 
problem associated with the use of pMDIs. Furthermore, studies showed that fast inhalation 
could lead to high oropharyngeal deposition which is not required for good inhalation therapy. 
Therefore slow inhalation followed by breath-holding duration was found to improve lung 
deposition (Newman et al., 1981a, Newman et al., 1981b, Newman et al., 1982, Everard et al., 
1995, Al-Showair et al., 2007a, Chrystyn and Price, 2009, Haughney et al., 2010). A 
minimum inspiratory flow rate of 20 L/min was reported to be sufficient for pMDIs 
(Newhouse et al., 1976) and holding the breath for 10 seconds found to provide better drug 
deposition than 4 seconds (Newman et al., 1981c). Several studies reported that lung 
deposition and clinical outcome were improved when correct inhalation technique was 
achieved by the patients (Al-Showair et al., 2007a, Lavorini et al., 2010). High velocity 
aerosol bolus was also associated with pMDIs poor lung delivery about 10 - 15% of the 
emitted dose reaches the lungs (Newman et al., 1981c). 
 pMDIs with spacer and valve holding chamber   
Over the years, a wide range of add-on devices such as spacer tubes, Valve holding chambers 
and mouthpiece extensions has been introduced to solve the coordination problem with 
pMDIs Figure 2.16. These add-on devices, if used properly, will help reduce the throat 
deposition and lead to a subsequent increase in the peripheral deposition in the lungs airways. 
The spacers were introduced to help to reduce the effect of the cold Freon effect, while valve 
holding chamber showed to reduce the medication dose waste especially in the patient with 
poor inhalation technique (Vaswani and Creticos, 1998, Fink, 2000, Aswania and Chrystyn, 
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2001). The dose of non-respirable particles that impact on the wall of the spacer tubes has 
only marginal effect on the dose of the respirable particle (particles with a diameter of > 5µm) 
(O'Callaghan et al., 1994, Terzano, 1999).  
The use of a spacer with pMDIs allow the patient to inhale at a distance from the inhaler 
mouthpiece to the patient mouth, thus allowing more time for the aerosol to slow and the 
propellant to evaporate and thereby reduction in the particle size ensuring more benefits from 
each dose by increasing the fraction of the inhaled aerosol (Broeders et al., 2009). The 
decrease in the oropharyngeal deposition with the use of spacer tubes attributed to the 
decrease in the aerosol particle velocity (Newman and Newhouse, 1996). The use of low 
volume spacer can lead to up to 60% decrease in the respirable dose. Therefore, it is 
recommended to use a spacer with a volume of > 100mL (Fink, 2000). 
 
Figure 2.16: pMDIs with spacer and valve holding chamber 
The pMDIs with the spacer can be as effective as nebulisers in the management of acute 
asthma attacks (Cates et al., 2006). Spacers are considered as an efficient method in adult and 
children patients who cannot use the pMDIs properly (Pedersen, 1996). Although, spacers 
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dose delivery inconsistency was reported to be due to the electrostatic charges of the aerosol 
causing drug particles attachment to the spacer plastic and holding chamber walls (Barry and 
O'callaghan, 1995). This effect of electrostatic charges can be significantly reduced by 
washing the spacer with 1: 5000 household detergent and left to dry, the spacers’ performance 
improved by using anti-static linings  (Barry et al., 1993, Wildhaber et al., 2000).  
 Breath actuated Pressurised metered dose inhalers  
The breath-actuated MDIs have been introduced, due to the coordination difficulties that 
patients have experienced when using the pMDIs between the dose actuation and the patient 
inhalation manoeuvre. About 50% of the pMDIs users have a poor inhalation technique 
(Donnell, 2001, Pothirat et al., 2015). Breathe actuated pMDIs contain a flow-trigger system 
that driven by a spring, the latter automatically release the dose from the canister of the MDIs 
upon the start of the patient inhalation manoeuvre which means coordination is automatic as 
shown in Figure 2.17. The examples of breath-actuated MDIs are the device developed by 
Teva Pharmaceuticals Ltd, UK such as low inhalation flow rates Autohaler® (30L/min) and 
Easibreathe® (20 L/min) (Newman et al., 1991b, Broeders et al., 2009, Laube et al., 2011).  
 
Figure 2.17: Breath actuated metered dose inhaler 
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The inhalation flow requirement for these devices is achievable by most of the patients 
including patients with severe airways blocking, furthermore the delivered dose, and dose 
consistency was not affected by any increase in the inspiration effort (Terzano, 2001). The 
breath-actuated MDIs have criteria that increase patient compliance and confidence such as 
the clicking sound upon actuation and the taste of the propellant in the dose which assure the 
patient that the dose has been delivered (Newman et al., 1991b, Donnell, 2001). 
Although, these devices have brought no improvement in a patient with good coordination 
technique. Several studies demonstrate that this device improves lung deposition and decrease 
the throat deposition in a patient with poor coordination technique (Newman et al., 1991b, 
Schecker et al., 1993, Soria et al., 2002). Breath-actuated MDIs can be a good substitute to the 
pMDIs because it is easier to use, teach, patient preference, complaince and improved lung 
depsotion (Chapman et al., 1993, Price et al., 2003, Giraud and Allaert, 2009).  
Nonetheless, when compared to pMDIs the breath actuated devices are requiring a higher 
flow rate of  20 L/min and 30 L/min respectively, in addition, it does not solve the cold Freon 
issue and limited to only salbutamol and beclomethasone dipropionate compared to a wide 
range of medications with pMDIs (Newman et al., 1991b). The pMDIs remain popular in the 
delivering of the medication for the management of asthma and other respiratory obstructive 
disease, notwithstanding the difficulties patient face when using this device. The advantages 
and disadvantages of drug delivery systems for the delivery of medications to the lungs are 
illustrated in Table 2.5. 
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Table 2-5: Advantages and disadvantages of different aerosol delivery systems (Dekhuijzen et al., 2016) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhaler devices Advantages Disadvantages 
Pressurised  
Metered dose 
Inhalers (pMDIs) 
Portable, convenient  and compact 
Multi-dose device 
Relatively cheap 
Available for most inhaled medication 
Cannot contaminate content 
Dose indicator 
 
Contains propellant 
Required coordination 
Patient cannot use it correctly 
High throat deposition 
pMDIs + Spacer Low flow rate dependency 
Easier to coordinate 
More convenient for large doses 
Less throat deposition 
Higher lung deposition  than pMDIs 
Bulky inconvenient 
Static charge for plastics spacers 
Additional cost to a pMDIs 
Breath actuated- 
MDIs 
Convenient, compact 
Multi-dose device 
No coordination required 
Cannot contaminate contents 
Cold Freon effect 
Required moderate flow to operate 
Dry powder 
inhalers (DPIs) 
Portable, convenient 
Breath actuated 
No propellant 
Dose indicator 
Locking system when empty 
Require a inspiratory flow 
Not appropriate in Emergency 
Many patient  cannot it use properly 
Most types are moisture sensitive 
Soft mist inhalers 
(SMIs) 
Portable, compact 
Multi-dose device 
Low flow rate dependency 
High fine particles 
High lung deposition 
No propellants 
Dose indicator 
Locking mechanism when empty 
Not breath actuated device 
Nebulizer Can be used at any age 
No technique required 
Vibrating mesh is portable and does not require an outside energy 
May dispense inhaled medications not available with pMDIs or DPIs 
Jet and Ultrasonic types required an outside energy source 
Long treatment time 
Inconsistent performance  between different types 
Risk of bacterial contamination 
Newer generation nebulizers are expensive 
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2.6.3 Soft mist inhalers (SMIs) 
Soft mist inhalers are new generation inhalers, which are neither pMDIs nor DPIs. Respimat® 
Soft mistTM is the only available SMI in the market, introduced by Boehringer Ingelheim GmbH 
(Dalby et al., 2004, Anderson, 2006). 
Respimat® is a handheld device similar in size to both pMDIs and DPIs. The mechanism of 
aerosol cloud generation from the drug solution require the metered dose of liquid to be 
converted into a small droplets with a high tendency for lung deposition without the need of 
additional force (e.g., propellants). In Respimat®, mechanical energy generated by the spring is 
responsible for aerosolisation mechanism. The spring can be easily compressed by the patient 
when using the device, therefore, using mechanical force ensure reproducible and reliable energy 
source, and also independent of the variable patient's flow. It is a ‘‘press and breathes’’ device 
(Zierenberg et al., 1996, Anderson, 2006, Dekhuijzen et al., 2016). Also the respimat® has a 
relatively long generation time of the aerosol cloud comparing to pMDIs ( approximately 1.5 sec) 
that allow more time for the patient and enhance the coordination between the patient inhalation 
and the dose actuation. The patients should use a longer inhalation time > 2second after dose 
actuation, to meet the long aerosol output by the device. Notwithstanding, the difference in the 
aerosol cloud generation time, the correct inhalation technique is similar to that used with pMDIs 
(Dalby et al., 2004).  The drug contained can be defined by the colour code and the internal 
mechanism of the respimat® illustrating the medication solution stored in the cartridge (Figure 
2.18). 
Respimat® device is designed to avoid the use of a spacer, battery or external power source. 
Furthermore, the fine particle fraction (FPF) in the aerosol cloud that is generated by the 
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respimat® is higher than that generated by pMDIs and DPIs 70% FPF, consequently reducing the 
throat deposition and enhancing the lower airways drug deposition. In clinical trials, respimat was 
equally effective in a patient with COPD, the bronchodilator at half of the dose delivered from a 
pMDIs,. The device was more preferred by the patient with COPD and other obstructive 
pulmonary diseases over the pMDIs (Dalby et al., 2004, Anderson, 2006). Studies on the 
performance of Respimat® showed that delivery of flunisolide ethanolic solution and an aqueous 
solution of fenoterol have a fine particle fraction of 66% and 81% of the nominal dose 
respectively (Zierenberg et al., 1996, Eicher and Zierenberg, 2002). The SMI device was shown 
to offer the same level of therapeutic efficacy and safety with less dose of combination 
bronchodilator when compared to pMDIs. 
 
Figure 2.18: Demonstrate structural components of Respimat® 
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2.6.4 Dry powder inhalers (DPIs) 
DPI were introduced into the market to overcome the CFC-propellant and poor patient 
coordination technique experienced with the pMDIs (Vidgren et al., 1988, Tarsin et al., 2006, 
Lavorini, 2013). Aerohaler® and Spinhaler® were the first DPIs introduced to the market in 1950s 
(Bell et al., 1971, Clark, 1995, Sanders, 2007). These devices were followed by other devices 
such as blister (e.g., Accuhaler® and Turbuhaler®) and reservoir DPIs (e.g. Clickhaler®, 
Easyhaler®). These DPIs differ in their internal design, resistance and thereby dose emission 
characteristics (Chrystyn, 2006, De Boer et al., 2017). 
DPIs are breath actuated devices and have some advantages over the pMDIs such as it is more 
stable, propellant free and large doses can be introduced (Ashurst et al., 2000).  Over the last 
decades, several DPIs devices have been introduced into the market to deliver inhaled 
bronchodilators and corticosteroids. They have shown a higher lung deposition and dose 
consistency with less technique error when compared to the use of pMDIs (Borgstrom et al., 
1994, Lenney et al., 2000, Molimard et al., 2003, Chrystyn et al., 2016). DPIs devices were 
classified depending on the design of the inhalers into single dose and multi-dose DPIs as shown 
in Table 2.6 (Srichana et al., 1998, Chrystyn, 2007).  
The formulation of DPIs is usually drug particles in combination with a carrier, which plays an 
important role in the formulation stability, mixing and uniformity. The most commonly used 
carrier is lactose. The principle of operation for most DPIs depend on the turbulent energy 
generated upon the patient inhalation manoeuvre inside the inhaler, this energy lead to dose de-
aggregation and dispersion of the drug formulation. Several studies showed that patient inability 
to achieve the threshold inspiratory flow lead to incomplete dose de-aggregation and 
consequently low lungs deposition (Palander et al., 2000, Weuthen et al., 2002).  
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Nonetheless, new generation DPIs have recently been introduced which have shown to require a 
low inspiratory flow rate (approximately 30 L/min) and produce higher fine particle fraction with 
a tendency to lower airways deposition (>  40 % of the nominal dose) (Colthorpe et al., 2013). 
Table 2-6: Types of DPIs available in the market (Chrystyn, 2007) 
Inhaler Device (Manufacturer) Dosage forms 
Single Dose Inhalers 
Spinhaler®( Aventis) Spincaps 
Rotahaler® ( GlaxoSmithKline) Rotacaps 
Aerolizer® ( Novartis Pharma) Capsules 
Breezhaler® (Novartis, Pharma) Capsules 
Handihaler® ( Boehringer Ingelheim) Capsules 
Multi-dose inhalers  
Multiple Unit-Dose Inhaler 
Diskhaler® ( GlaxoSmithKline) Rotadisk (4-8 doses) 
Elipta® ( GlaxoSmithKline) Powder on strip 
Accuhaler® ( GlaxoSmithKline) Powder on strip 
Reservoir Systems 
Turbuhaler® (AstraZeneca) Reservoir 
Clickhaler® ( Innovata Biomed) Reservoir 
Easyhaler® (Orion Pharma) Reservoir 
Novolizer® (Meda) Reservoir 
Genuair® ( AstraZeneca) Reservoir 
Twisthaler® (Merk) Reservoir 
NEXThaler® (Cheisi) Reservoir 
The DPIs can be classified depending on the functional element composition into two main 
groups: single dose inhalers and multi-dose inhalers as described in the Figure 2.19. 
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Where, in single dose inhalers the dose separate in the form of capsules and has to be filled into 
the device and pierced by the patient prior to inhalation to allow dose aerosolisation (Chrystyn, 
2007). 
 
Figure 2.19: Schematic diagram of the marketed DPIs (a: Aerolizer®; b: Accuhaler®; c: 
Turbuhaler®)  
The fact that DPIs require  a minimum PIF to activate the device and release the dose, therefore, 
forceful inhalation manoeuvre is required (Borgstrom et al., 1994, Haidl et al., 2016). It is 
considerd as the main drawback of the DPIs, as each DPI needs a defined inspiratory flow rate to 
produce the respirable dose after dispersion. Several studies have shown that not all the patients 
are capable of producing the required inspiratory flow, furthermore, pre-school asthmatic 
children, patient with severe COPD and patients with acute exacerbation  have a problem to 
achieve these conditions (Pedersen et al., 1990, Bentur et al., 2004, Al-Showair et al., 2007b). 
The dose wastage in the use of the DPIs can be reduced by coating the device and capsule with 
force control agent. Coating has shown to reduce drug retention in the device and increase the 
fine particle dose (Heng et al., 2013). In fact,  there is no ideal inhaler and not all the inhalers are 
the same. Therefroe, patients using DPIs are recommended to achieve a strong, forceful, deep 
inhalation maintained for as long as possible (Laube et al., 2011, Scichilone, 2015).  
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 Breezhaler®  
It is a single dose, capsule based DPI that was introduced by Novartis (Basel, Switzerland) as 
shown in Figure 2.20. it is being approved for the delivery of both LABA indacaterol and 
anticholinergic glycopyrronium bromide for the treatment of COPD (Lavorini et al., 2017). 
 
Figure 2.20: Schematic diagram of Breezhaler® Capsule based inhaler  
Before an inhalation manoeuvre, the patient has to open the mouth piece of the device, put the 
capsule in the device chamber, and pierce it by pushing the buttons on the both side of the inhaler 
device. The audible click sound upon piercing the capsule means that the device is primed, during 
the inhalation manoeuvre the patient should hear a whirring noise to reassure dose emitted from 
the capsule. The patients are advised to check if the inhalation manoeuvre was correct by 
checking amount left in the see-through capsule (Buhl and Banerji, 2012, Berkenfeld et al., 
2015). It is a low resistance with an airflow resistance of 0.017 kPa0.5 min/L an inhalation flow of 
approxiemtly 111L/min was required to achieve 4kPa thorugh the inhaler (Pavkov et al., 2010, 
Dal Negro, 2015). It  has been reported that Breezhaler® is more preffered by patients with COPD 
when compared to Handihaler® (Colthorpe et al., 2013). 
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 Aerolizer®  
It is a single dose capsule based DPI was introduced mainly to deliver formoterol (Foradil 
Aerolizer, Novartis, Pharma AG) (Criée et al., 2006). Figure 2.21 shows a schematic diagram of 
the main functional element of the device. It should be used as instructed in the patient 
information leaflet (PIL) similar to that illustrated for Breezaler®  
 
Figure 2.21: Schematic diagram of parts Foradil Aerolizer®  
The Foradil Aerolizer is used for the delivery of single dose 12µg doses of LABA formoterol 
with rapid onset of bronchodilation. It has been shown to effectively provide a long-term control 
in patients with a different grade of asthma and COPD severity (Bensch et al., 2001, Rossi et al., 
2002). It is a low resistance device with an airflow resistance of 0.019 kPa0.5min/L and high 
inhalation flow rate is achievable through this device (Dal Negro, 2015). It has been reported that 
dose emission from Aerolizer® is flow dependent  (Nielsen et al., 1997). Furthermore, high 
inhalation flow through Aerolizer® may result in unwanted oropharyngeal deposition, therefore, 
reduction in the amount of drug particles reaching the lower airways (Nielsen et al., 1997, 
Broeders et al., 2001, Usmani et al., 2005).  
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 Easyhaler® 
It is a multiple dose inhaler device, which contains 200 doses of medication. It is a high 
resistance device 0.050 kPa0.5 min/L and an inhalation flow of approximately 41 L/min was 
required to achieve 4 kPa through the device (Dal Negro, 2015). The mixture of APIs and carrier 
(formoterol and lactose) is stored in a hopper at the bottom of the device. The drug powder is 
filled on a rotating drum using dosing cup, whereas, shaking the inhaler vertically is a good 
practice to ensure even dispersion. Upon use, the device is held upright and by pressing the top of 
the Easyhaler® dosing cup deposit the drug formulation into the inhalation channel and it 
becomes available for inhalation (Chrystyn, 2006). 
 
Figure 2.22: Schematic diagram of Easyhaler®  
The turbulent energy generated by the patient de-aggregates the dose into fine respirable particle 
(≤ 5µm) which have high tendency to reach lower airways. The Easyhaler® was designed to 
overcome the problem of double dosing, with the help of counter mechanism, the patient can see 
if the dose was loaded or not and prevent the use of an empty device (Azouz and Chrystyn, 
2012).  
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 Mechanism of dose de-aggregation from DPIs  
Drug particles for inhalation are generally small ≤ 5µm. Drug partricles are high cohesive and 
exhibit poor flow rate for this reason they are either formulated as an adhesive mixture using a 
large carrier such as lactose or formulated as soft spherical pellets of drug alone (De Koning et 
al., 2002, Chrystyn, 2003, Hoppentocht et al., 2014).  
DPIs are breath actuated and an adequate force of inhalation  is required to disintegrate the soft 
pellets or detach drug particles from the surface of the carrier to produce an aerosol cloud for 
lung deposition. The design of the inhaler device plays an important role in disintegration, de-
aggregation and dispersion of DPIs formulation (De Koning et al., 2002, Telko and Hickey, 
2005). There are different mechanisms of disintegration varying from the simple screen 
mechanism such as Rotahaler® and Diskhaler® to a cyclone and twisted powder channels 
mechanism in Spiromax® and Turbuhaler® respectively. The disintegration systems are divided 
into two types: - non-specific and specific disintegration (Figures 2.23 and 2. 24). Non-specific 
system is related to devices with low resistance to inspiratory airflow. These devices are 
characterised by their large variation to the respiratory flow, inconsistency in dose emission and 
low fine particle dose (De Boer et al., 1996). In contrast, the specific system is related to devices 
where the resistance to airflow is high resulting in a reduction in the velocity of the inhaled 
particles and hence minimising the unwanted oropharyngeal deposition. Therefore, the amount of 
the inhaled particles reaching the lungs will be maximised (De Koning et al., 2002). 
Patient inhalation manoeuvre generates turbulent  energy inside the device (Pressure drop), the 
latter is the product of  inspiratory flows and the resistance of the inhaler device (Clark and 
Hollingworth, 1993) as shown in the mathematical equation highlighted below: 
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√∆𝐏 =  𝐑 𝐱 𝐐          Eq.2.1 
 
 
 
Where ∆P; is the turbulent force, Q; inhalation flow, R; the device resistance  
Airflow 
Carrier/drug
Powder bed
Carrier/drug
aerosol
Disintegration
mechanism
Carrier and drug aerosol
After disintegration  
Figure 2.23: Schematic diagram of the dose de-aggregation mechanism of drug particle lactose 
crystals carrier through non-specific system (De Koning et al., 2002). 
Airflow 
Packed
Powder bed
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spherical
Disintegration
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drug aerosol  
Figure 2.24: Schematic diagram of the dose de-aggregation mechanism of soft spherical pellets 
through a specific system (De Koning et al., 2002). 
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The pressure drop that occurs inside the DPIs represent the turbulent energy; it can be measured 
by different related units either kilopascals (kPa) or cmH2O [1kPa equal 10.1972 cmH2O]. This 
energy force disintegrates the formulation into emitted dose that contains particles with the 
likelihood for lung deposition (Chrystyn, 2003, Chrystyn, 2009). Passive DPIs require an 
inspiratory flow which is an important factor to de-aggregate the formulation and produce the 
respirable dose, whereas large lactose carrier particles will hit the back of throat and which are 
then swallowed (Pitcairn et al., 1994, Srichana et al., 1998, Virchow et al., 2008).  
The successful dose de-aggregation will result in a more lung deposition and low oropharyngeal 
deposition. DPIs development focuses on achieving maximum fine particle fraction (FPF) which 
represent particles with ≤ 5 μm, these particles have the tendency for lower airways deposition 
(Chrystyn, 1999, Bisgaard et al., 2001). Furthermore, particles in the range 2–5 μm are also 
important for performance effectiveness. Generally, FPFs form approximately 20 -70 % of the 
emitted dose for which a lung deposition vary between 5 -30% for conventional DPIs (Newman 
and Busse, 2002, Islam and Cleary, 2012). The device performance and the fine particle dose are 
dependent on the formulation particle size, strength of cohesive and adhesive forces between 
drug particles and carriers and finally the patient inspiratory flow to overcome these forces 
(Telko and Hickey, 2005).  
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 Factors affecting inhaled drug particles deposition in the lungs  
There are different factors that govern inhaled drug particles into the lower airways such as  
 The physical characteristics of aerosol inhaled particles (particle velocity, size, density, 
shape, and porosity) 
  Patients’ characteristics (disease state, degree of airways obstruction, BMI and age) 
  Breathing pattern and the inhalation technique (including MIF, Vin and ACIM) (Heyder, 
2004, Tena and Clarà, 2012) 
2.8.1 Physical characteristics of inhaled aerosol particles 
The particle size of the inhaled aerosol particles plays an important role in the deposition of the 
inhaled particles. Aerosol’s particle size affects both the extent and the site of particles deposition 
(Chrystyn, 1997, Usmani et al., 2003). The fraction of the fine particles in the dose determines 
the lung distribution, the dose with high fraction of particles in the range of 2-5µm produce good 
lung distribution (Chrystyn, 1997). The size of the inhaled particles is characterised by both the 
mass median aerodynamic diameter (MMAD) and the geometric standard deviation (GSD). The 
MMAD obtained from the particle size distribution of the emitted dose that divides the 
cumulative weight into half in which 50% of the particles are larger than the median and 50% of 
the particles are smaller than the median of the particles. The GSD is representing the dispersion 
of the inhaled particles whereas particles with ≤ 2.1 are monodisperse and particle with GSD of ≥ 
2.1 are polydisperse. The fine particle size dose (FPD) is representing the particles that ≤ 5µm 
aerodynamic diameter which is related to a therapeutic dose that reaches lower airways (Pritchard 
et al., 1986, Schulz, 1998, Musante et al., 2002). The respiratory airways Anatomy has been 
evolved in a very sophisticated manner and act as a filter to prevent the airborne particle to be 
inhaled into the lungs. 
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The particles with MMAD of ≥ 5µm tend to deposit in the oropharyngeal region, while particle 
with smaller MMAD ≤ 0.5µm penetrates deeper into the airways. However, it can be exhaled 
before reaching the surface of the airways and produce no therapeutic effect. The FPD divided 
into three categories depending on particle size 3-5 μm, 1-3 μm and <1 μm (Morén, 1987). 
Several studies have been conducted to investigate the effect of holding the breath post inhalation 
to increase the deposition of the particle with very small MMAD. The exhalation of these 
particles had been dramatically decreased by holding the breath after the inhalation manoeuvre 
(Suarez and Hickey, 2000, Usmani et al., 2003, Haughney et al., 2010, Carvalho et al., 2011). 
The lung deposition is enhanced when inhaled particles are within 2 to 5 µm aerodynamic 
diameter especially in a patient with obstructive lung diseases as the airways become narrower 
and aerosol is unlikely to penetrate deeper (Chrystyn, 1999). In contrast particles with an 
aerodynamic diameter of 2 µm are likely to deposit in the lower airways and alveoli (Usmani et 
al., 2003, Pedersen et al., 2010). The velocity of inhaled particle can influence the deposition 
location of the inhaled particles. The impaction of the inhaled particles is increased by increasing 
the flow rate leading to an increase in the throat deposition (Kleinstreuer et al., 2007). Study 
conducted on 10 asthmatic patients using salbutamol consisting of particles with MMAD of 1.2, 
2.8 and 5µm showed that particles with 2.8µm diameter provided the best bronchodilator 
response (Zanen et al., 1996). The peripheral airways deposition found to increase with smaller 
aerosol particles. However, because of no smooth muscle in the alveoli area, dilatation response 
is less. Suggesting that the particle size of β-2 agonist should be  approximately 2.8µm, and for a 
patient with COPD particles should be within the range between 2-3 µm (Terzano, 2001). 
Targeting the desired site for inhaled particles for deposition is crucial for effective treatment 
(Asgharian et al., 2006). The role of the small airways is significant in the treatment of asthma 
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and COPD, whereas inflammation have been found to be more in the respiratory zone. For an 
instant, a patient with frequent exacerbation has a higher obstruction in the small airways due to 
the high air trapping in these airways (Hamid et al., 1997, Battaglia et al., 2005). The submicron 
particle sizes (≤ 1µm) are not suitable for inhalation, because these particles are normally exhaled 
from the lungs. Particles in the range of 1-3 µm are preferable for deeper lung deposition. When 
these particles are inhaled with an adequate flow rate, holding the breath (ideally 10s) will 
enhance the distal airways deposition (Usmani et al., 2005, De Boer et al., 2015). The particles 
with an aerodynamic diameter of ≤ 3µm have 80% chance of deposition in lower airways of 
which 60% being deposited in the alveoli (Patton, 1996, Laube et al., 1998). The particle size of 
inhaled aerosol with an MMAD ≤ 2µm should be used to enhance the lung deposition of jet 
nebulisers, thus reducing the dose used for providing therapeutic effect. 
Furthermore, the safety and efficacy of the inhaled aerosol is dependent on the particle size as it 
affects both extent and site of deposition (Clay and Clarke, 1987). Another study showed that less 
amount of terbutaline was produced from formulation containing drug with particle size ≥ 5µm 
diameter, resulting in most of the dose deposited in the oropharyngeal region (Rees et al., 1981). 
Particles diameter, particles shape of drug and carrier are other important parameters to consider 
when formulating DPIs. Elongated drug particles  and carrier have been shown to enhance in-vivo 
salbutamol deposition (Larhrib et al., 2003). The optimum lung deposition site varies between 
different inhaled medications. Furthemore, Usmani et al., 2005 highlighted that for 
bronchodilators (β-2 agonists and anticholinergic) smaller particles 1.5 µm showed no therapeutic 
effect notwithstanding reaching the lower airways. Therefore, proximal deposition for particles 
with 3-6 μm diameter have been found to provide more bronchodilatation effect (Usmani et al., 
2005, Virchow et al., 2008, Haughney et al., 2010) 
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Figure 2.25: Total and regional deposition of unit density spheres in the human respiratory tract 
predicted by the ICRP deposition model for oral inhalation at rest (Heyder, 2004). 
Studies have shown that most currently prescribed corticosteroids are deposited mostly in the 
central airways (Esmailpour et al., 1997), uniform central and periphral distribution is more 
preferred for inhaled corticosteroid (Hamid and Tulic, 2007). Mitchel et al., 1987 showed that no 
difference in the particle size and therapeutic effect of two aerosol particle sizes of salbutamol 
(1.4 and 5.5 µm) diameter in a patient with stable severe asthma (Mitchell et al., 1987). The drug 
particles in the formulation of DPIs are normally hygroscopic. Therefore, particles grow in size 
when they entering the lungs. The relative humidity of the lungs are approximately 99.5% which 
may cause change in size distribution of inhaled particles (Labiris and Dolovich, 2003).  
The initial particle size is an important factor that determines the rate of particles growth, 
whereas particles with aerodynamic diameter of ≤ 1µm can be increased up to 5 folds in size in 
contrast to only three folds rate of growth for particles with aerodynamic diameter of ≥ 2µm 
(Labiris and Dolovich, 2003). The change in the particle size as result of the growth that takes 
place in the respiratory airways can alter the deposition site of the inhaled aerosol particles, and 
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thereby result in more proximal or central deposition (Barnes and Godfrey, 1998). The particles 
emitted from pMDIs have shown to be less affected by the hygroscopicity when compared to 
particles emitted from DPIs (Terzano, 1999). The particles deposition in lower airways affected 
by the density and porosity of the particles in the formulation. The deposition of particles with 
high density and a small GSD was higher when compared to particles with similar aerodynamic 
characteristics but had lower density and larger geometric size (Heyder, 2004). It has been 
reported, “Polydisperse aerosols containing a significant proportion of submicron particles will 
deposit in the pulmonary airways with greater efficiency than aerodynamically similar aerosols 
comprised of geometrically larger porous particles” (Musante et al., 2002). 
2.8.2 Patient’s inhalation variables and characteristic  
 Airways obstruction  
The patient’s characteristics can influence the particle deposition in the respiratory airways for 
example COPD and asthma lead to narrowing and obstruction in the respiratory airways. The 
airways geometry has been shown to have an effect on the deposition of the particles especially 
that ≥ 6µm (Inthavong et al., 2010). The air stream is diverted from the obstructed to 
unobstructed airways resulting in an increase in the airstream velocity and hence deposition in the 
central airways by the high impaction force, and thereby fewer particles in the obstructed airways 
(Dolovich and Labiris, 2004, Luo et al., 2007). Several studies have shown the correlation 
between the patients FEV1 and the particle deposition in the lungs. COPD patients have shown 
less total lungs deposition compared to healthy volunteers. This difference was attributed to 
lower FEV1 in the COPD patients in addition to high obstruction in the airways (Pavia et al., 
1977). The increase in the peripheral lungs deposition can be achieved when the FEV1 increase 
following bronchodilation (Sanchis et al., 1973, Zainudin et al., 1990, Usmani et al., 2005). 
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 Age and Gender  
The age and gender also affect the inhaled particles deposition (Figure 2.26), the decrease in the 
lung volume as well as the anatomical changes to the respiratory airways with age lead to 
decrease in the overall particles deposition and more central deposition (Agnew, 1984, Hussain et 
al., 2011). The gender, studies found that women have a high amount of inhaled particles 
deposited in the upper airways due to the changes in the geometry of the respiratory tract 
(Pritchard et al., 1986). Kim and Hu, (1998) study shown that ‘‘Total lung deposition was 
comparable between men and women for fine particles (0.1 to 2.5µm particles diameter) but drug 
particles deposition was consistently greater in women than men for coarse particles regardless of 
flow rates used’’(Kim and Hu, 1998). 
 
Figure 2.26: The difference in the geometry of the lungs and the total lung deposition for 5, 10 and 
15 children and adult for 3µm particle size (Hussain et al., 2011)  
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 Breathing pattern and inhalation technique  
The regional deposition of inhaled aerosol particles is affected by patients’ inspiratory flow rate. 
Increasing the tidal volume at constant flow can result in an increase in the residence time of 
particles, so more particles tend to get deposited in the peripheral airways by the gravitational 
mechanism (Gehr and Heyder, 2000, Musante et al., 2002). The technique of breath holding after 
each inhalation when using pMDIs for 10s was found to increase inhaled aerosol particle 
deposition (Newman et al., 1982), whilst allowing monodisperse particle deposition in the 
peripheral airways (Heyder, 2004). Furthermore, inhalation speed is correlated with the particle 
size of MDIs, which ranges from 3 to 6 μm; MDIs were found to have a greater bronchodilation 
effect when inhaled slowly (Usmani et al., 2005, Virchow et al., 2008). The deposition in the 
lungs generally increases with the duration of the breathing cycle (Adcock and Chung, 2008). 
Slow flow rate was found to increase the deposition in the small airways by up to 70% 
(Svartengren et al., 1996). In the case of DPIs, forceful inhalation is required to de-aggregate the 
formulation into respirable particles, given the low rate of deposition (Everard, 2001, Everard, 
2003, Chrystyn, 2007, Haughney et al., 2010).  
Patients’ inhalation techniques as well as the correct use of the inhaler device are important 
factors that affect the deposition of inhaled aerosols in the lungs. In fact, maximising drug 
deposition involves a complex inter-relationship between the formulation, patient’s inhalation 
manoeuvre (including the inhaled volume, inspiratory flow, breath holding after inhalation), and 
inhaler device (Timsina et al., 1994, Azouz and Chrystyn, 2012). Several studies have shown that 
training patients on how to use the inhaler devices can help enhance the overall therapy outcome 
and increase deposition in the lungs (Giraud and Allaert, 2009, Bonini and Usmani, 2015). 
Patient preference for specific inhaler devices should be taken into consideration, as the 
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appropriate device can enhance patient adherence and therapy outcome (Lavorini and Fontana, 
2014). Dal Negro and Povero (2016) stated, “Substantial differences exist in patient’s preference 
and acceptability of inhalation devices, mainly related to the handling and the understanding of 
the different devices” (Dal Negro and Povero, 2016). Choosing the right inhaler device for the 
right patient is as important as the medication itself owing to the differences in patient preference 
and the inhalation capability. It is also important to increase patient adherence to the inhaler 
device (Al-Showair et al., 2007b, Chrystyn and Price, 2009, Haughney et al., 2010, Scichilone, 
2015). Some patients with asthma and COPD find it difficult to achieve the required inspiratory 
flow rate for effective dose emission and training them on how to use their inhaler devices was 
found to be useful in improving inhalation flow through DPIs. In contrast to DPIs, patients have 
shown good practice of slow inhalation through pMDIs (Al-Showair et al., 2007b). Therefore, 
educating the patients and providing training support can be helpful in improving poor inhalation 
technique and the use of inhaler devices (Lavorini et al., 2014, Canonica et al., 2015).  
 
Figure 2.27: Factors affecting the optimal aerosol dose delivery (Ibrahim et al., 2015)  
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 Patient inhalation profiles  
The difference in the patient’s COPD and asthma results in a difference in the patient lungs 
capabilities, whereas the inhalation profile (IP) of the patient can be  characterised by different 
parameters, starting from the flow patient use to inhale and exhale, lungs volume and finally the 
initial acceleration rate of inhalation manoeuvre.    
The IP of the patient as shown in (Figure 2.28) characterised by following main parameters: 
 Peak inspiratory flow rate (PIF) expressed in unit of [L/min or mL/s] 
 Inhalation volume (Vin) [ L or mL] 
 Initial acceleration rate ( ACIM) [ L/s2] 
 Time to the peak inhalation flow (Tp) and the inhalation time (Ti) 
The pressure profile that occurs as result of the patient inspiratory flow and inhaler resistance 
can be transferred into flow profile (2.28) if the device resistance is known (Clark and 
Hollingworth, 1993, Olsson and Asking, 1994, De Boer et al., 1996, Olsson et al., 2013). 
 
Figure 2.28: Schematic diagram showing different inhalation profiles among patient with COPD 
[Red; Low profile, Green; Medium profile, Blue; high profile]  
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Breath-actuated DPIs depend on the PIF, which is one the most important parameters of the IP 
to achieve adequate dose de-aggregation. The minimum PIF for each DPI should be achieved to 
generate the required turbulent energy for effective release of the dose (Clark and Hollingworth, 
1993, Laube et al., 2011, Price and Chrystyn, 2015). For instance, Easyhaler® requires a PIF of 
approximately 28 L/min (Koskela et al., 2000) whereas Accuhaler® requires of 30 L/min 
(Nielsen et al., 1998) and Aerolizer® requires forceful inhalation to release the dose (Nielsen et 
al., 1997). An inhalation flow rate greater than 30 L/min was required for effective dose 
emission from Turbuhaler® (Pedersen et al., 1990, Nadarassan et al., 2010). Several studies 
demonstrated that during the routine use of DPIs, some patients found it difficult to achieve a 
fast flow rate (Pedersen, 1986, Pedersen and Steffensen, 1986, Chrystyn, 2003, Azouz et al., 
2015b). Failure to achieve the minimum flow rate might result in the patient receiving no 
medication. Patients who cannot achieve the desired inhalation flow, such as children and 
patients with severe asthma and COPD, through the DPIs should be prescribed low-resistance 
DPIs or pMDIs (Pedersen, 1986, Chrystyn et al., 2002, Price et al., 2013). 
Chrystyn and Price (2009) discussed the relationship between the dose emissions from different 
DPIs (capsule, blister, or reservoir-based DPIs) and patient IP (Figure 2.29). As compared to 
other devices, dose emission from the capsule-based DPIs does not occur immediately after the 
start of the inhalation manoeuvre. Capsule-based DPIs require more inhaled volume than blister 
and reservoir devices to empty the dose. For this reason, in the PIL, the manufacturers 
recommend the patients inhale twice for each capsule to ensure dose emptying (Chrystyn and 
Price, 2009, Laube et al., 2011).  
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The PIF achieved through DPIs differs depending on the intrinsic resistance of the device; for 
instance, fast inhalation flow through low-resistance devices (e.g., Aerolizer® and Breezhaler®) 
can lead to undesired oropharyngeal deposition (Borgström, 2001, Haughney et al., 2010). Low-
resistance DPIs show less flow rate dependency than other types of DPIs (Palander et al., 2000, 
Weuthen et al., 2002).  
 
Figure 2.29:  Schematic design of patient inhalation profile through different type of DPIs 
formulation (Chrystyn and Price, 2009) 
In contrast, high resistance DPIs devices showed a high lung deposition and less oropharyngeal 
deposition, which might be as result of the high-pressure change in these type of the DPIs 
(Borgström, 2001). Figure 2.29 also highlights the difference in the ACIM (Fast and slow ACIM) 
for two profiles despite the fact both profiles have the same PIF. Several studies have shown the 
importance of fast inhalation from the start of the inhalation manoeuvre to effectively de-
aggregation the dose formulation (Everard et al., 1997). Fast acceleration rate was found to 
increase the total emitted dose (TED), Fine particle dose (FPD) and reduce the MMAD (Kamin et 
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al., 2002, Laube et al., 2011). The efficiency of the DPIs depending on the PIF achieved by the 
patient and this must be generated from the start of the inhalation (De Boer et al., 1997). It has 
also been shown that PIF and fast ACIM are directly related and playing an important role in 
appropriate dose de-aggregation from DPIs (Broeders et al., 2001).  
Vin is another important factor in the dose emission from the DPIs (Kamin et al., 2002, Alaboud 
et al., 2010). The Vin was found to be different between DPI devices; some devices require more 
inhaled volume than others do. For example, the Diskus® requires a Vin as low as 150 mL in 
contrast to the Turbuhaler® which require a minimum of 1 Litre inhaled volume to empty the 
dose (Azouz et al., 2015b). The difference in the inhaled volume between DPIs was attributed to 
their internal design and the intrinsic resistance. For example, a significant increase in fine 
particle fraction was observed with the Aerolizer® when the air inlet size was reduced. These 
results were explained by the increase in the air velocity and turbulent inside the inhaler device 
(Zhou et al., 2013, Shur et al., 2015).  
The difference in the Vin between the Diskus® and Turbuhaler® was attributed to the length of 
the inhalation channel. The inhalation channel in the Turbuhaler® is relatively long and includes a 
cyclone, whereas the inhalation channels of the Diskus® is very short, thus dose is expected to be 
released rapidly from the Diskus® compared to Turbuhaler®. The low resistance devices have 
also been reported to require larger inhaled volume when compared to the higher resistance 
devices (Azouz and Chrystyn, 2012). The Vin is an important factor for dose emptying and 
delivers the particles deeper into the respiratory airways especially for capsule-based DPIs 
(Laube et al., 2011).  
Pavia et al., 1977 showed that inhaled drug particle could travel deeper into the lungs by 
increasing the Vin during the inhalation manoeuvre (Pavia et al., 1977). Focusing on the 
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minimum force to de-aggregate the dose from the DPIs should be considered for successful dose 
emission. The patients cannot inhale in the same manner, therefore prescribing the right inhaler 
for the right patient and evaluating whether the patient can achieve the minimum inhalation flow 
to actively operate the device is critical for successful therapy outcome (Chrystyn, 2003, Al-
Showair et al., 2007b, Chrystyn, 2009).  
 DPIs internal resistance to airflow   
The dose emission from DPIs depends on the effect of different inspiratory parameters such as 
MIF, Vin and ACIM. In addition, dose emission from the device relies on its resistance, which 
differs from one device to another (Clark and Hollingworth, 1993). The equation (2.1) relates the 
peak inhalation flows, the resistance of the inhaler device and Clark and Hollingsworth (1993) 
describe the turbulent energy as follows: 
√∆𝐏 =  𝐑 𝐱 𝐐          
           Where ∆P; is the turbulent force, Q; inhalation flow, R; the device resistance  
The DPIs resistance to airflow can be defined as following: R= √∆𝐏/𝑄. The change in the 
pressure across the device is directly related to the inhaler resistance to airflow (R) and the 
inspiratory flow rate (Q) (Clark and Hollingworth, 1993). Therefore, the inhalation flow for a set 
inspiratory effort will be lower when the resistance inside the device is high, generally the 
inspiratory flow rate through high resistance device is lower than low resistance device (Assi and 
Chrystyn, 2000, Azouz and Chrystyn, 2012). The intrinsic resistance is usually deduced from the 
slop of the line of the √Δ𝑝 vs inhalation flow, examples of intrinsic resistance of some 
marketed DPIs are reported in Table 2.7 
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Table 2-7: The resistance of some marketed DPIs (Frijlink and De Boer, 2004)  
Inhaler  Resistance( KPa0.5.min/l)  
Spinhaler® (Aventis) 0.016 
ISF Inhaler  Cyclohaler 0.019 
Novolizer® (Viatris) 0.028 
Diskhaler (GlaxoSmithKline) 0.032 
Diskus® (GlaxoSmithKline) 0.034 
Ratiopharm® Jethaler (Ratiopharm) 0.036 
Handihaler® ( Boehringer Ingelheim) 0.042 
Turbuhaler® (AstraZeneca) 0.0367 
Inhalator® (Boehringer-Ingelheim) 0.0540 
Drug deposition in the oropharyngeal cavities can be reduced by using a mouthpiece, which 
controls the resistance of the inhaler to the airflow and the direction of the aerosol cloud in the 
mouth and throat (De Boer et al., 1997). Each DPI is unique characterised by its intrinsic 
resistance, which results in a difference in the PIF generated during the inhalation manoeuvre and 
the dose emission released from the inhaler device. The relationship between PIFs and pressure 
drop through the inhaler device (Chrystyn, 2009). The relation between the √∆𝐏  and inhalation 
flow is linear for all the inhaler devices. The slope of the line represents the intrinsic resistance of 
the device. The slope of the line is higher for high resistance devices and Vice versa. To achieve 
for example a pressure drop of 6 Cm H201/2 requires an inhalation flow of 100 L/min from an 
Aerolizer® (Low resistance device) and about 45 L/min from an Easyhaler® (High resistance 
device). The Figure 2.30 shows that all DPIs are not the same and prescribing the right inhaler is 
important to ensure that patient is comfortable using the device and more importantly can receive 
the required dose (Chrystyn, 2007, Chrystyn, 2009). 
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The difference in the DPIs devices design, geometry and dimension result in an intrinsic 
resistance to airflow through the inhalers. The intrinsic resistance of DPIs differ between devices 
due to the difference in the design (Dal Negro, 2015). There are different elements that determine 
the intrinsic resistance of DPIs including air inlet, inhalation channel and the mouthpiece of the 
inhaler. These elements lead to an increase in the kinetics energy of the airflow during the 
inhalation manoeuvre. 
 
Figure 2.30: The resistance of different DPIs (Chrystyn, 2009)  
The quality of the emitted dose from DPIs are controlled by different parameters such as 
inspiratory flow rate generated by the patient, intrinsic resistance and type of the inhaler device 
and the powder formulation (Clark and Hollingworth, 1993, Chrystyn, 2003, Chrystyn, 2007, 
Ibrahim et al., 2015). The resistance of the DPIs is an important factor in air flow restriction and 
therefore in minimising the oropharyngeal deposition of the aerosol particles  (Dolovich, 1995, 
Price and Chrystyn, 2015). The  inhaler devices were classified into 4 categories according to 
their inhalation flow requirement to achieve 4kPa pressure drop across the inhaler device as 
follow: low, medium, medium-high and high resistance inhaler (Dal Negro, 2015).  
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Lung deposition was found to be greater with a high resistance DPIs (Svartengren et al., 1995, 
Chrystyn, 2009). Thus inhaling against a high resistance device has been shown to reduce the 
oropharyngeal deposition and enhance the peripheral deposition of the drug particles due to 
reduction of inhaled particles momentum (De Boer et al., 1996, Borgström, 2001). The DPIs with 
high resistance along with greater patient airways obstruction will result in low inspiratory flow 
rate achieved by the patient (Chrystyn, 2009, Azouz et al., 2015b).  
 
Figure 2.31: Mean (SD) peak inhalation flows of asthmatic patients inhaling through different 
marketed inhalation devices MDI and DPIs (Azouz et al., 2015b) 
Since DPIs are flow rate dependent and achieving the desired flow rate is crucial for overall 
management of airway disease. Therefore the efficacy of the medication can be affected when a 
patient of acute wheeze or low lungs function fail to meet inhalation manoeuvre requirements to 
release the dose from the inhaler device (Pedersen, 1987). Not all the patient inhale through DPIs 
in the same manner due to the difference in the inhaler resistance, then DPI design and 
formulation should be suitability tailored for a wide range of patients of all age and disease 
severity. It is widely accepted that an inhalation flow rate of 30L/min through a DPI is the 
minimum threshold energy for dose emission as demonstrated with the Turbuhaler® device 
(Newman et al., 1991a, Bisgaard et al., 1998). 
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 In-vitro dose emission from DPIs 
The DPIs are known to operate due to the turbulent energy that created inside the inhaler by the 
inhalation manoeuvre. The interaction between the patient inspiratory flow rate and the specific 
resistance of the device determine the quality of the emitted dose (Clark and Hollingworth, 1993, 
Chrystyn, 2003, Al-Showair et al., 2007b). The turbulent energy increase with the inhalation flow rate 
therefore forceful and fast inhalation from the start of inhalation manoeuvre through DPI will lead to 
a much better dose de-aggregation (Laube et al., 2011, Dal Negro, 2015). Several studies have been 
conducted to show the flow dependent dose emission of different DPIs.The size distribution and 
dispersions pattern of aerosol from DPIs are dependent on the flow rate through the device. 
Formoterol emitted from an Aerolizer® was examined within the flow range of asthmatic school 
children aged 3-10 years (Nielsen et al., 1997). The results of the study show the flow 
dependency of Foradil Aerolizer® within the PIF obtained from the schoolchildren. 
 
Figure 2.32: Relationship between the Peak inspiratory flow (PIF) through Aerolizer® and age in 
126 asymptomatic, asthmatic children aged 3-10 years 
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Ross and Schultz (1996) have compared the dose delivery of three different inhaler devices 
Diskhaler®, Rotahaler® and Turbuhaler® at two MIF values of 30 and 60 L/min, the study results 
have shown that DPI dose emission was less than the labelled dose and more dependent on the 
inhalation flow (Ross and Schultz, 1996). The performance of two inhaler device MDI and DPI 
containing the same drug powder and strength was studied at different MIF values of 30, 60 and 
90 L/min. the results showed that DPI was more flow rate dependent than MDI (Feddah et al., 
2000). 
 
Figure 2.33: dose emission from a salbutamol pMDIs and Diskhaler® at different inhalation flows 
(Ross and Schultz, 1996)  
The dose de-aggregation of three DPIs namely (Turbuhaler®, Spinhaler® and Diskhaler®) have 
been shown to increase with PIF. Hence fine particle dose as a percentage of the nominal dose 
has been shown to be high 35-40% with Turbuhaler®. In contrast, the percentage of fine particle 
dose was only 10 and 23% for Spinhaler and Diskhaler respectively at 60L/min flow rate (De 
Boer et al., 1996). Furthermore, dose emission from the Accuhaler® has been shown to be 
independent to flow rate (Ashurst et al., 1998). 
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The effect of PIF and IFR on different DPIs was studied, results showed that Turbuhaler® is more 
sensitive to IFR and producing higher fine particle dose when compared to Accuhaler® and 
Cyclohaler® (De Koning, 2001). The de-aggregation of the inhaled aerosol (formoterol) was 
dependent on the PIF for both Aerolizer® and Turbuhaler®. The amount of formoterol reaching 
the alveolar is significantly increased for PIF > 28.3 L/min (Hill and Slater, 1998) suggesting 
breakage of drug aggregates to produce fine aerosol for deep lung penetration. The impaction of 
the PIF was further confirmed using gamma scintigraphy (Dolovich et al., 1988, Newman et al., 
1991a, Borgstrom et al., 1994) showing an increase of the total lung deposition with increasing 
the PIF for both terbutaline and budesonide from Turbuhaler®. The inhaled particles sizes have 
shown to be affected by the PIF, both Aerolizer® and Turbuhaler® found to have the same fine 
particle (Figure 2.34). However, Turbuhaler® shows more dose emission dependency than 
Aerolizer® (Weuthen et al., 2002). 
 
Figure 2.34: In-vitro dose emission comparison of two DPIs (Turbuhaler® and Aerolizer®) at 
different PIFRs (Weuthen et al., 2002)  
There is a required threshold for each DPIs for adequate dose dispersion and more respirable 
particle with high lung deposition (≤ 5µm) (Chrystyn, 2003, Haughney et al., 2010). Sumby et 
86 
 
al., (1992) demonstrate that low resistance device such as Diskhaler® requires an inspiratory 
flow which is half that required for high resistance device such as Turbuhaler®.  The study 
determines that inspiratory effort which is a function of pressure drop and the inhaled volume is 
more insightful than inspiratory flow when assessing patient usage of DPIs (Sumby et al., 
1992). The performance of the Foradil Aerolizer® and Oxis Turbuhaler® at high and low 
inhalation flow rates were investigated using ten doses out of the entire content. Results showed 
that the fine particle dose was equivalent at high PIF but not at low; this might be due to the 
difference in the formulation or aerosolisation mechanism (Chew and Chan, 2001).  
The flow dependent dose of combination (Formoterol and Budesonide) emitted from 
Turbuhaler® has been studied. The results showed (Figure 2.35) the effect of increasing PIF was 
more noticeable in the fine particle dose. Furthermore, dose emission was ≥  100% of the 
nominal dose at 90 L/min, comparing to less dose emitted at a flow rate of 30 and 60 L/min 
(Tarsin et al., 2004).  
 
Figure 2.35: The amount of budesonide and formoterol (% of labelled dose) from six inhalers tested 
using in-vitro inhalation flow rates 30, 60 and 90L/min (Tarsin et al., 2004) 
In a different study, within the clinical range of inhalation flows (15 to 60 L/min), the Clickhaler 
showed inhalation flows independence for adults or children above six years (Newhouse et al., 
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1999). The fast inhalation flow rate showed significant dose emission compared to slow flow rate 
from Bricanyl Turbuhaler® (500µg), suggesting Patients with low inhalation flow rate and those 
who cannot achieve a high Vin should inhale twice and as deep and hard as possible 
(Abdelrahim, 2010).  
The flow dependent dose emission property of three different DPIs was studied, as shown in 
Figure 2.36. When inhalation flows increased a significant difference in the emitted dose, and 
fine particle fraction was shown with Turbuhaler® (Palander et al., 2000). On the other hand, 
increasing the inhalation flows from 30 to 90 L/min produced less difference in the emitted dose 
and the fine particle fraction from an Easyhaler® and Accuhaler® suggesting that DPI 
performance is also inhalation device dependent  (Palander et al., 2000). 
 
Figure 2.36: Fine particle dose (% of labelled dose) for three types of salbutamol containing DPIs 
(Palander et al., 2000)  
The in-vitro study was conducted to assess the dose consistency from Salbutamol Diskus® and 
Terbutaline Turbuhaler®; the results showed that dose emitted from Diskus® was more consistent 
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throughout the device life when compared to Turbuhaler® at flow rates of 30, 60 and 90 L/min 
(Malton et al., 1995). The changes up to 6 folds in the inhalation flow rate showed no changes in 
the total emitted dose and fine particle fraction for Diskus® inhaler. Suggesting that Turbuhaler® 
is more dependent on the inhalation flow rate (Prime et al., 1995). 
In another study, most of the young patients including three years old children were able to 
achieve PIF of ≥ 30 L/min through Accuhaler®, which means 100% labelled dose would be 
received by the patients (Gunawardena et al., 1995). The Turbuhaler® and Diskus® should be 
used with caution in young children, the reason for that is the children are unable to achieve the 
required flow rate through Turbuhaler® resulting in low and variable dose emission (Bisgaard et 
al., 1994). Several studies investigated the inhalation flow through different DPIs; in some 
devices, 30L/min was not sufficient to de-aggregate the dose such as Turbuhaler® (Nadarassan et 
al., 2010). However, 30L/min was found to be sufficient to operate the Easyhaler® (Koskela et 
al., 2000) and provided a similar result to that achieved with pMDIs attached to a spacer which 
requires a flow rate < 30L/min (Newman et al., 2001).  
Newman et al., (2001) have reported that MMAD decreased with an increase in the PIF. 
Therefore, the central lung deposition can be avoided with the smaller MMAD during the fast 
inhalation flow. Novolizer® showed an increase in the lung deposition with the flow rate, but no 
improvement in the penetration index. Abdelrahim et al., (2013) showed Turbuhaler® flow rate 
dependency, whereas TED and FPD have improved significantly with the increase in the flow 
rate over the range of (10-60 L/min). The more effect was seen at a flow rate of 30 L/min 
suggesting that pharmacopoeia should consider more flow rates than the one corresponds to 4kPa 
pressure drop through the inhaler (Abdelrahim et al., 2013). 
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The effect of the Vin on the dose emitted from three DPIs Autohaler®, Accuhaler® and 
Turbuhaler® have been investigated using Andersen cascade impactor with different inhaled 
volumes (Vins) 0.15, 0.5 and 1L (Kamin et al., 2002). The results showed that the change in the 
Vin showed no effect on the MMAD of the particles that were emitted from the Turbuhaler®; 
nevertheless, changing the Vin had a significant effect on the mass output. Furthermore, the 
Turbuhaler® showed a high variation in the fine particle fraction, with 3.4% to 22.1% of the 
labelled dose, but less effect was observed with Accuhaler® 10.6% to 18.5 % of the labelled dose. 
The Autohaler® showed more constant output and a high fine particle fraction of 43.1% to 56.6% 
of the labelled dose. 
 
Figure 2.37: Fine particle mass for three different types of DPIs (Kamin et al., 2002)  
The study showed that not only does inhalation flow affect the mass output and particle size 
distribution of the aerosol emitted dose, but there are other factors that have an impact on the 
dose emission from the DPIs such as ACIM and Vin (Kamin et al., 2002).  
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Recently, modifications of the in-vitro and in-vivo methodologies were introduced to obtain more 
accurate results that represent the real life use of the patients. In these methods, various inhalation 
flow rates and volumes were used instead of using pharmacopoeia recommendations for DPIs 
performance testing. For example, the use of in-vivo recorded profiles in the laboratory to 
determine the fine particle dose using breath simulator to mimic patient real life use. Patients 
were unable to replicate vacuum pump square wave profile (Azouz et al., 2015b). 
The technique was used to record the IPs of asthmatic children aged 4-8 years when these 
patients inhaled through two DPIs namely Accuhaler® and Turbuhaler®. The fine particle mass of 
fluticasone propionate from the Diskus® was compared with Turbuhaler® in delivering 
budesonide fine particles in children with asthma (Bisgaard et al., 1998). 
 
Figure 2.38: Fine particles mass (% of labelled dose) obtained from Turbuhaler®; the Diskus® using 
inhalation profile for four and eight year’s children (Bisgaard et al., 1998)  
The results showed that the emitted dose was 87-89% and 56-62% of the labelled dose for 
Diskus® and Turbuhaler®, respectively. Conversely, a lower fine particle dose was emitted from 
the Diskus® ranging from 15-18%, whilst, a fine particle dose emitted from the Turbuhaler® 
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found to be 21-23%. The Diskus® has shown more dose consistency, and both devices showed a 
flow rate dependent dose emission. Surprisingly the study found that aerosol cloud was released 
before even achieving the peak inspiratory flow. 
Tarsin et al., (2006) have also studied the performance of Accuhaler® Seretide (Fluticasone 
Propionate and Salmeterol) and Turbuhaler® (Budesonide and Formoterol) dose emission 
characteristics using recorded IPs of twenty severe asthmatic patients using an Electronic 
LungTM. The study demonstrated the less flow rate effect on the dose emission from Diskus® 
compared to more pronounced flow dependent dose emission from Turbuhaler®. In addition, a 
reverse trend was observed between the flow rate and the MMAD of the inhaled particles from 
both devices (Tarsin et al., 2006). 
 
Figure 2.39: The FPD (% nominal dose) and MMAD (µm) of (a). Turbuhaler® and (b) Accuhaler® 
versus the peak inhalation flow rate (Tarsin et al., 2006)  
Nadarassan et al., (2010), adapted the traditional method for in-vitro dose emission 
characteristics. The introduction of mixing inlet allowed dose emission characteristics to be 
measured at flow rates below 28.3L/min as shown in Figure 2.40. The mixing inlet was aimed to 
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extrapolate the required flow rate from the ACI constant flow. The flow rate set at the 
mouthpiece was the desired flow, while constant flow rate as recommended by the ACI 
manufacturer was pass through the stages. The compressed air role was to introduce the 
supplementary air from the mixing inlet side port. They have used this method to study the dose 
emission characteristics of Turbuhaler® using a range of inhalation flow rate ranging from 5-60 
L/min at the mouthpiece and 4L Vin; the ACI assembled to be operated at 60 L/min. The results 
showed that dose emission from Turbuhaler® is more flow rate dependent with flow rate above 
30 L/min, suggesting flow rate below 30L/min was not enough to efficiently de-aggregate the 
dose. Furthermore, the result of MMAD showed the steepest decrease with flow rates above 30 
L/min (Nadarassan et al., 2010).  
 
Figure 2.40: Schematic diagram of the ACI-mixing inlet method (Nadarassan et al., 2010) 
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Yakubu et al., (2013) have used the method mentioned above to assess dose emission 
aerodynamic characteristics from four inhalers (Accuhaler®, Easyhaler®, Clickhaler® and the 
Turbuhaler®) aerodynamic dose emission characteristics at different inhalation flow rates (10-60 
L/min) and two Vins 2 and 4 L. The outcome of this study showed that flow rate dose emission 
dependency for all assessed inhalers (Yakubu et al., 2013). However, no significant difference in 
the dose emission characteristics was observed when inhaled volume increased from 2 to 4 L. 
Suggesting that the use of flow rate equivalent to 4 kPa pressure drop should be revised, and also 
4 L Vin required by the pharmacopoeia should be replaced by the use of 2 L Vin since no 
difference in dose emission was shown by increasing the inhaled volume from 2 to 4 L. 
The method developed by Nadarassan et al., (2010) was modified afterwards to compensate the 
flow from the vacuum pump with a supplementary air flow introduced by the mean of mixing inlet 
(Olsson et al., 2013, Chrystyn et al., 2015). This method allows airflow of 0 L/min to be achieved 
at the mouthpiece and a constant flow through the ACI (e.g., 60 or 90 L/min). The dose emission 
from the device as an inhalation profile is replayed by using the breath simulator (Copley 
scientific Ltd, UK). This method is a more realistic approach to represent the dose patient would 
receive in real life use.  
Olsson et al., (2013) have used aforementioned ex-vivo methodology by replacing the compendial 
square waved profiles by patients’ IP. Figure 2.41 demonstrates the experiment set-up, where the 
impactor was set 80L/min flow rate the complementary air was then opened, and flow was 
adjusted to 0 L/min at the mouthpiece. After that, the breath program generated (BPG) is being 
connected to the piston of the electronic lungs. Flow through the inhaler that is equivalent to the 
IP occurs as a result of piston movement. The compressed air was used to compensate the 
remaining airflow to keep the flow constant.  
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Figure 2.41: Demonstrate the method set-up by Olsson et al., 2013; whereas (A) inhaler with no flow 
(B) flow generated through the inhaler using BPG system (Olsson et al., 2013)  
 Chapman et al. (2011) and Colthorpe et al. (2013)  have used the similar ex-vivo methodology, 
but instead of using electronic lungs the  Next Generation Impactor (NGI) was coupled with flow 
volume simulator as shown in Figure 2.42. Supplementary air flow of 100 L/min was provided 
through the side arm of the mixing inlet in order to equalise the constant vacuum pump flow 
through the impactor. Therefore, during the experiment, a flow of 0 L/min was kept at the 
mouthpiece of the impactor. Patient profiles were reproduced at the mouthpiece by modulating 
the air flow using flow –volume simulator(Chapman et al., 2011, Colthorpe et al., 2013).  
Chapman et al. (2011) assessed the aerodynamic dose emission characteristics of Breezhaler® 
(Indacaterol) and Handihaler® (tiotropium). The results showed that fine particle fraction (FPF) 
was higher with Breezhaler® than Handihaler® 27% and 10% respectively. The Handihaler® 
showed a higher oropharyngeal deposition than Breezhaler®. Furthermore, the patients were able 
to use both devices correctly after seven days and showed more preference using the Breezhaler®. 
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Figure 2.42: Schematic diagram of experimental set-up with flow-volume simulator  
Colthorpe et al. (2013) used the same methodology to investigate the performance of Breezhaler® 
(Glycopyrronium) and Handihaler® (tiotropium) capsule-based devices. The results showed that 
low resistance device Breezhaler® provided higher FPF and emitted dose with greater consistency 
compared to the Handihaler®. Therefore, it might be useful for COPD patient with different 
severity to use Breezhaler®. Furthermore, Zanker et al., (2013) have used the COPD patients’ IP 
to assess the performance of Breezhaler in delivering dose glycopyrronium dose. The study 
results demonstrate that over the range of the IPs used dose emission showed high consistency, 
additionally inter and intra-thoracic dose deposition consistency(Zanker et al., 2013).  
A similar principle was adapted by Chrystyn et al. (2015) to investigate the effect of COPD 
patients’ IPs and throat geometry on the dose emitted from Spiromax® and Turbuhaler®. Three 
categories of patient profiles were selected (weak, medium and strong) based on the inspiratory 
flow achieved by the patients. Furthermore, three sizes of throat were used. The results showed 
that Spiromax® produces higher dose consistency and higher fine particle dose (FPD) than 
Turbuhaler for all the profiles used. 
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Buttini et al. (2016) have also adapted the method to study the effect of patients’ IPs and the 
throat change on the in-vitro inhalation performance of two DPIs (NEXThaler®, Cheisi 
Pharmaceutics S.p.A., Parma, Italy) and (RS01, Plastiape, Lecco, Italy). The results showed that 
NEXThaler® produced high fine particle dose of the formulation containing Formoterol fumarate 
and Budesonide dipropionate for all the IPs used despite the change in the parameters (PIF, Vin 
and ACIM). Contrarily, capsule based inhaler required a higher inspiratory volume, whereas the 
fine particle mass of the two drugs was decreased significantly when low volume IP used. The 
study was analysed using multivariate analysis to predict the system performance ((Buttini et al., 
2016a). 
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 Summary 
The DPIs flow rate dose emission dependency in-vitro have been studied over the years using the 
inhalation flow produced by the vacuum pump which does not reflect the routine use of the 
inhaler devices. The square wave profile achieved by the pump is not realistic, and patients 
cannot replicate this profile in real life. Several in-vivo studies showed that most of the patient 
with asthma and COPD were unable to achieve flow (4 kPa) and volume (4 L) suggested by for 
in-vitro dose emission testing of DPIs. Instead, using a range of the MIFs and Vins to test the 
DPIs will be useful to determine the optimum condition of using each DPI. The square profile is 
not reflecting the inhalation manoeuvre parameters correctly (MIF, Vin and ACIM) especially 
acceleration rate ACIM]. Therefore the IPs use is so important to determine the effect of each 
parameter on the dose emission from DPIs. Additionally, to determine the limit of inhalation 
manoeuvre condition below which dose de-aggregation is not complete and less dose of 
medication to be released from the inhaler device. Recently, breath simulator and other 
instruments were developed in order to enable the use of IPs instead of square wave profiles. The 
breath simulator (BRS) introduction brought a new prospect to study the dose emission 
uniformity as well as aerodynamic dose emission characteristics. It can be coupled with either 
Andersen cascade impactor (ACI) or next generation impactor (NGI) using mixing inlet side arm. 
Mixing inlet enables supplementary air to be introduced and therefore flow rate of 0 L/min at the 
impactor mouthpiece is achieved. Several studies have used this ex-vivo methodology to 
determine the dose emission characteristics from different DPIs. 
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 Material  
3.1.1 General apparatus and materials: 
o Analytical weight  balance (Mettler Toledo, Leicester, UK)  
o pH meter (Jenway, UK) 
o Ultrawave U300 benchtop bath (Ultrawave Scientific Laboratory Supplies Ltd, UK)  
o Glass Pasteur pipettes (Fisher Scientific, UK)  
o ParafilmM  (Fisher Scientific Ltd, UK) 
o Hot plate and Magnetic stirrer (Cole-Parmer®, UK) 
o Luer-slip plastic syringes 1 ml (Thermo Scientific, UK) 
o 17 mm syringe filter Nylon 0.45 µm (Thermo Scientific, UK) 
o HPLC 2mL amber vials (Thermo Scientific, UK) 
o Glass volumetric flasks different volumes  (Fisher Scientific Ltd, UK) 
o Petri dishes ( Fisher Scientific Ltd, UK) 
3.1.2 Dose emission measurement Apparatus and material: 
 Dose unit sampling apparatus  for DPIs (DUSA; Copley Scientific Ltd, UK) 
 47mm glass fibre filter (Whatman, UK) 
 High capacity pump HCP5 (Copley Scientific Ltd, UK) 
 Critical flow controller TPK2000 (Copley Scientific Ltd, UK) 
 Digital flow meter 2000 (Copley Scientific Ltd, UK) 
 Inhaler devices ( Foradil Aerolizer®, Onbrez Breezhaler® and Easyhaler®) 
 Mouthpiece Adapter for (Aerolizer® , Breezhaler® and Easyhaler®)   
3.1.3 Aerodynamic dose emission characteristics material and apparatus  
 Onbrez Breezhaler® Mouthpiece Adapter for Alberta's throat 
 Inhaler device ( Onbrez Breezhaler®) 
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 Idealised Alberta throat (IAT) (Copley Scientific, UK) 
 Mixing Inlet (MI) (Copley Scientific, UK) 
 Andersen Cascade Impactor (ACI) (Copley Scientific, UK) 
 High capacity vacuum pump (HCP) (Copley Scientific, UK) 
 Critical Flow controller, TPK 2000 (Copley Scientific, UK) 
 Breathing Simulator, BRS3000 (Copley Scientific, UK) 
 Compressed air cylinder ( Thermo Scientific, UK) 
 Glass microfiber filter papers 82.6 mm (Whatman™, UK) 
 Pro-power silicone lubricant  (Premier Farnell plc, UK ) 
 Digital flow meter 2000 (Copley Scientific Ltd, UK) 
 Copley Inhaler Testing Data Analysis Software (CITDAS) version 2.00 (Copley 
Scientific, UK) 
3.1.4 Laboratory apparatus 
 Dose unit sampling apparatus (DUSA) 
DUSA for dose emission testing of DPIs is shown in Figure 3.1. It consists of the collection 
tube, two rinsing caps, one filter support base and metal ports to connect the DUSA to the 
critical flow controller during the experimental set-up at one end, while the other end forms a 
mouthpiece adapter to attach the DPIs. The collection tube was fitted with 25mm glass fibre 
filter to increase the aerosol retention upon aerosolisation, which enhances particle retention 
down to 0.3 microns. The volume of the collection tube is 500 mL which approximates the 
volume of the human oropharynx (Copley, 2015).  
Over the years, DUSA is used to measure the dose emission uniformity as well as the 
consistency of the dose emitted from both MDI and DPIs. Additionally, it is widely used to 
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determine the intra and inter-device variability (Hindle and Byron, 1993, Byron, 1994, Hindle 
and Byron, 1995).  
 
Figure 3.1: Dose unit sampling apparatus (DUSA) components for DPIs testing  
The DUSA collection tube has a pressure tap (P1) which is connected to the critical flow 
controller and allow device resistance measurements during the experiment. The filter 
attached to the collecting tube allows dose collection with high precision at a high flow rate 
(100 L/min).  Figure 3.2 show procedure of achieving stable high flow rate (120L/min) when 
two HCP-5 connected in series (Copley, 2015). 
 
Figure 3.2: Schematic diagram of series connection of vacuum pumps (Copley, 2015)  
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 Andersen Cascade Impactor (ACI) 
Andersen cascade impactor (ACI) consists of an induction port, pre-separator and eight stages 
stacked in series. Each stage has different number and size of holes drilled precisely, 
underneath each stage is a collecting plate designed to collect the aerosolised dose 
corresponding to a different aerodynamic particle size of the inhaled particles. The last stage 
is known as the filter stage which collects the very fine particles as shown in Figure 3.3 (EP, 
2013, USP, 2014, Copley, 2015). The ACI is widely used to determine the aerodynamic 
characteristics of the aerosol dose emitted from different inhaler devices (Copley, 2008). It 
provides useful data about the emitted dose, fine particle dose and mass fraction to assess the 
performance of inhaled aerosol. The aerodynamic characteristics of the emitted dose 
determined by ACI will provide detailed information about both the dose emitted from the 
device as well as the dose that has the potential to reach the lungs (Chrystyn, 2003, Mitchell 
et al., 2007). 
 
Figure 3.3: Andersen cascade impactor (ACI) set-up for (A) MDI (B) DPI (Copley, 2015)  
The particles less than 10 µm in size aerosolised from the device into the ACI will be 
measured accurately. Each stage of the ACI is specified with a cut-off diameter corresponding 
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to certain particle size, particle within this size will deposit into the collection plates, while 
particles below that size will pass through to the next stage. After the aerosolisation of the 
dose, deposited particles on each of the collection plates are recovered, and the quantity of the 
drug deposited is analysed using an appropriate validated analysing method (Copley, 2008). 
The stages hole diameter is decreased in descending order. Consequently, the air velocity 
increases as the particles travel through the ACI. Initially, ACI was calibrated to operate at a 
flow rate of 28.3L/min, and then modification was introduced to enable the ACI to work at 
high flow rates such as 60 and 90 L/min. The stages cut-off diameter (µm) at different flow 
rates are shown in Table 3.1. At 60 L/min, two stages 0 and 7 are replaced with stages -1 and -
0, while at 90 L/min three stages 0, 6 and 7 are replaced with stages -2, -1 and -0. The 
changes are also made to collection plates (plates with a centre hole) (Copley, 2015). 
Table 3-1: The cut-off diameter (µm) and stages configuration of ACI at different MIFs  
Cut-off diameter 
(µm) 
28.3 L/min 60 L/min 90 L/min 
*Stage -2 …………… …………. 8.0 
*Stage -1 …………….. 8.6 6.5 
*Stage -0  6.5 5.2 
*Stage 0 9.0 ……….. …….. 
*Stage 1 5.8 4.4 3.5 
Stage 2 4.7 3.2 2.6 
Stage 3 3.3 1.9 1.7 
Stage 4 2.1 1.2 1.0 
Stage 5 1.1 0.55 0.22 
Stage 6 0.7 0.26 ………. 
Stage 7 0.4 ………… ……….. 
*= Stages with collection plate that has a centre hole (Holo plates). 
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The ACI configuration can be adjusted to work at flow rates below 28.3L/min and above 90 
L/min using the equation Eq. 3.1 (Van Oort, 1995):  
 
𝐄𝐂𝐃𝐅𝟐 = 𝐄𝐂𝐃 𝟐𝟖. 𝟑 (𝟐𝟖. 𝟑/𝐅𝟐)𝟎.𝟓 Eq. 3.1 
                                
Where; 
ECDF2 = is the effective cut-off diameter at another flow rate,  
ECD28.3 = is the effective cut-off diameter at standard flow rate of 28.3 L/min  
F2 = is the other flow rate in L/min 
Although laser diffraction was introduced to provide a quick assessment of the inhaled 
aerosol, this technique is limited to the measurement of the geometric of the inhaled aerosol 
but not the aerodynamic diameter. Inertial impaction techniques such as Twin stage impinger 
(TSI) and multi-stage liquid impactor (MSLI) provide an assessment of the aerodynamic 
characteristics of the inhaled aerosol with less detailed information due to the fewer stages 
(Zeng et al., 2006).  
ACI is widely used as it provides more detailed information regarding the quality of inhaled 
product by simulating the aerodynamic particle distribution in different regions of the 
respiratory tract (Figure 3.4), in addition to a forecasting on the dose the patient will receive 
when using the inhaler device  (Dunbar and Mitchell, 2005, Mitchell et al., 2007). The multi 
stages composition of the ACI enable the differentiation between the API and other 
components in the formulation and it measures the whole dose and not only part of it which 
allows complete characterisation (Copley, 2008).  
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Figure 3.4: Description of regional lung deposition (Dunbar and Mitchell, 2005)  
The experimental procedure of using ACI can be explained as follow: The inhaler under test 
is connected to the ACI by the means of a mouthpiece adapter; the latter plays an important 
role ensuring no air leaking between the device and the ACI during the test. Then, the stages 
of the ACI are stacked accordingly in descending order according to the stages hole size. The 
ACI is operated by the impaction mechanism, upon the aerosolisation; the dose will be drawn 
through the impactor by the mean of a high capacity vacuum pump (HCP) which is connected 
to the outlet of the ACI. Therefore, the particles deposition on each stage is governed by their 
inertia. The nozzles or jets play a role in directing the air as well as the airborne particles into 
the collection plate (Copley, 2008, Copley, 2015). According to the particles inertia, a particle 
with sufficient inertia will influence the specific stage plate, while particles which are smaller 
or having insufficient inertia will carry on with the air stream and travel to the next stage. This 
mechanism is continuous until the very fine particles reach the filter stage of the impactor the 
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mechanism is illustrated in Figure 3.5. The ACI measurement accuracy of emitted dose from 
either DPIs or MDIs can be affected by the particle bouncing back into the air stream when 
they hit the collection plates and travel to next stage (Copley, 2008). This drawback can be 
overcome by introducing a washing solution in the pre-separator when testing DPIs and pre-
coating the surface of the ACI collection plates with a media that provides a tacky surface to 
minimise particle bounce and re-entrainment (Table 3.2). There is no standard approach in 
terms of either material used or method of applying the coating. Standardisation is 
unnecessary since each research group has independently selected and validated their 
procedure with their own formulations (Allen, 1990).  
The particle loss in the stages part which is known as the ‘‘inter-stage loss’’ is not a major 
drawback of ACI use as it remains low compared to the recovery dose from the impactor.  
Some studies reveal that only 5% is the inter-stage loss in most of the cases (CDER, 1998, 
Byron et al., 2004, Kamiya et al., 2009). 
  
Figure 3.5: Principle of Andersen cascade impactor operation (USP, 2014)  
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Table 3-2: Coating materials and procedures used by European pharmaceutical aerosol group 
EPAG member organisation (Mitchell, 2003) 
EPAG 
Member 
Impactor Inhaler Surface Coating material Procedure 
1 ACI pMDIs 
Stainless 
steel 
Ethanolic solution of 
Brij35(polyoxyethyle
nelaurylether) is 
mixed with glycerol 
Dip plate into coating 
solution, leave in a 
fume hood to allow 
solvent to evaporate 
before assembly of 
impactor 
2 ACI DPI 
Stainless 
steel 
11% polypropylene 
glycol in Hexane 
Submerge plate, 
remove plate allowing 
the bulk to drain off, 
then air dry 
3 
ACI, 
NGI 
DPI 
Stainless 
steel 
A solution of Brij, 
glycerol and ethanol 
(ethanol evaporates 
after applying, before 
analysis) 
Apply the standard 
amount of coating 
material (thin) evenly 
(in practice done with a 
sponge). 
4 ACI 
pMDIs
, DPI 
Stainless 
steel or 
aluminium 
alloy 
Glycerol or Brij 35. 
Applied only if 
required 
Apply a standard 
quantity of solution to 
give a thin film of 
coating substance on 
each plate. 
5 ACI 
pMDIs
, DPI 
Stainless 
steel 
1 ml of Brij 35 in 20 
ml ethanol dissolved 
in 5 g glycerol 
Distribute 50 µl per 
plate For DPI, 
distribute 100 µl in pre-
separator 
6 
ACI, 
NGI 
DPI 
Stainless 
steel 
n-hexane + 1% of 
SPAN 85 (sorbitan 
trioleate) 
Immerse each plate in a 
crystalizer containing 
the coating material. 
Allow 0.5 hr for solvent 
evaporation in a fume 
hood before assembly 
of impactor 
7 
ACI, 
NGI 
pMDIs
, DPI 
Stainless 
steel 
1% w/v silicone oil in 
hexane 
Dip plates in solution 
and allow hexane to 
evaporate prior to 
assembly of impactor 
8 
ACI, 
NGI 
DPI Inox Glycerine 
Coat with a thin layer 
of glycerine 
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 Breath Simulator (BRS) 
The breath simulator instrument was firstly introduced for testing the nebulisers with a 
maximum Vin of 1 L. In 2012, the breath simulator BRS 3000 was designed and launched to 
test the inhaler devices with a wider specification. Whereas an inhalation flow of up to 
240L/min can be achieved, an acceleration rate of 25 L/s2 and the capacity of the inhaled 
volume for testing was increased up to 5 L (Copley Scientific, 2015). The last version BRS 
3000 is able to obtain a flow rate, volume and acceleration rate to test the inhaler devices such 
as DPIs and MDIs with more realistic approach to mimic the patient inhalation and exhalation 
pattern. Furthermore, it enables the testing of spacers, nebulisers and valve holding chambers. 
The BRS replays the in-vivo profiles that have been recorded from the patient with COPD and 
asthma, thereby providing an insight into the dose that the patient would inhale in routine use 
of the inhaler device. The BRS can also be used to generate either dose uniformity data using 
DUSA or aerodynamic particle size distribution data using ACI. 
The compendial method of testing the inhalers using the vacuum pump clearly does not 
reflect the capabilities of a typical patient. The applied inhalation profile is a square wave 
taking the flow rate from 0 L/min to a pre-determined constant value (X L/min) for short 
duration of time and then back to 0 L/min. This profile is by no mean achievable by healthy 
subject never mind an asthmatic patient (Copley, 2015).  
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 High performance liquid chromatography  
3.2.1 HPLC Overview  
High performance liquid chromatography is one of the chromatography types, which is highly 
used in the pharmaceutical field to separate a mixture of different components. It is also used 
in the others fields such as analytical chemistry and biochemical for the purification and the 
identification of a compound in a mixture (Snyder et al., 2012, Bhardwaj  et al., 2015).  
 
Figure 3.6: Schematic diagram of High performance liquid chromatography instrumentation 
presenting the main components (Bhardwaj  et al., 2015)  
 
It is a qualitative and quantitative technique, the mode of the system operation differ 
according to the solubility and the polarity of the compound as well as the polarity of the 
aqueous phase and the stationary phase. The principle of the compound separation depends on 
the affinity or the partitioning of the compound between the mobile phase and stationary 
phase. In different words,   like attract the like which determine the speed the compound 
elution time. Therefore different compounds can be separated (McPolin, 2009a). The HPLC 
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types differ according to the polarity of the phase system used for the separation. The most 
common types are the normal phase and reversed phase (Table 3.3). 
Table 3-3: The normal and reversed phase mode of HPLC (Snyder et al., 2012).  
Normal phase HPLC Reversed phase HPLC 
 Non-polar mobile phase  Polar mobile phase 
 Hydrophilic silica particles in the 
solid phase 
 Hydrophobic hydrocarbon chain in 
the solid phase 
 Hydrophobic molecules elute first  Hydrophilic molecules elute first 
 Less common  Most common 
 Elution most to least hydrophobic  Elution least to most hydrophobic 
 
 In the RP-HPLC, the non-polar molecules form an attraction to the hydrocarbon chain of the 
silica in the column due to Van der Waals force. These compounds are less soluble in the 
mobile phase. Therefore, the elution time will be longer compared to more polar compounds 
(Watson, 2015). The polar compounds are more soluble in the mobile phase and spend less 
time in the column, and tend to elute with the solvent of the mobile phase (McPolin, 2009b). 
The mobile phase for RP-HPLC consists of the aqueous solution, and organic modifier, the 
most commonly used aqueous solutions are water and buffer salts. The organic modifiers used 
in the mobile phase composition are acetonitrile, methanol and tetrahydrofuran. However the 
most common used are acetonitrile and methanol, and both solvents have many advantages 
such as water miscibility, availability, safety and compatibility with HPLC (Aguilar, 2004). 
In RP-HPLC   peak tailing resulting from the interaction of the unbonded silanol group (Si-
OH) which is exposed on the surface of the silica in the column with the sample. This 
interaction is more strong with basic compounds that contain an amine group (positive 
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charge). The interaction can be explained as the positive- negative interaction between the 
sample and the silica (Snyder et al., 1997, Dolan, 2003). The problem of peak tailing can be 
fixed by adopting different strategies depending on the extent of peak tailing. Firstly, it can be 
fixed by using a buffer solution in a certain range (depending on the compound of interest 
PKa) to minimise the interaction between the compound of interest and the silica. Secondly, 
the use of low pH is an important solution to reduce the peak tailing. For example, at pH 3 in 
the separation of formoterol fumarate using phosphate buffer, silanol group were protonated, 
and peak tailing was minimised. Furthermore, the use of a pH lower or higher than the pKa of 
the compound has also been effective. Thirdly, the use of a surfactant such as sodium dodecyl 
sulphate SDS or a competing base such as Triethylamine (TEA) to reduce the interaction of 
silanol group with a compound of interest (Dolan, 2003, McPolin, 2009b).  
In this thesis, two HPLC methods were used to quantify recovered samples of formoterol and 
indacaterol after aerosolisation into DUSA and ACI. The formoterol peak initially was not 
symmetrical, and peak tailing, as well as broadening, was observed. The peak tailing problem 
with formoterol fumarate was solved by combining all the above mentioned solutions 
together. The mobile phase of the HPLC method used for the quantification of formoterol was 
phosphate buffer with TEA, and the latter was adjusted to pH 3. The indacaterol peak was 
better than formtoerol peak therefore the addition of TEA was unnecessary.  The column used 
in the separation of formoterol fumarate was phenomenex, Luna C18 (Sigma Aldrich Ltd, 
UK), which provides a very good peak shape with optimum pressure. It was the column of 
choice for the separation of the basic compounds 
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3.2.2  HPLC Apparatus  
The HPLC system used for samples quantification was Prominence liquid chromatography 
LC-20 AT (Shimadzu, UK). The specifications of the system component are as follow  
 Pump: LC-20AT prominence pump. Oven: column oven (CT0-10AS VP )  
 Autosampler: Prominence Auto Sampler (SIL-20A HT) fitted with a 200 μL loop 
(Shimadzu Ltd, UK)  
 Degasser: Prominence degasser (DGU-20A5) (Shimadzu Ltd, UK)  
 Detector: SPD-20A prominence UV-vis detector (Shimadzu Ltd, UK)  
3.2.3 Materials  
 Laboratory apparatus and Solvents for HPLC   
 Nylon filter membranes pore size 0.45 μm (Sigma Aldrich, Ltd, UK)  
 Filtration Apparatus for Mobile phase (Supelco® .Sigma Aldrich, Ltd, UK)  
 Ultra-purified  water apparatus  (Thermo Scientific Ltd, UK)  
 HPLC vials with screw caps made from borosilicate glass/PE pre-fitted with 
rubber/PTFE liner amber 2 mL (Fisher Scientific Ltd, UK )  
 Acetonitrile and HPLC HPLC grade ( Fisher Scientific Ltd, UK) 
 Ultra purified water (Barnstead™ Nanopure™, Thermo Scientific Ltd, UK) 
 Glass Pasteur Pipettes (Fisher Scientific Ltd, UK) 
 Glassware: Volumetric Flasks  and Beakers (Fisher Scientific Ltd, UK) 
 Buffer and salt additives  
 Potassium dihydrogen orthophosphate ( Fisher Scientific Ltd, UK) 
 Disodium hydrogen orthophosphate ( Fisher Scientific Ltd, UK) 
 Orthophosphoric acid ( Fisher Scientific Ltd, UK) 
 Triethylamine (TEA) ( Fisher Scientific Ltd, UK) 
 Pharmaceutical standard compounds 
 Formoterol fumarate dihydrate and Dexamethasone  (Sigma Aldrich Ltd, UK) 
 Indacaterol maleate (MedChem, USA) 
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3.2.4 HPLC method for the determination of Formoterol  
The formoterol HPLC method developed by (Assi et al., 2006)  was adjusted and optimised to 
be used in this thesis for the quantification of formoterol. The pump flow rate was reduced 
from 1.5 mL/min to 0.7 mL/min and peak tailing was reduced by the addition of TEA. The 
optimised chromatographic conditions used are illustrated in Table 3.4  
Table 3-4: The chromatographic condition of the RP-HPLC method used for Formoterol. 
Stationary phase 
(Column) 
Phenomenex, Luna 250 mm x 4,6 mm, 5 µm (Phenomenex, UK) 
 
Mobile phase  Acetonitrile: Buffer (60:40% v/v)  
 
The Buffer used was 5mM Disodium Hydrogen Orthophosphate with 
1% TEA, adjusted to PH 3.00 using Orthophosphoric acid. Then, the 
buffer was filtered using 0.45µm membrane filter.   
Internal standard  400 ng/mL Dexamethasone 
Flow rate  0.7 ml/min 
Injection volume 10 µl 
Wavelength  214 nm 
Temperature  30oC 
Run time 7 minutes 
Measurement  Formoterol and Dexamethasone peak area 
 
Figure 3.7: A typical chromatogram of formoterol (200 ng/mL) and dexamethasone (400ng/mL) 
114 
 
 Method Validation 
3.2.4.1.1 Calibration (Linearity)  
The calibration curve of Formoterol was prepared using six points over the range (50-800 
ng/mL). The samples were from the stock solution using mobile phase solution proportion 
60:40 % (v/v) Acetonitrile: Water. The standard formoterol samples were injected three times 
on 3 different days. The average peak area was plotted against the nominal concentration (x) 
of the calibration standards. A straight line was fitted to the data using linear regression. A 
representative plot, described by the equation y = 107.8x - 1478.3 (R2 =0.99), was obtained as 
shown in Figure 3.8.The detector response was found to be linear over the concentration 
range used with a correlation coefficient of ≥ 0.99. Dexamethasone 400 ng/mL was used as 
internal standard. The method was linear over the range of the concentrations used. The 
amount of the formoterol in the second emitted dose is expected to be low therefore; the 
calibration curve was plotted using a low concentration of 50 ng/mL formoterol standard. 
 
Figure 3.8: Calibration curve of formoterol at 214nm (n=3).  
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3.2.4.1.2 Precision  
According to ICH and FDA guidelines, precision is the closeness of agreement; in other 
words, the degree of the scatter between a series of individual measurements is obtained from 
multiple sampling of the same homogeneous sample under the prescribed condition (ICH, 
1994, Guideline, 2005). 
The precision of the method was determined by analysing three concentrations of Formoterol 
fumarate (low 100 ng/mL, medium 400 ng/mL and high 800 ng/ml) on 3 different days in 
triplicate to determine both the intra-day and inter-day variation. The Intra-day and inter-day 
variations expressed as the coefficient of variation (% CV) which was calculated by the ratio 
of standard deviation to the mean. The results of intra-day and intra-day variations of 
formoterol fumarate are shown in Table 3.5.  
Table 3-5: Intra-day and inter-day precision of formoterol [n=3].  
Nominal Concentration 
of Formoterol (ng/ml) 
Intra-day %CV Inter-day %CV 
100 0.61 0.94 
400 0.56 0.78 
800 0.24 0.89 
 
3.2.4.1.3 Accuracy  
The accuracy of an analytical method describes the closeness of the test result obtained by the 
method to the true value (concentration of the analyte). Accuracy is determined by a replicate 
analysis of a sample containing a known amount of the analyte and should be measured using 
a minimum of three determinations. A minimum of three concentrations in the range of the 
expected concentration is recommended (ICH, 1994). The accuracy was calculated as the 
percentage ratio of the measured concentration (obtained from the linear regression line over 
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the concentration range investigated) to the nominal concentration. The results of formoterol 
accuracy are shown in Table 3.6. 
Table 3-6: Intra-day and inter-day accuracy results of Formoterol [n=3].  
 
3.2.5 HPLC method for the determination of Indacaterol  
The chromatographic condition of the indacaterol HPLC method is reported in Table 3.7. The 
method was developed using HPLC method development strategies reported by Koerner et 
al., 2013. 
Table 3-7: Chromatographic condition of RP-HPLC method used for Indacaterol  
Stationary phase 
(Column) 
Phenomenex, Luna 250 mm x 4,6 mm, 5µm (Phenomenex, UK) 
 
Mobile phase  Methanol: Buffer (60:40%v/v)  
 
The Buffer used was 25 mM potassium dihydrogen Orthophosphate 
adjusted to pH 2.50 using Orthophosphoric acid. Then, the buffer was 
filtered using 0.45 µm membrane filter.   
Internal standard  1µg/mL Dexamethasone 
Flow rate  1 ml/min 
Injection volume 20 µl 
Wavelength  259 nm 
Temperature  40oC 
Run time 12 minutes 
Measurement  Indacaterol and Dexamethasone peak area 
Nominal concentration 
(ng/ml) 
Mean (SD) of 
Measured concentration 
Mean (SD) % to nominal 
concentration  
 Intra-day Variation Intra-day Variation 
100 101.7 (1.87) 101.7 (1.87) 
400 402.9 (2.27) 100.7 (0.56) 
800 795.3 (1.1) 99.4 (0.14) 
 Inter-day Variation Inter-day Variation 
100 103.6 (1.7) 103.6 (1.7) 
400 393.5  (10.2) 98.4  (2.55) 
800 796.8 (16.4) 99.6 (2.05) 
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Figure 3.9: A typical chromatogram of indacaterol (2.5 µg/ mL) and dexamethasone (1µg/ mL) 
 
 Method development  
The method development was firstly started with a general HPLC method using water: 
acetonitrile, then Acetonitrile was changed with Methanol because indacaterol was found be 
more soluble in methanol and gave a good absorbance intensity when compared with 
Acetonitrile (El-Sherbiny et al., 2015). Two different columns were used during the 
development of this method C18, RP-Luna 250×4.6 i.d (5µm particle size) and  RP- Kinetex 
250mm × 4.6mm i.d (5µm particle size) (phenomenex, UK). RP-Kinetex column gives high-
resolution peaks with shorter elution time compared to RP-Luna. Three different aqueous 
mobile phases were used, firstly water was adjusted to pH 2.5 using formic acid the peaks 
were eluted early within the column’s dead volume, then hexane sulfonic acid was used 
instead of water (formic acid), but the resolution between indacaterol peak and internal 
standard was not good. Afterwards, potassium hydrogen phosphate buffer adjusted to pH 2.5 
was found the best aqueous mobile phase for the determination of indacaterol. The pH was 
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lowered to eliminate the interaction between the ionised silanol group and the solutes. The 
ratio of the aqueous phase to the organic modifier was investigated at 70% 60% and 50% 
methanol, the proportion of 60:40% (methanol: potassium dihydrogen orthophosphate buffer) 
was found to give the best peak in terms of resolution and sensitivity. The internal standard 
used was Dexamethasone. Initially, we tried different internal standards namely formoterol, 
bamethane and salbutamol but all these compounds were eluted within the dead volume of the 
column or overlap with an indacaterol peak (Snyder et al., 2012, Koerner, 2013). 
 Method Validation  
Following the similar validations protocols, indacaterol HPLC method was validated and the 
results are as following: 
3.2.5.2.1 Calibration (Linearity) 
The method showed a good linearity throughout the range of 0.1 µg/ mL to 10µg/ mL with a 
correlation coefficient of R2= 0.999.  
 
Figure 3.10: Calibration curve of indacaterol at 259nm (n=3).  
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3.2.5.2.2 Precision 
Three different concentrations levels (low, medium and high) of indacaterol (2.0 µg/mL, 6.0 
µg/mL and 9.0 µg/mL) were used to assess the Intra-day and inter-day precision of the 
method. Each concentration was injected 3 times on three different days.  The results of 
method precision are shown in Table 3.8.  
Table 3-8: Intra and inter-day precision of indacaterol [n=3].  
3.2.5.2.3 Accuracy 
The method accuracy was determined by injecting three concentrations of indacaterol 3 times 
(Table 3.9). The concentrations of (2, 6.0 and 9.0µg/mL) indacaterol were used. The 
calculated relative error was used to determine the accuracy of the method for each 
concertation. 
Table 3-9: Intra and inter-day accuracy of indacaterol [n=3]. 
Concentration (µg/mL) Intra-Day %CV Inter-Day %CV 
2 0.37 0.58 
6 0.20 0.37 
9 0.66 0.83 
Nominal concentration 
(µg/ml) 
Mean (SD) of measured 
concentration 
 
Mean ± SD % to nominal 
concentration  
 Intra-day Variation Intra-day Variation 
2.0 1.99 (0.01) 99.5 ± 0.5 
6.0 5.98 (0.06) 99.6 ± 0.8 
9.0 9.07 (0.03) 100.7 ± 0.3 
 Inter-day Variation Inter-day Variation 
2.0 1.97 (0.03) 98.50 ± 1.5 
6.0 5.95 (0.04) 99.29  ± 0.7 
9.0 8.98 (0.12) 99.78 ±1.3 
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 Detection and Quantification Limits 
The limit of detection (LOD) can be defined as the lowest concentration of an analyte in a 
sample that can be detected but not quantified according to the ICH guidelines. In contrast, 
the limit of quantification (LOQ) is known as the lowest amount of an analyte in a sample that 
can be determined quantitatively with suitable precision and accuracy under the standard 
operating conditions of the method. According to the ICH, there are two options to determine 
the LOD and LOQ of an assay. Firstly, by calculating LOD and LOQ as a concentration at a 
specified signal to noise ratio, in which 3:1 for the signal to noise ratio can determine LOD, 
and it is 10:1 for LOQ. Secondly using the mathmatecial equation to calculate the LOD and 
LOQ based on the standard deviation (Standard error) and the slope of the calibration curve. 
The equations for calculation LOD and LOQ are shown as following: 
LOD Standard deviation 
Slope
 x 3.3 
Eq. 3.2 
LOQ Standard deviation 
Slope
 x 10 
Eq. 3.3 
Indacaterol method LOQ and LOD were 0.17µg/mL and 0.07µg/mL  
Formoterol method LOQ and LOD were 49.8 ng/ml and 17.9 ng/ml respectively. 
 Robustness  
Both HPLC methods were considered robust and no change in the methods performance were 
observed when slight but deliberate changes were introduced to the flow rate, column oven 
temperature, buffer pH and % of the organic modifier. (See appendix for robustness results).  
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Aerolizer® and indacaterol Breezhaler® at 
different MIFs and Vins using two separate 
inhalations  
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 Chapter overview  
DPIs are breath actuated devices relying on the inhalation effort generated by the patient 
during the inhalation manoeuvre to de-aggregate and disperse the powder formulation and 
release the dose for lung deposition (Chrystyn, 2003). The design of the device inhalation 
channel, metering cup and the air inlet determine the specific intrinsic resistance of the inhaler 
device (De Boer et al., 1997). The DPIs are classified into three main groups Low, Medium, 
and High depending on their intrinsic resistance. This classification is usually determined by 
the inhalation flow required to generate a pressure drop of 4 kPa across the inhaler device 
(Dal Negro, 2015). The patient's inhalation flow through the inhalers depends on the 
resistance of the device; a fast flow rate is produced through lower resistance device when 
compared to slow flow with high resistance devices (Al-Showair et al., 2007b, Azouz and 
Chrystyn, 2012, Chrystyn et al., 2016). Beside the MIF, Vin is another inspiratory parameter 
contributing to dose emptying from single dose capsule based DPIs. For this reason, the 
manufacturer patient information leaflet (PIL) instructs the patients to inhale twice for each 
capsule dose to empty the dose efficiently (Haughney et al., 2010, Laube et al., 2011). The 
patients with limited lung capacity have limited inspiratory capabilities along with low Vin 
and they are unable to generate sufficient inhalation manoeuvre, thus resulting in low dose 
being delivered to the lungs (Azouz et al., 2015a, Azouz et al., 2015b). Several studies have 
used the inhaled volume of 2 L and 4L to investigate the dose emission aerodynamic 
characteristics from DPIs. These studies demonstrate that DPIs dose emission performance 
show no significant improvement when using Vin ≥ 2 L (Abdelrahim, 2010, Alaboud et al., 
2010, Yakubu et al., 2013).For in-vitro DPIs dose emission testing the pharmacopoeia 
recommended the use of a MIF corresponding to 4kPa pressure drop and a Vin of 4 L (EP, 
2013, USP, 2014). The Food and Drug Agency (FDA) recommends the use of 2 L Vin when 
testing the DPIs (FDA, 1998). The Vin value recommended by FDA seems to be more 
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reasonable because majority of the patients cannot generate the pharmacopeial recommended 
4 L inhaled volume (Azouz et al., 2015b). Each DPIs has a minimum flow requirement to 
efficiently de-aggregate the dose and release the medication when patient unable to achieve 
that certain flow dose de-aggregation will be incomplete resulting in less drug being delivered 
to the lungs (Laube et al., 2011, Haidl et al., 2016). Laube et al., (2011) pointed out in their 
task force report that ‘‘no manufacturer has stated the minimum flow for their DPIs although 
it is clear that this information is needed’’.   
The inhaled aerosol dose quality emitted from DPIs depends on patient’s inspiratory flow, 
inhaler specific resistance and the formulation (Clark and Hollingworth, 1993, De Boer et al., 
1997, Chrystyn, 2009, Hira et al., 2012). In the present chapter, the dose emission of two low 
resistance capsule based inhaler devices Foradil Aerolizer® (12 µg) and Onbrez Breezhaler® 
(150 µg) will be determined. Furthermore, Evaluating the impact of increasing the MIF and 
Vin on the dose emission after two separate inhalations. Therefore, the present chapter was 
designed to determine the minimum MIF and Vin of clinical relevance to operate both 
formoterol Aerolizer® and indacaterol Breezhaler®. A range of MIF and Vin was used [MIF 
of 28.3 L/min, 60 L/min, 90 L/min and 120 L/min] [Vin of 0.5 L, 0.75 L, 1 L, 1.5 L and 2 L]. 
The dose delivery uniformity (DDU) for both devices will be determined by using 16 
randomly chosen capsule for each set of MIF and Vin (n=16).      
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 Materials and methods 
The materials and instrumentations for the determination of dose emission  using DUSA were 
listed in Chapter 3 (section 3.1.2 and 3.1.4.1). The general laboratory material and apparatus 
used in the study were listed in Chapter 3 (section 3.1.1). For the quantification of formoterol 
and indacaterol, two HPLC methods were developed validated, explained in details Chapter 3 
(section 3.2.4 and 3.2.5).  
4.2.1 Experimental set-up 
The method set-up for the determination of DPIs dose emission is shown in Figure 4.1. The 
compendial method described in the USP (2014) was used to determine the dose emitted from 
Foradil Aerolizer® and Onbrez Breezhaler® at different MIFs and Vins. Dose emission at high 
inhalation flow rate (up to 100 L/min) can be determined by using the high capacity vacuum 
pump (Copley Scientific, 2015). The mouthpiece adapter was used to avoid any loss of drug 
between the collection tube of DUSA and the device’s mouthpiece. Inhalation flow up to 
100L/min is achievable by using a high capacity vacuum pump, However, to produce higher 
stable inhalation flow (P3/P2≤ 0.5 ) two vacuum pumps were connected in series together 
(Copley scientific Ltd, 2015. See section 3.1.4.1). In between flow controller and vacuum 
pump, a timer controlled two ways solenoid valve was connected.  
The latter enables a set of volume air to be withdrawn from the device mouthpiece at the 
desired inhalation flow. Flow controller was used to ensure that critical (sonic) flow is 
achieved for the flow control valve, in other words, the downstream pressure of the valve 
should be equal or less than half of upstream pressure as P3/P2 ≤ 0.5 (Copley, 2015). 
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Figure 4.1: Schematic diagram of the instrument set-up to determine dose emission at different 
MIFs and Vins 
 
The duration of inhalation was set for different Vins and MIFs by using the mathematical 
relationship that was described in the pharmacopoeia (USP, 2014), whereas the duration of 
inhalation was calculated using Eq. 5.1 relating to MIF, Vin and time.  
𝐓(𝐬𝐞𝐜) =
𝐕𝐢𝐧 (𝐋)
𝐌𝐈𝐅 (
𝐋
𝐦𝐢𝐧)
 𝐱 𝟔𝟎 
Eq.  4.1 
Where; 
T = duration of inhalation for a given set of MIF and Vin  
MIF = maximum inhalation flow  
Vin = the volume to be drawn through the device  
Table 4-1: Calculation of inhalation time (T sec) for each set of MIF and Vin 
MIF (L/min) 
Vin (L) 
0.5 0.75 1 1.5 2 
28.3 1.1s 1.6s 2.1s 3.2s 4.2s 
60 0.5s 0.7s 1.0s 1.5s 2.0s 
90 0.3s 0.5s 0.7s 1.0s 1.3s 
120 0.2s 0.4s 0.5s 0.7s 1.0s 
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4.2.2 Dose emission procedure: 
The emitted dose was determined using DUSA as shown in Figure 4.1. Instead of  using the 
standard pharmacopeial condition Vin of 4 L and  MIF corresponding to 4 kPa pressure drop, 
different values  MIFs (28.3 L/min, 60 L/min , 90 L/min  and 120 L/min) and Vins (0.5 L, 
0.75 L, 1 L, 1.5 L and 2 L) were used. In this chapter, two DUSA (Copley Scientific Ltd, UK) 
were used for the determination of the emitted dose after the first and second inhalations i.e. 
DUSA1 to collect ED1 and DUSA2 to collect ED2. 
Firstly, the DUSA was fitted with a glass fibre filter (47mm, Whatman Ltd, UK) to collect the 
aerosolised drug powder into the sampling apparatus. For each DUSA a rubber mouthpiece 
adapter (especially designed for each inhaler device, Copley Scientific Ltd, UK) was used to 
connect the inhaler device to the DUSA tube. A high capacity vacuum pump was used to 
produce the desired MIF during the experiment. The vacuum pump was switched on before 
each determination to ensure the flow stability would be maintained during the experiment. 
The inhalation flow through the device mouthpiece was set to 28.3, 60, 90 and 120 L/min 
with a calculated duration of inhalation (Table 4.1) corresponding to each set of MIFs and Vin 
to allow the inhaled volumes to be withdrawn through the Aerolizer® device. 
Once the MIF and Vin were adjusted to the required conditions, a single capsule dose was 
loaded into the device capsule chamber as instructed in the patient instruction leaflet (PIL). 
The capsule was then pierced, and whilst keeping the fingers on the side buttons of the device 
it was horizontally connected to the DUSA1 tube. Thereafter, the TPK timer controlling the 
solenoid valve was started to aerosolise the dose (ED1) into the DUSA1. Then, using the 
same capsule (already being pierced) the ED2 was aerosolised into DUSA 2. For each set of 
MIF and Vin, 16 capsules randomly chosen (Table 4.2) were aerosolised to determine the 
dose delivery uniformity of both formoterol Aerolizer® and indacaterol Breezhaler®. The 
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procedure was carried out for all the 16 capsules using one inhaler device, and the dose 
retained in the device was recovered after finishing dose emission procedure for all the 16 
capsules.  
Table 4-2: The randomisation of the capsules chosen throughout lifetime of device 
MIF (L/min) Vin (mL) Randomised capsules form Aerolizer® 
and Breezhaler® label claim of 60 Doses 
 
28.3 
60 
90 
120 
 
500 
750 
1000 
1500 
2000 
 
 
1 - 4 - 8 - 12 
16 - 20 - 24 - 28 
32 -  36 - 40 - 44 
48  -  52 - 56 - 60 
The dose emitted washing procedure was then taken place to collect the dose emitted into 
DUSA 1 and 2, mouthpiece 1 and 2, residual dose in both capsule and device. For formoterol, 
dose emission washing procedure of 60 % v/v Acetonitrile/ water was used, while for 
indacaterol washing solution of 60 % v/v methanol/ water was used. The selection of washing 
solution proportion is depending on the percentage of organic modifier in the HPLC method. 
In practical, using a higher percentage of diluent in sample preparation may lead to peak 
shape problems and affect the quantification accuracy of the HPLC method.  
DUSA was washed by firstly sealing the metal end of the tube with Parafilm (Fisher 
Scientific Ltd, UK). Then, the cap of the DUSA was opened to add appropriate volume of 
washing solution, after that, the cap was closed tightly and shaken gently for 2 minutes to 
recover all the drug powder inside the DUSA tube. The solution with the drug powder was 
transferred into a beaker, and the  DUSA filter was removed and immersed in the solution. 
The beaker was sealed with Parafilm (Fisher Scientific Ltd, UK) and sonicated for 15 minutes 
to ensure drug detachment from the filter.  
128 
 
The mouthpiece (MP) was washed by sealing the base of the MP with Parafilm, then 
appropriate volume of washing solution was added to collect drug particles deposited in the 
MP. The capsule was taken from the device, and then placed into clean beaker with 
appropriate volume of washing solution. The stirring plate was used to allow the washing 
solution to enter the capsule; therefore, drug lodged in the capsule would be recovered. 
The device was washed only with water, because acetonitrile and methanol are harsh solvent 
and they may affect the linning layer of the device. After washing the device with water, 60% 
methanol or acetonitirle was added to the solution before soniction. The recovered samples 
were transferred into 20 mL glass vials, then all vials were sonicated for 15 miuntes to ensure 
solubility of drug particles in the solution. The sonicated samples were then transferred into 
amber 2 mL HPLC vials ( Fisher Scientific Ltd, UK).  A validate HPLC methods were used 
to quntify the amount of formoterol and indacaterol in the recovered samples ( Chapter 3, 
section 3.2.4 and 3.2.5).  
4.2.3 Data analysis  
The ED1 and ED2 representing first and second inhalation respectively and were obtained 
from the amount of the drug emitted into the DUSA1 and DUSA2. The RA was the residual 
amount retained in the capsules (16 caps) and the inhaler device. The TED was obtained as 
the sum of the dose emitted after first and second inhalations. A one-way and Two-ways 
ANOVA were used to determine the difference in the ED1, ED2, TED, and RA. Tuckey test 
was used to determine the difference between the different parameters used. The hypothesis 
of (P-value = 0.05) was used to determine the significant difference.  
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 Results  
4.3.1 In-vitro formoterol dose emission results at different MIFs and Vins. 
The results were classified according to the MIF into 4 levels (28.3 L/min, 60 L/min, 90 
L/min and 120 L/min). ED1 was the dose emitted into DUSA 1 + MP 1; ED2 was the sum of 
DUSA 2 + MP2. TED was calculated as the sum of ED1 + ED2. TRA was obtained by 
adding the amount retained in the capsule to that retained in the device (residual amount in 
capsule + residual amount in device). TRD total dose recovery (TED + TRA).   
The results show that the increase of the MIF result in a significant increase (p < 0.05) in ED1 
for all the Vins used. The impact of MIF was higher when low Vins (0.5 L and 0.75 L) were 
used in comparison to high Vins (1L, 1.5 L and 2 L) (Figure 4.6).  
 At low MIFs 28.3 L/min and 60 L/min the dose emission after first inhalation (ED1) 
increased significantly ( p < 0.05) with the increase of the Vins,  In contrast, the dose 
emission after second inhalation (ED2) decreased significantly (p < 0.05) Tables 4.3 and 4.4. 
At high MIFs 90 L/min and 120 L/min the ED1 increased with increasing the Vin, most of the 
dose was emitted from the capsule during first inhalation and amount left for second 
inhalation was below the detection limit of the HPLC method Table 4.5 and 4.6.  
TRA decreased significantly (p < 0.05) with the increase of MIF from 28.3 to 120 L/min 
(Tables 4.3 to 4.6). TED significantly increased (p < 0.05) with the increase of the MIF 
(Figure 4.6). The Vin increase has a significant effect (p < 0.05) on the TED only at low MIF 
28.3 and 60 L/min. In contrast, at high MIF 90 and 120 L/min increasing the Vin result in 
insignificant difference in the TED.  The dose delivery was consistent for all 16 capsules used 
with an average of 11.5µg TRD. [See appendix for DDU results]   
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Table 4-3: Mean (SD) of the amount of formoterol in (µg) dose emission results at MIF of 
28.3L/min using different Vins. [n=16]. [TRA (ED1+ED2) TRD (Cap +Dev) highlighted are the 
main parameters] 
 
Dose 
emission 
(µg) 
Inhalation Volume ( Vin) 
500 mL 750 mL 1000 mL 1500 mL 2000 mL 
ED1 5.51 (0.56) 5.86 (0.32) 6.05 (0.54) 6.21 (0.21) 6.44 (0.32) 
ED2 2.16 (0.54) 2.06 (0.72) 2.02 (0.19) 1.92 (0.50) 1.71 (0.46) 
TED 7.67 (0.23) 7.92 (0.30) 8.07 (0.55) 8.13 (0.51) 8.16 (0.61) 
MP1 0.07 (0.01) 0.11 (0.03) 0.19 (0.05) 0.24 (0.08) 0.27 (0.09) 
Cap 3.56 (0.43) 3.21 (0.44) 3.18 (0.53) 2.90 (0.65) 2.57 (0.35) 
TRA 4.13 (0.24) 3.89 (0.16) 3.75 (0.1) 3.58 (0.10) 3.47 (0.10) 
TRD 11.80 (1.00) 11.81 (1.10) 11.82 (0.80) 11.71(1.20) 11.63 (0.70) 
 
 
 
Figure 4.2: Mean (SD) of the total emitted dose (TED) and total residual amount (TRA) of 
formoterol emitted from Aerolizer® at different Vins using a MIF of 28.3L/min. 
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Table 4-4: Mean (SD) of the amount of formoterol in (µg) dose emission results at MIF of 
60L/min using different Vins. [n=16]. [TRA (ED1+ED2) TRD (Cap +Dev) highlighted are the 
main parameters]  
 
Dose 
emission 
(µg) 
Inhalation Volume ( Vin) 
500 mL 750 mL 1000 mL 1500 mL 2000 mL 
ED1 6.33 (0.32) 6.51(0.47) 6.91 (0.72) 6.91 (0.72) 7.22 (0.47) 
ED2 1.40 (0.21) 1.34 (0.16) 1.29 (0.20) 1.29 (0.20) 1.10 (0.21) 
TED 7.73 (0.35) 7.84 (0.46) 8.20 (0.79) 8.20 (0.79) 8.32 (0.59) 
MP1 0.12 (0.03) 0.18 (0.04) 0.23 (0.09) 0.23 (0.09) 0.26 (0.03) 
Cap 2.81(1.08) 2.61 (0.86) 2.31 (0.86) 2.32 (0.86) 2.46 (0.56) 
TRA 3.59 (0.86) 3.49 (0.56) 3.37 (1.00) 3.31 (1.03) 3.28 (0.99) 
TRD 11.32 (0.99) 11.33 (1.03) 11.57 (1.31) 11.51 (1.31) 11.60 (1.00) 
 
 
Figure 4.3: Mean (SD) of the total emitted dose (TED) and total residual amount (TRA) of 
formoterol emitted from Aerolizer® at different Vins using a MIF of 60 L/min. 
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Table 4-5: Mean (SD) of the amount of formoterol in (µg) dose emission results at MIF of 90 
L/min using different Vins. [n=16]. [TRA (ED1+ED2) TRD (Cap +Dev) highlighted are the main 
parameters] 
 
Dose 
emission 
(µg) 
Inhalation Volume ( Vin) 
500 mL 750 mL 1000 mL 1500 mL 2000 mL 
ED1 7.89(0.36) 8.42(0.80) 8.60(0.19) 8.63(0.40) 8.68(0.67) 
ED2 0.47(0.22) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 
TED 8.35(0.30) 8.42(0.80) 8.60(0.19) 8.63(0.40) 8.68(0.67) 
MP1 0.18(0.04) 0.22(0.06) 0.27(0.02) 0.25(0.07) 0.28(0.08) 
Cap 2.12(0.56) 2.12(0.36) 2.01(0.35) 1.96(0.21) 1.93(0.28) 
TRA 3.21(0.36) 3.09(0.40) 2.96(0.30) 2.86(0.07) 2.78(0.37) 
TRD 11.56(0.65) 11.51(0.56) 11.68(0.45) 11.49(0.33) 11.46(0.60) 
 
 
Figure 4.4: Mean (SD) of the total emitted dose (TED) and total residual amount (TRA) of 
formoterol emitted from Aerolizer® at different Vins using a MIF of 90 L/min. 
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Table 4-6: Mean (SD) of the amount of formoterol in (µg) dose emission results at MIF of 
120L/min using different Vins. [n=16]. [TRA (ED1+ED2) TRD (Cap +Dev) highlighted are the 
main parameters] 
Dose 
emission 
(µg) 
Inhalation Volume ( Vin) 
500 mL 750 mL 1000 mL 1500 mL 2000 mL 
ED1 8.49(0.37) 8.60(0.38) 8.72(0.40) 8.81(0.60) 8.85(0.77) 
TED 8.49(0.37) 8.60(0.38) 8.72(0.40) 8.81(0.60) 8.85(0.77) 
MP1 0.29(0.04) 0.33(0.06) 0.34(0.06) 0.36(0.07) 0.37(0.07) 
Cap 2.31(0.35) 2.28(0.35) 2.22(0.45) 2.05(0.34) 2.02(0.41) 
TRA 2.75(0.13) 2.64(0.32) 2.51(0.05) 2.35(0.16) 2.30(0.10) 
TRD 11.24(0.59) 11.24(0.50) 11.22(0.62) 11.16(0.74) 11.15(0.67) 
 
 
Figure 4.5: Mean (SD) of the total emitted dose (TED) and total residual amount (TRA) of 
formoterol emitted from Aerolizer® at different Vins using a MIF of 120 L/min 
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Figure 4.6: Mean (SD) of formoterol dose emitted after one and two inhalations at different MIF and Vin values
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4.3.2 In vitro indacaterol dose emission at different MIFs and Vins 
The dose emission performance of indacaterol Breezhaler® using wide range of MIFs and Vin 
was determined after two separate inhalations. Furthermore, the dose delivery uniformity of 
indacaterol was also determined by randomly chosen 16 doses out of 60 capsules pack for 
each set of MIF and Vin.  
The results demonstrate that ED1, TED increased significantly (p < 0.05) with increasing the 
MIF from 28.3 L/min to 120 L/min for all Vins used. The impact of the MIF was more 
pronounced when low Vin values (0.5, 0.75 and 1 L) were used (Figures 4.7, 4.8, 4.9 and 
4.10). In contrast, dose retained in capsule, TRA and ED2 decreased significantly (p < 0.05) 
with increase the MIF (Tables 4.7 to 4.10) (Figures 4.8, 4.10, 4.12 and 4.14).  
Similarly, ED1 increased and ED2 decreased significantly (p < 0.05) with increasing the Vin. 
The impact of the Vin was more observed at low MIFs 28.3 and 60 L/min ( Tables 4.7 and 
4.8) , at high MIFs most of the dose delivered after first inhalation and no much dose left for 
the second inhalation ( Tables 4.9 and 4.10). TRD of indacaterol Breezhaler® was consistent 
with an average dose delivery of 149 µg was recovered for all Vin and MIF used. [See 
appendix DDU results]   
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Table 4-7: Mean (SD) of the amount of Indacaterol in (µg) dose emission results at MIF of 28.3 
L/min using different Vins. [n=16]. 
Dose 
emission 
(µg) 
Inhalation Volume (mL) 
500 mL 750 mL 1000 mL 1500 mL 2000 mL 
ED1 99.85 (5.06) 108.21(7.00) 113.89 (6.58) 119.47 (6.47) 127.73 (5.73) 
ED2 24.02 (5.08) 19.76 (5.02) 16.01(3.31) 11.90 (3.74) 5.90 (2.67) 
MP1 1.92 (0.70) 2.04 (1.04) 2.19(0.78) 2.51(0.60) 2.76 (0.45) 
MP2 0.88 (0.62) 0.84 (0.57) 0.66 (0.57) 0.35 (0.10) 0.21 (0.08) 
TED 123.87 (4.87) 127.96 (7.91) 129.90 (8.25) 131.37 (7.41) 133.63 (6.00) 
% TED* 82.58 (3.25) 85.31(5.27) 86.60(5.50) 87.58(4.94) 89.09(4.00) 
CAP 9.04 (2.88) 6.22 (1.69) 5.53 (1.83) 4.89 (1.01) 3.69 (1.24) 
TRA 30.68 (2.31) 25.00 (2.67) 18.89 (1.35) 17.43 (1.65) 15.31(0.83) 
TRD 150.42 (2.35) 152.97 (5.00) 148.78 (4.36) 148.80 (5.43) 148.94 (3.17) 
*= Total emitted dose as % of the nominal dose 150µg indacaterol from Onbrez Breezhaler® 
 
Figure 4.7: Mean (SD) of the emitted dose after one inhalation (ED1), and two (TED) inhalations 
at different Vins using a MIF of 28.3 L/min. 
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Figure 4.8: Mean (SD) of the total emitted dose (TED) and total residual amount (TRA) at 
different Vins using a MIF of 28.3 L/min.  
Table 4-8: Mean (SD) of the amount of Indacaterol in (µg) dose emission results at MIF of 60 
L/min using different Vins. [n=16]. 
Dose 
emission 
(µg) 
Inhalation volume (mL) 
500 mL 750 mL 1000 mL 1500 mL 2000 mL 
ED1 112.32(7.45) 120.73(8.77) 126.41(6.99) 130.52(8.58) 133.96(4.23) 
ED2 14.09(6.09) 10.56(4.95) 8.90(3.50) 5.55(2.28) 3.87(1.58) 
MP1 2.76(1.17) 2.96(0.90) 3.74(1.17) 4.55(0.77) 4.57(0.88) 
MP2 0.74(0.35) 0.70(0.45) 0.34(0.40) 0.22(0.06) 0.21(0.12) 
TED 126.42(8.99) 131.29(8.78) 135.31(6.95) 136.07(7.80) 137.83(4.04) 
% TED* 84.28(6.00) 87.53(5.85) 90.21(4.63) 90.72(5.20) 91.89(2.69) 
CAP 5.86(2.39) 4.64(1.09) 3.78(1.59) 3.49(0.89) 2.90(0.46) 
TRA 19.06(0.95) 16.42(1.02) 15.84(0.86) 13.84(1.28) 12.79(0.66) 
TRD 145.48(6.80) 147.71(5.68) 151.15(6.88) 149.91(7.71) 150.62(4.12) 
*= Total emitted dose as % of the nominal dose 150µg indacaterol from Onbrez Breezhaler® 
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 Figure 4.9: Mean (SD) of the emitted dose after one inhalation (ED1), and two inhalations 
(TED) at different Vins using a MIF of 60 L/min. 
 
Figure 4.10: Mean (SD) of the total emitted dose (TED) and total residual amount (TRA) at 
different Vins using a MIF of 60 L/min. 
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Table 4-9: Mean (SD) of the amount of Indacaterol in (µg) dose emission results at MIF of 90 
L/min using different Vins. [n=16]. 
Dose emission 
(µg) 
Inhalation volume ( mL) 
500 mL 750 mL 1000 mL 1500 mL 2000 mL 
ED1 126.24(7.71) 130.70(8.59) 135.41(7.59) 137.12(8.73) 138.94(6.73) 
ED2 10.87(4.57) 6.95(2.94) 3.19(1.25) 2.36(1.01) 2.10(1.59) 
MP1 3.56(0.53) 4.23(1.35) 4.36(0.41) 4.68(1.01) 4.78(0.91) 
MP2 0.33(0.22) 0.23(0.12) 0.15(0.11) 0.13(0.09) 0.09(0.07) 
TED 137.11(7.46) 137.65(8.02) 138.61(8.01) 139.49(8.11) 141.04(6.26) 
% TED* 91.41(4.97) 91.77(5.35) 92.40(5.34) 92.99(5.41) 94.02(4.17) 
CAP  4.14(2.65) 2.83(1.41) 2.68(1.47) 2.74(1.71) 2.57(1.46) 
TRA 13.83(0.84) 12.44(0.54) 11.21(0.32) 10.32(0.41) 10.17(0.65) 
TRD 150.94(4.13) 150.09(5.96) 149.82(3.81) 149.80(5.63) 151.20(6.86) 
*= Total emitted dose as % of the nominal dose 150µg indacaterol from Onbrez Breezhaler® 
 
Figure 4.11: Mean (SD) of the emitted dose after one inhalation (ED1), and two inhalations 
(TED) at different Vins using a MIF of 90 L/min. 
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
160.0
500 750 1000 1500 2000
In
d
ac
at
er
o
l 
d
o
se
 e
m
it
te
d
 (
µ
g
) 
af
te
r 
o
n
e 
an
d
 t
w
o
 
in
h
al
at
io
n
s
Vin (mL)
ED1
TED
140 
 
 
Figure 4.12: Mean (SD) of the total emitted dose (TED) and total residual amount (TRA) at 
different Vins using a MIF of 90 L/min. 
Table 4-10: Mean (SD) of the amount of Indacaterol in (µg) dose emission results at MIF of 120 
L/min using different Vins. [n=16]. 
*= Total emitted dose as % of the nominal dose 150µg indacaterol from Onbrez Breezhaler® 
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Dose 
emission 
(µg) 
Inhalation volume ( mL) 
500 mL 750 mL 1000 mL 1500 mL 2000 mL 
ED1 129.44(5.39) 136.16(6.38) 138.73(7.46) 140.75(6.22) 142.85(8.68) 
ED2 8.73(4.00) 4.48(1.62) 3.01(0.77) 2.28(0.87) 1.67(0.88) 
MP1 3.84(1.53) 4.55(0.86) 4.78(0.92) 4.80(1.01) 5.28(0.50) 
MP2 0.54(0.43) 0.24(0.16) 0.25(0.20) 0.14(0.07) 0.07(0.04) 
TED 138.18(4.62) 140.64(6.08) 141.74(7.66) 143.03(6.18) 144.52(8.85) 
% TED* 92.12(3.08) 93.76(4.06) 94.50(5.11) 95.35(4.12) 96.35(5.90) 
CAP  2.38(1.44) 2.20(1.10) 2.26(1.25) 2.08(1.12) 1.75(0.80) 
TRA 11.56(0.49) 8.71(0.21) 7.79(0.35) 6.57(0.19) 6.10(0.26) 
TRD 149.74(4.22) 149.35(5.51) 149.54(7.67) 149.60(6.53) 150.62(3.04) 
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Figure 4.13: Mean (SD) of the emitted dose after one (ED1), and two inhalations (TED) at 
different Vins using a MIF of 120 L/min. 
 
Figure 4.14: Mean (SD) of the total emitted dose (TED) and total residual amount (TRA) at 
different Vins using a MIF of 120 L/min. 
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Figure 4.15: Mean (SD) of the dose emitted after one (ED1) and two (TED) inhalation at different MIF and Vin values
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 Discussion  
The effect of increasing the MIF and Vin on the dose emission performance of both 
formoterol Aeroliser® and indacaterol Breezhaler® was determined using two separate 
inhalations. The dose delivery uniformity was determined for each set of MIF and Vin using 
16 randomly chosen capsules.  
Aeroliser® and Breezhaler® are low resistance devices and a MIF exceeding 100 L/min is 
required to achieve a pressure drop inside device equivalent to 4kPa when using both devices 
(Dal Negro, 2015). Inhaling fast from the start of the inhalation manoeuvre would lead to a 
sufficient turbulent inside the inhaler causing the aggregates to break up into particle small 
enough to be carried into the lower airways and also to separate drug particles from the 
surface of the carrier (Labiris and Dolovich, 2003, Al-Showair et al., 2007b, Laube et al., 
2011). The fast inhalation achieved from low resistance device such as Aerolizer® may not 
de-aggregate the formulation inside the inhaler which is along with the high momentum of the 
particles in the fast moving airstream causes a substantial amount of drug particles being 
deposited in the oropharyngeal region resulting in less therapeutic effect (Haughney et al., 
2010). The pharmacopoeia methods for in-vitro dose emission testing of DPIs are that a 
vacuum pump is used to generate a constant MIF corresponding to 4kPa pressure drop with 
an inhalation volume of 4 L or 2 L (EP, 2013, USP, 2014). The patients with asthma and 
COPD are not able to achieve these parameters when inhaling though DPIs in real life (Azouz 
et al., 2015b).  
Most DPIs are breath actuated and are highly dependent on the patients’ MIF. The threshold 
inhalation flow required to de-aggregate and disperse the drug powder is not determined for 
each DPI, and more effort is needed to shade the light on the minimum flow required to 
operate each DPI more efficiently to benefit the patients (Scichilone, 2015, Haidl et al., 2016).  
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4.4.1  Formoterol Aeroliser® 
The results show that the dose emission after the first inhalation (ED1) significantly (p < 0.05) 
increased with increasing the MIF from 28.3 to 120 L/min while dose emission after the 
second inhalation reduced significantly (p < 0.05) with increasing the MIF (Figure 4.6) 
(Tables 4.3 to 4.6). Suggesting that increasing the MIF was corresponding to an increase in 
the turbulent energy inside the device and therefore more powder emitted when MIF 
increased. The results also demonstrate the reverse relationship between TED (ED1+ ED2) 
and RA (Cap +Dev) where the increase in the MIF significantly ( p < 0.05) lead to an increase 
in the TED and therefore a reduction in the RA (Figures 4.2 to 4.5). The flow dependent dose 
emission of formoterol from Aerolizer® demonstrated in the present chapter is in line with the 
findings of previous studies (Nielsen et al., 1997, Weuthen et al., 2002, Alaboud et al., 2010).  
The marked decrease in the RA at a flow rate above 60 L/min suggesting this would be the 
minimum flow rate to operate Aerolizer® efficiently. This study showed that formoterol 
emitted dose from an Aerolizer increased with the MIF especially at a MIF ≥ 60 L/min 
suggesting the effectiveness of the Aerolizer at high flow. This finding is in line with Haidle 
et al., (2016) who demonstrated that minimum MIF of 65 L/min is required for optimum dose 
de-aggregation from Aerolizer®. It is understood that the relationship between the inhalation 
flow and the turbulent force inside the inhaler is not linear and increasing the inhalation flow 
above 60 L/min suggest an increase in the level of the turbulent force de-aggregating the 
powder formulation. It is widely accepted that breath activated DPIs are often associated with 
flow rate dependent changes in the emitted dose (Johal et al., 2013).  
Patient with asthma and COPD inhaling through the Aerolizer® were reported to achieve a 
Mean (SD) MIF and Vin of 86.5 (26.3) and 1.8 (0.8) respectively(Azouz et al., 2015b). The 
Vin is another inspiratory parameter that affects the dose emission of DPIs especially those 
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with the capsule based design. The capsule based inhalers require a prolonged inhalation 
manoeuvre to empty the capsule (Kamin et al., 2002, Chrystyn and Price, 2009, Laube et al., 
2011).The design of the inhaler device suggests whether dose emission occurs at the start of 
the inhalation or require a prolonged inhalation. Failure to achieve the required inhaled 
volume may result in incomplete dose emission and dispersion resulting in a lower dose of 
drugs to reach the lungs and compromising therapeutic efficacy (Abadelah et al., 2017). 
Therefore, determination of the minimum inhaled volume required to operate each DPI is 
needed. 
The results show that ED1 increased and ED2 decreased with increasing the Vin from 0.5 L to 
2 L especially at low MIF 28.3 and 60 L/min (Figures 4.6) while at high MIF 90 and 120 
L/min most of the dose was emitted from the device after the first inhalation (Tables 4.5 and 
4.6). Suggesting that, when low MIF was used more dose was left for the second inhalation, 
Therefore, increasing the Vin result in an increase in the ED1. In contrast, at high MIF most 
of the dose was emitted from the Aerolizer® after the first inhalation. 
Chan and Chew (2001) have measured eformoterol dose emission uniformity from Foradil 
Aerolizer® using ten separate capsules for set of MIF values (30-90L/min) using standard 
pharmacopeial method, the results showed that comparing to Turbuhaler®, Foradil Aerolizer® 
was less dependent on the MIF as TED (% of nominal dose ) were 80% and 90% at 30 L/min 
and 90L/min respectively . The Aerolizer® showed less variation in the normalized emitted 
dose uniformity than the Turbuhaler®. The results of present chapter are in line, and 16 
capsules dose emission from Aerolizer® was consistent with Mean (SD) of 97% (2.13) of the 
nominal dose of 12µg formoterol Aerolizer®. 
The total residual amount (TRA) decreased significantly (p < 0.05) with an increase of both 
MIF and Vin. At low MIF and Vin, the TRA was approximately 39% of the nominal dose.  
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While at high MIF and Vin it was approximately 16 % of the nominal dose (Figures 4.2 to 
4.5). Foradil Aerolizer® showed a flow dependent dose emission especially at a flow rate > 60 
L/min, and Vin becomes of less importance. Suggesting that, 60 L/min may be considered as 
the minimum MIF required for successful dose de-aggregation. 
4.4.2 Indacaterol Breezhaler® 
Indacaterol Breezhaler® has flow dependent dose emission after first inhalation (ED1) at all 
Vins used. These results are in line with previously published data on indacaterol dose 
emission (Pavkov et al., 2010, Chapman et al., 2011, Colthorpe et al., 2013). Emitted dose 
after the second inhalation (ED2) decreased with the inhalation flow rate significantly ( p < 
0.05) however the most significant decrease in the emitted dose occurred at MIF of 28.3 and 
60 L/min ( Table 4.7 and 4.8). At these low MIFs, more indacaterol was left in the capsule 
after the first inhalation and second inhalation needed to withdraw most of the dose remained 
in the capsule and device. The results also show that (TED) which is the sum of two 
inhalations increased with the increase of inhalation flow rate (Figure 4.15). 
 The Vin was shown to have an impact on the dose emptying, and total emitted dose 
especially for capsule based devices (Kamin et al., 2002, Laube et al., 2011). The dose 
emission after the first inhalation (ED1) significantly increased (p < 0.05) with increasing the 
inhaled volume (Vin) at low MIF 28.3 and 60 L/min (Figures 4.7 and 4.9). At high MIF 
values > 60 L/min increasing the Vin did not bring much difference in ED1 as shown in 
Figures 4.11 and 4.13. The ED2 showed a reverse trend and significantly decrease (p < 0.05) 
with increasing the Vin, suggesting that dose de-aggregation was incomplete at low MIF and 
therefore the dose remained in the capsule and device for second inhalation (ED2). At high 
MIF most of the dose was emitted after one inhalation and the second inhalation showed less 
impact on the overall TED (ED1 + ED2) (Figure 4.15). The patients with COPD are liable to 
have reduced inhalation capacity hence to get the most benefit of the inhaled dose it would be 
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better to inhale twice for each capsule dose when using Breezhaler® mainly for those patients 
with small Vins and cannot generate high MIF as demonstrated in Tables 4.7 to 4.10. For 
Breezhaler® the dose is emitted latter, and inhalation quality depends on the inhaled volume 
(Figure 4.15). However, at high MIF values > 60 L/min and Vin of 1 L there was not much 
difference between emitted dose after one inhalation (ED1) and two inhalations (TED). 
Therefore, it is important when using the Onbrez Breezhaler® to inhale as fast, deep and for as 
long as possible. 
Onbrez Breezhaler is a low resistance device, and the turbulent energy inside the device relies 
more on the flow rate. Furthermore, the increase in the pressure drop inside the device is less 
pronounced at MIF of ≤ 60 L/min. Thus, the flow dependent dose emission of indacaterol 
Breezhaler® could be due to the incomplete de-aggregation of the indacaterol from the device 
at low MIF as was previously shown by De Boer et al., (1996) or the insufficient emptying of 
the capsule and device at low MIF as shown from the TRA results (Figures 4.8 and 4.10). It is 
clear from the results (Tables 4.7 to 4.10) that the residual amount left in the device is higher 
compared to the capsule. Therefore, it is important to clean the device after use to avoid 
overdosing during next inhalation. 
TRD results approached the nominal dose of 150µg indacaterol at all MIF and Vin suggesting 
that the procedure of washing DUSA, mouthpiece, device and capsule, and that the validated 
HPLC method for indacaterol quantification was accurate and reproducible. 
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 Conclusion  
In the present in-vitro dose emission of formoterol Aeroliser® and indacaterol Breezhaler® 
delivery systems has shown stable and consistent drug delivery characteristics. The results for 
both devices have demonstrated the need for second inhalation especially at low MIF to 
ensure dose emptying and maximise dose emission. For both devices, dose emission was 
shown to be dependent on the MIF generated by the patients with high MIF producing the 
greater dose emission. The Vin has shown an impact on the dose emission especially at low 
MIF, furthermore, a minimum MIF of 60 L/min and Vin of 1 L was required for efficient 
dose aerosolisation. Consequently, patients should be encouraged to inhale twice and as hard 
and deep as they can for each single dose especially for patients with low MIF or limited lung 
capacity  
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 Chapter overview  
DPIs have been extensively used for delivering medication to the lungs, especially for 
bronchodilators and corticosteroids, in the management of asthma and chronic obstructive 
pulmonary disease (COPD) (Price and Chrystyn, 2015). Most of the pharmaceutical DPIs on 
the market are passive devices, relying on the patient's inhalation manoeuvre as an energy 
source to de-aggregate and disperse the static bulk powder formulation into an aerosol for 
lung deposition (Chrystyn, 2003). Beside the MIF and ACIM, another important aspect of the 
inhalation manoeuvre to consider is the Vin. This parameter ensures that the entire dose 
leaves the dose metering cup during an inhalation. Pharmacopoeia Methods (EP, 2013, USP, 
2014) for dose emission recommend that a Vin of 4 L should be drawn through each DPI with 
a MIF that corresponds to a pressure change of 4 kPa inside the DPI. In-vitro dose emission 
studies have traditionally used 2 L (FDA, 1998) or 4 L Vin (Abdelrahim, 2010, EP, 2013, 
USP, 2014). 
However, most of the patient with asthma and COPD are not able to achieve neither 4kPa 
pressure drop inside the inhaler device nor 4L inhaled volume (Azouz et al., 2015b). The 
design of the inhaler device suggests whether dose emission occurs at the start of the 
inhalation manoeuvre or requires a prolonged inspiration. Thus, a patient inhaling through a 
reservoir or blister based device would require a smaller Vin to withdraw the dose compared 
with the single-dose capsule based devices (Chrystyn, 2009, Laube et al., 2011). Devices with 
a short inhalation channel between the metered dose and the mouthpiece exit will require a 
lower Vin. Also, the presence of a cyclone in the inhalation channel of the DPI, to help de-
aggregate the formulation, would have an effect on the required inhaled volume (Azouz and 
Chrystyn, 2012, Haidl et al., 2016). Failure to achieve the required inhaled volume may result 
in incomplete dose emission and dispersion which may result in a lower dose of the drug 
delivered to the lungs and compromising therapeutic efficacy (Broeders et al., 2003). In 
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addition to the traditional focus on the influence of the MIF, attention should be directed 
towards identifying the minimum required an inhaled volume to ensure that the entire metered 
dose is emitted from the DPI during routine use. For each DPI there will be a minimum Vin 
for the emission of a dose with sufficient potential for lung deposition. Therefore, this work 
was aimed to investigate the effect of Vin, when using a low and high MIF, on the dose 
emission and drug deposition of formoterol fumarate from an Easyhaler® DPI. 
The present chapter was designed to investigate the effect of wide range of MIFs and Vins  on 
the dose emission as well as the aerodynamic characteristics of the emitted dose of formoterol 
fumarate from 12 µg Easyhaler® DPI device. The inspiratory condition of both MIF and Vin 
were 28.3 L/min, 60 L/min and 90 L/min and 240 mL, 750 mL, 1500 mL and 2000 mL 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
 
 Material and Methods 
5.2.1 Dose emission material and instrumentation 
The materials and instrumentations for DUSA experiment were provided in Chapter 3 
(sections 3.1.2 and 3.1.4.1). The general laboratory apparatus and material used were listed in 
Chapter 3 (see section 3.1.1).  
5.2.2 Dose emission methodology  
The methodology and experimental set-up used for the determination of DPIs dose emission 
using dose unit sample apparatus (DUSA) in vitro was explained in the previous Chapter 4 
(section 4.2.1 and 4.2.2).  
5.2.3 Easyhaler® resistance to airflow  
The specific resistance to airflow (R), of 10 Easyhaler devices were determined by calculating 
the slopes of the linear relationships between the square root of pressure drop (ΔP) against the 
volumetric flow rate (Q) between 28.3 and 90 L/min) according to Clark and Hollingsworth 
(1993):     √∆𝐏 =  𝐑 𝐱 𝐐            
Each of the 10 inhalers was assessed at different MIFs, and the corresponding pressure drops 
were recorded. The mean ± SD pressure drop of  Easyhaler® at different MIF 28.3 L/min, 60 
L/min and 90 L/min  were 2.01 ± 0.04, 5.99 ± 0.04 and 13.96 ± 0.07 respectively. These 
result showed that there is a low variability in airflow resistance between separate inhalers  
5.2.4 Aerodynamic Particle Size Distribution (APSD) characteristics of the emitted 
dose and collection of the residual amount of formoterol fumarate. 
Figure 5.1 shows the ACI schematic diagram used to determine the APSDs of formoterol 
fumarate from an Easyhaler at MIF values of 28.3, 60 and 90 L/min with Vin values of 240, 
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750, 1500 and 2000 mL using the Andersen Cascade Impactor (ACI ;Copley Scientific Ltd, 
UK). To enable determinations at 28.3 L/min stages 0 to 7 and the pre-separator designed for 
use at 28.3 L/min were used. For 60 L/min stage 7 was replaced by stage -1, for 90 L/min, 
stages 0, 6 and 7 were replaced by stages -2A, -1A and -0 and the pre-separator designed for 
use at 90 L/min was used. The collection plates were sprayed with silicone lubricant (Pro-
Power Premier Farnell plc, UK) and allowed to dry at room temperature before use.  
 
 
Figure 5.1: Andersen cascade impactor (ACI) set-up for the determination of formoterol 
aerodynamic characteristics emitted from an Easyhaler®. 
The ACI was connected to a vacuum pump (HCP5, Copley Scientific Ltd, UK) via the critical 
flow controller (model TPK ; Copley Scientific Ltd, UK). The ACI stages were assembled 
with 10 mL of 60 % acetonitrile: 40 % ultra-purified water (% v/v) in the pre-separator and a 
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glass fibre GF50 (Whatman; UK) filter was placed in the final stage. For each determination, 
one dose from 10 separate inhalers was used. Each dose was prepared according to the 
manufacturer’s recommended patient instructions. Three separate determinations were made 
for each set of MIFs and Vin. Once one dose was discharged into the ACI, and then the 
residual amount remaining inside the device was captured using a MIF of 90L/min and a 4L 
Vin using   a dose unit sampling apparatus (DUSA; Copley Scientific Ltd, UK). 
The MIF and Vin values were chosen because they reflect the maximum and minimum values 
achieved by patients (Azouz et al., 2015b). The amount of formoterol after each determination 
was determined using a validated HPLC method (Explained in Chapter 3 section 3.2.4). 
5.2.5 Data Analysis 
The Copley Inhaler Testing Data Analysis Software (CITDAS version 2.0, Copley 
Scientific Ltd, UK)) was used to calculate the aerodynamic dose emission parameters. 
The total emitted dose (TEDACI) was obtained from the cumulative amounts of formoterol 
fumarate deposited in the induction port (IP), using the USP throat, the pre-separator (PS) and 
all the stages of the ACI. The fine particle dose (FPD) was the mass associated with particles 
< 5 µm, and the extra-fine particle dose (EFPD) was the mass of powder associated with 
particles less than 2 µm . The fine particle dose was expressed as a % of the label claim, and 
the fine particle fraction (FPF) was the FPD divided by the TEDACI. The total recovered dose 
(TRDACI) was the sum of the total emitted dose (TEDACI) and the residual amount (RAACI). A 
one way and two ways ANOVA, as well as Tuckey test, were used to determine significant 
difference the hypothesis of (p < 0.05) was used. 
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 Results  
The aerodynamic dose emission characteristics of formoterol Easyhaler® was determined 
using both DUSA and ACI at wide range of MIF and Vin. A summary of the deposition data 
for ACI are shown in Tables 5.1, 5.2 and 5.3 respectively, in addition to DUSA results in 
Table 5.5. The use of DUSA was to evaluate the DDU of the device.  
Table 5-1: Deposition profile data (µg/actuation) from Easyhaler at different inhalation volumes 
using a MIF of 28.3 L/min (n=3). 
Vin 240 mL 750 mL 1500 mL 2000 mL 
Deposition location Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Mouthpiece (MP) 0.71 (0.28) 0.54 (0.06) 0.55 (0.01) 0.56 (0.02) 
Induction port (IP) 0.94 (0.16) 1.15 (0.08) 1.02 (0.13) 1.03 (0.03) 
Pre-separator (PS) 5.14 (0.64) 4.49 (0.17) 4.48 (0.19) 5.38 (0.20) 
LPM (µg) 6.08 (0.76) 5.64 (0.18) 5.50 (0.29) 6.41 (0.17) 
S 0 0.28 (0.09) 0.27 (0.01) 0.26 (0.02) 0.26 
S 1 0.27 (0.06) 0.45 0.43 (0.04) 0.45 (0.01) 
S 2 0.19 (0.03) 0.47 (0.03) 0.49 (0.02) 0.51(0.02) 
S 3 0.20 (0.04) 0.90 (0.05) 1.01(0.05) 1.02 (0.05) 
S 4 0.26 (0.11) 1.00 (0.13) 1.06 (0.06) 1.08 (0.03) 
S 5 0.14 (0.06) 0.45 (0.06) 0.43 (0.06) 0.45 (0.01) 
S 6 0.01 (0.01) 0.05 (0.01) 0.04 0.04 
S 7 0 0 0.01 (0.01) 0 
Filter 0.04 0.05 0.06 0.07 (0.01) 
 
FPD (µg) 0.86 (0.25) 2.93 (0.26) 3.11 (0.17) 3.16 (0.09) 
EFPD (µg) 0.19 (0.07) 0.55 (0.07) 0.54 (0.07) 0.56 (0.02) 
MMAD [µm] 4.93 (0.15) 3.70 (0.17) 3.67 (0.06) 3.67 (0.06) 
GSD 2.20 1.80 1.70 1.70 
FPD; Fine particle dose, EFPD; Extra fine particle dose, LPM; Large particle mass, MMAD; 
mass median aerodynamic diameter, GSD; Geometric standard deviation. 
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Table 5-2: Deposition profile data (µg/actuation) from Easyhaler® at different inhalation 
volumes using a MIF of 60 L/min (n=3). 
Vin 240 mL 750 mL 1500 mL 2000 mL 
Deposition location Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Mouthpiece (MP) 0.62(0.32) 0.57(0.12) 0.50(0.12) 0.55(0.06) 
Induction port (IP) 0.99(0.12) 1.21(0.06) 1.12(0.10) 1.08(0.13) 
Pre-separator (PS) 5.08(0.58) 4.54(0.11) 4.62(0.14) 5.22(0.24) 
LPM (µg) 6.07 (0.76) 5.75 (0.18) 5.74 (0.29) 6.30 (0.17) 
S -1 0.31(0.07) 0.25(0.03) 0.27(0.01) 0.24(0.01) 
S 0 0.26 (0.05) 0.38(0.06) 0.32 (0.02) 0.32 (0.01) 
S 1 0.20 (0.04) 0.36 (0.04) 0.29 (0.04) 0.46 (0.01) 
S 2 0.21(0.01) 0.84 (0.15) 0.94 (0.03) 0.95 (0.10) 
S 3 0.27 (0.09) 1.03 (0.09) 1.02 (0.11) 0.99(0.08) 
S 4 0.16 (0.01) 0.58 (0.02) 0.78(0.05) 0.63(0.02) 
S 5 0.02 (0.01) 0.06 0.08 (0.01) 0.09 
S 6 0.00 0.04 0.04 0.08 (0.01) 
Filter 0.03 0.06 (0.01) 0.05 0.06 (0.02) 
 
FPD (µg) 0.89 (0.17) 2.97 (0.14) 3.20 (0.18) 3.26 (0.19) 
EFPD (µg) 0.21 (0.09) 0.74 (0.12) 0.95 (0.10) 0.86 (0.09) 
MMAD [µm] 4.80 (0.06) 3.20 (0.15) 3.10 (0.17) 3.10 (0.06) 
GSD 2.40 2.10 2.10 1.9 
FPD; Fine particle dose, EFPD; Extra fine particle dose, LPM; Large particle mass, MMAD; 
mass median aerodynamic diameter, GSD; Geometric standard deviation. 
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Table 5-3: Deposition profile data (µg/actuation) from Easyhaler at different inhalation volumes 
using a MIF of 90 L/min (n=3). 
Vin 240 mL 750 mL 1500 mL 2000 mL 
Deposition location Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Mouthpiece (MP) 0.57 (0.04) 0.59 (0.10) 0.65 (0.04) 0.56 (0.01) 
Induction port (IP) 1.37 (0.07) 1.18 (0.18) 1.02 (0.14) 0.96 (0.01) 
Pre-separator (PS) 4.66 (0.20) 4.63 (0.29) 4.79 (0.22) 4.92 (0.28) 
LPM (µg) 6.03 (0.67) 5.81 (0.46) 5.81 (0.35) 5.88 (0.29) 
S -2A 0.46 (0.01) 0.26 (0.01) 0.21 (0.06) 0.22 (0.01) 
S -1A 0.29 (0.03) 0.14 0.17 (0.07) 0.12 
S -0 0.25 (0.01) 0.27 (0.04) 0.25 (0.01) 0.24 (0.02) 
S 1 0.27 0.51 (0.02) 0.58 (0.03) 0.56 (0.03) 
S 2 0.37 (0.01) 0.68 (0.02) 0.78 (0.05) 0.79 (0.02) 
S 3 0.57 (0.03) 1.09 (0.01) 1.26 (0.04) 1.29 (0.04) 
S 4 0.25 (0.02) 0.57 (0.02) 0.64 (0.04) 0.67 (0.02) 
S 5 0.04 0.12 0.12 0.13 (0.01) 
Filter 0.16 0.29 (0.01) 0.34 (0.03) 0.34 (0.02) 
 
FPD (µg) 2.2 (0.09) 3.68 (0.02) 4.14 (0.25) 4.14 (0.09) 
EFPD (µg) 1.02 (0.05) 2.07 (0.04) 2.36 (0.11) 2.43 (0.09) 
MMAD [µm] 3.30 (0.2) 2.50 (0.1) 2.41 (0.1) 2.40 (0.02) 
GSD 2.10 2.20 2.10 2.00 
FPD; Fine particle dose, EFPD; Extra fine particle dose, LPM; Large particle mass, MMAD; 
mass median aerodynamic diameter, GSD; Geometric standard deviation 
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Table 5-4: Effect of inhalation volume on the total emitted dose (TEDACI), residual amount (RAACI) and total recovered dose (TRDACI) of formoterol 
left in the Easyhaler at low (28.3 L/min), medium (60 L/min) and high (90 L/min) inhalation MIF values. Results expressed as mean (SD) [n=3] 
MIF 28.3 L/min 60 L/min 90 L/min 
Vin [mL] TED [µg] RA [µg] TRD [µg] TED [µg] RA [µg] TRD [µg] TED [µg] RA [µg] TRD [µg] 
240 7.47 (0.27) 1.95 (0.29) 9.42 (0.50) 7.53(0.24) 2.03 (0.11) 9.56(0.42) 8.69 (0.23) 0.62 (0.12) 9.31 (0.33) 
750 9.28 (0.06) 1.71 (0.17) 10.99 (0.18) 9.35 (0.19) 1.69(0.09) 11.04(0.12) 9.74 (0.19) 0.49 (0.09) 10.22 (0.27) 
1500 9.29 (0.51) 1.68 (0.04) 10.97 (0.51) 9.53(0.27) 1.58(0.18) 11.11(0.10) 10.16 (0.37) 0.48 (0.08) 10.64 (0.43) 
2000 10.29 (0.24) 1.64 (0.15) 12.00 (0.10) 10.12(0.63) 1.52(0.08) 11.64(0.09) 10.24 (0.18) 0.49 (0.06) 10.71 (0.13) 
 
Table 5-5: Effect of inhalation volume on the total emitted dose (TEDDUSA), residual amount (RADUSA) and total recovered dose (TRDDUSA) of 
formoterol left in the Easyhaler at low (28.3 L/min), medium (60 L/min) and high (90 L/min) MIF. Results expressed as mean (SD) [n=3] 
MIF 28.3 L/min 60 L/min 90 L/min 
Vin [mL] TED [µg] RA [µg] TRD [µg] TED [µg] RA [µg] TRD [µg] TED [µg] RA [µg] TRD [µg] 
240 7.59 (0.17) 3.65 (0.69) 11.23 (0.86) 8.50 (0.27) 2.68 (0.11) 11.18 (0.16) 9.24 (0.20) 1.84 (0.71) 11.07 (0.90) 
750 8.11 (0.60) 2.93 (0.12) 11.04 (0.72) 9.13 (0.07) 2.18 (0.64) 11.31(0.56) 10.13 (0.24) 1.19 (0.05) 11.32 (0.19) 
1500 8.59 (0.38) 2.46 (0.13) 11.04 (0.13) 9.79(0.02) 1.86 (0.08) 11.65 (0.10) 10.49 (0.24) 0.77 (0.16) 11.26 (0.40) 
2000 9.26 (0.12) 1.77 (0.16) 11.03 (0.28) 10.18(0.48) 1.39 (0.07) 11.57 (0.40) 10.67 (0.06) 0.62 (0.17) 11.29 (0.23) 
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Figure 5.2: Mean (SD) of formoterol dose emission using dose unit sampling apparatus (DUSA). [n=10]. The results presented as % of the nominal 
dose. 
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Figure 5.3: Mean (SD) of formoterol aerodynamic dose emission characteristics using Andersen cascade impactor (ACI). [n=3]. The results 
represented as % of the nominal dose 12 µg formoterol Easyhaler®.
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Figure 5.4: Mean (SD) of fine particle dose (FPD) of formoterol emitted from Easyhaler® at 
different MIF and Vin. [Results presented as % of the nominal dose 12µg formoterol] 
 
Figure 5.5: Mean (SD) of fine particle Fraction (%FPF) of formoterol emitted from Easyhaler® 
at different MIF and Vin. 
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Figure 5.6: Mean (SD) of mass median aerodynamic diameter (MMAD) of formoterol emitted 
dose from an Easyhaler® at different MIF and Vin. 
 Discussion  
New inhaler devices are being developed to improve compliance, targeting and uniformity of 
the delivery of the emitted dose of the drug for routine use by the patient. In the present 
chapter, reliability testing of Easyhaler DPIs was carried out using 10 devices chosen 
randomly. Each of the 10 inhalers was assessed at different MIFs, and the corresponding 
pressure drops were recorded . The calculated airflow specific resistance ranged from 0.1333-
0.1355 (cm.H2O)
 0.5 *min. L-1 (0.0417-0.0424 (kPa) 0.5 *min. L-1), with a coefficient of 
variation (%CV), within the 10 inhaler devices, of < 0.5%. These result showed that there is a 
low variability in airflow resistance between separate inhalers. DPI devices are classified into 
4 groups based on their resistance: low, medium, medium-high and high resistance devices 
(Laube et al., 2011, Dal Negro, 2015) and each device have its own unique inhalation 
technique which is recommended in each patient information leaflet (Azouz and Chrystyn, 
2012). To achieve a 4 kPa pressure drop across the Easyhaler, an inhalation flow of about 48 
L/min would be required. The results suggest that the Easyhaler is a high resistance device 
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(Dal Negro, 2015). Patients with greater airflow obstruction will achieve a lower inhalation 
flow rate when using a high-resistance inhaler device. Azouz and Chrystyn (2012) showed 
that an inhaler device with a high resistance and low flow rate had the same turbulent energy, 
as a device that had a low resistance and high flow rate hence the amount of de-aggregation 
should not be affected. 
It is widely accepted that breath-activated DPIs are often associated with flow rate-dependent 
changes in the emitted dose and also the aerodynamic characteristics such as the fine particle 
dose (FPD), fine particle fraction (%FPF) and mass median aerodynamic diameter (MMAD) 
(Hill and Slater, 1998, Taylor and Gustafsson, 2005, Telko and Hickey, 2005, Johal et al., 
2013). The emitted dose from an Easyhaler® was measured at different inhalation flow rates 
28.3, 60 and 90 L/min using both DUSA and ACI Figures 5.2 and 5.3.  The difference in the 
total dose emission between 28.3 and 60 L/min was pronounced with the DUSA (Figure 5.2) 
than with the ACI (Figure 5.3), and the total recovered dose was more consistent with the 
DUSA.  Increasing the MIF from 28.3 L/min to 90 L/min resulted in a significant increase (p 
< 0.05) in the emitted dose (Figures 5.2 and 5.3). FPD (Figure 5.4), % FPF (Figure 5.5) and a 
decrease in the MMAD (Figure 5.6).  Although this de-aggregation was significantly (p < 
0.05) more efficient at 90L/min the differences were relatively small. Whereas, the difference 
in the dose emission results (TEDACI and FPD) between 28.3 L/min (Table 5.1) and 60 L/min 
(Table 5.2) was insignificant. The dose emission characteristics (TEDACI, RAACI, TRDACI, 
FPD and MMAD) results using ACI at 90 L/min (Table 5.3) was slightly higher than both 
28.3 L/min and 60 L/min.  The shallow flow dependent dose emission of formoterol in our 
study is similar to that previously reported for the salbutamol Easyhaler (Palander et al., 
2000). Our results at the low MIF highlight why the Easyhaler has been shown to be effective 
at inhalation flows of 28 L/min (Koskela et al., 2000). 
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There was an inverse relationship between the FPD, %FPF and MMAD. As MMAD 
decreased, the FPD and %FPF increased. The steepest increase in pressure drop above 60 
L/min. suggests an increase in the level of the turbulent force, which is in accordance with the 
relationship between the pressure changes and the flow described by Clark and Hollingsworth 
(1993). This turbulent force would be able to generate sufficient shear forces overcoming the 
adhesive forces between drug/carrier and/or cohesion forces between drug-drug particles. 
Such a phenomenon would be causing further de-aggregation and dispersion of drug particles 
in the emitted dose as demonstrated by the shift towards much smaller particles with 
increasing the flow rate.  MMAD values ranged between 1.9 and 4.9 µm (Figure 5.6). An 
MMAD < 5 µm is considered to be necessary for sufficient airway deposition (Mitchell et al., 
1987). The present results suggest that inhaled formoterol from Easyhaler® should reach the 
lungs irrespective of the Vin and MIF used, but with a high dose expected to reach the lungs 
at a high flow rate (Figures 5.2, 5.3 and Figures   5.4 and 5.5). 
Examination of the residual amounts (RADUSA and RAACI), presented in Table 5.4 and Table 
5.5 from DUSA and ACI, as well as the FPD (Tables 5.1, 5.2 and 5.3), suggests that when 
using an inhaled volume of 240 mL not all of the formoterol dose was emitted.  Residual 
amounts above 750 mL show that an adequate volume was passed through the device to 
empty the dose. Although Azouz et al., (2015b) have shown that some patients (especially 
children) can only achieve a Vin between 200 and 750 mL, the delivered dose and the fine 
particle dose would be sufficient to provide an adequate therapeutic response.  The data 
confirms why the Easyhaler provides an adequate response when used by young children 
(Koskela et al., 2000). A 240 mL volume was used because we measured that the dead space 
in the horizontal section of the induction port (from the mouthpiece of the adapter to the 90 
degree bend) was 40 mL and so the APSD results represented a true volume of 200 mL 
inhaled through the Easyhaler and passed through the ACI. 
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Drug retention inside the inhaler continues to be a factor plaguing the performance of novel 
inhalers (Tajber et al., 2009). Drug retention varies between inhaler devices in that some 
studies have reported between 30-50% of the nominal dose is retained within the device 
(Heng et al., 2013).  It is important that the complete dose is released from the inhaler to 
maximise the therapeutic effect, minimising drug wastage and avoiding potential dosage 
errors during the next inhalation.  Our results showed that the amount of drug retained in the 
Easyhaler was smaller than those reported in the above studies, i.e., between 14-16% at 28.3 
L/min for 2000 mL and 240 mL Vin, respectively, whereas, the amount of formoterol retained 
in the Easyhaler device at 90 L/min was ≤ 5% (Figures   5.2 and 5.3). The ACI with the 
induction port (IP) and the pre-separator (PS) has an internal volume of 1155 mL (Copley et 
al., 2005). An inhaled volume of 240 mL, therefore, represents only about 21% of the entire 
internal volume of the ACI. Hence, this small volume of air should not be sufficient to pull 
the entire aerosol bolus through the impactor causing a premature deposition of the aerosol in 
the inhalation channel of the device or in the upper parts of the impactor. Our results showed 
that the amount of formoterol deposited as a large particle mass was almost unaffected by the 
Vin (Tables 5.1, 5.2 and 5.3), but the amount of aerosol (especially the extra fine particle 
dose) reaching the lower stages of the impactor was less when a 240 mL was used.  The lower 
TEDACI (Figure 5.3), as well as the FPD (Figure 5.4) and % FPF (Figure 5.5) at this volume of 
240 mL, are more likely to be due to insufficient air pumped through the ACI.  The MMAD 
results (Figure 5.6) do suggest that deposition into the lower stages may not have been 
efficient when 240 mL was pulled through the ACI. However, as mentioned above, the high 
residual amount at both MIFs when using a 240 mL suggests that the results could also be due 
to incomplete emptying of the dose. The results show that a volume of 750 ml is sufficient 
when using the ACI. This volume is lower than the 1 L inhaled volume previously reported 
(Mohammed et al., 2012, Mohammed et al., 2014) and the internal capacity of the ACI. The 
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results show that a volume lowers than the internal capacity of the ACI can be used. The 
reason for this is unknown so required investigating. Hence, the ACI could be used to study 
the effect of low Vin and MIF values on the dose emission characteristics of DPIs.  This 
method could be used if facilities to study in-vitro dose emission by replaying patients’ 
inhalation profiles (Olsson et al., 2013, Chrystyn et al., 2015) are not available. 
At higher MIFs, increasing the Vin above 750 mL had a less significant effect on the residual 
amount. The Vin was found to be different between DPI devices; some devices require more 
inhaled volume than others. For example, the Diskus® requires a Vin as low as 150 mL in 
contrast to the Turbuhaler® which require a minimum of 1 Litre Vin (Azouz et al., 2015b). 
Genuair® inhaler showed no difference in the total emitted dose and fine particle dose using 2 
and 4 L inhaled volume (Chrystyn and Niederlaender, 2012). The Ellipta® DPI showed no 
variation in the total emitted dose and fine particle dose by increasing the inhaled volume 
from 0.7 L to 4.2 L (Hamilton et al., 2015).  
The difference in the inhaled volume between DPIs was attributed to their internal design and 
the intrinsic resistance, for example a significant increase in the fine particle fraction was 
shown with the Aerolizer® when the air inlet size was reduced and the results were explained 
by the increase in the air velocity and turbulent inside the inhaler device (Zhou et al., 2013, 
Shur et al., 2015). The difference in the Vin between the Diskus® and Turbuhaler® was 
attributed to the length of the inhalation channel. The inhalation channel in the Turbuhaler® is 
relatively long and includes a cyclone, whereas the inhalation channels of the Diskus® is very 
short. The low resistance devices have also been reported to require larger inhaled volume 
than higher resistance devices (Azouz and Chrystyn, 2012). The Easyhaler® design, i.e., short 
inhalation channel together with a high intrinsic resistance may have both accounted for only 
a small inhaled volume been required by this device, thus allowing the dose to leave the 
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inhaler. To minimise drug wastage and avoiding potential dosage errors during the next 
inhalation, it is therefore essential that patients inhale as hard as they can from the start of the 
inhalation manoeuvre to inhale the entire dose when using an Easyhaler. 
 Conclusion 
An inhaled volume of 750 mL was sufficient to study the dose emission characteristics 
of formoterol from an Easyhaler. When using the Andersen Cascade Impactor, it is likely that 
an inhaled volume down to 750mL can be used to study the aerodynamic particle size 
characteristics. The in-vitro results suggest that although the Easyhaler demonstrates some 
flow dependent dose emission, as demonstrated by both the ACI and DUSA results, it was 
effective at low inhalation flows and inhaled volumes. 
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 Chapter overview 
Inhaled therapy is the mainstay treatment of choice to control the symptoms of asthma and 
chronic obstructive pulmonary disease (COPD) (Laube et al., 2011) using either pMDIs or 
DPIs. The quality and the amount of the emitted dose from a DPI depend on patient’s 
inhalation manoeuvre, the type of device and its formulation (Clark and Hollingworth, 1993, 
Chrystyn, 2003). Each inhalation manoeuvre is characterised by a flow versus time profile, 
which includes the inhaled volume. Upon use, inhalation flow interacts with the resistance 
inside the DPI to generate a ‘force’ that deaggregates the formulation such that active drug 
particles, with the greatest likelihood of lung deposition, are entrained in the air stream as it 
leaves the device. The inhaled volume ensures that the dose is emptied from the metering 
cup/capsule (the latter applies if the DPI is a single dose capsule product). When inhaling 
from a single dose capsule DPI product it is essential that the inhaled volume is sufficient to 
empty the entire dose out of the capsule, It is for this reason that the patient information 
leaflet (PIL) for these DPIs should direct patients to make two separate inhalation manoeuvres 
from each prepared capsule dose (Haughney et al., 2010, Laube et al., 2011). 
The Breezhaler® is a low resistance device and has a resistance of 0.0177 (kPa)0.5(min L- 1) 
(Dal Negro, 2015). Patients with COPD have reduced inspiratory capacities together with low 
inhaled volumes (Azouz et al., 2015b), and so many use sub-optimal inhalations when using 
DPIs which means that the dose they inhale is reduced. 
  Inhalers play an important role in the management of patients with COPD, and it is being 
recognised that the choice of the inhalation device appears to be as important as that of drug 
molecule (Chapman et al., 2011, Lavorini and Usmani, 2013). Inhaled long-acting 
bronchodilators are used for the treatment of patients with moderate and more severe COPD 
(Cazzola and Page, 2014), and now agents are available for once-daily administration. 
Indacaterol is an inhaled, once-daily, ultra-long-acting β2-agonist (Cazzola et al., 2005). The 
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micronised indacaterol is mixed with lactose (to increase the bulk and enhance powder flow 
of the formulation).  It is packaged in transparent hard gelatine capsules each containing 75 
µg, 150 µg or 300 µg of indacaterol inhalation powder inhaled from a Breezhaler® inhaler. 
Published data shows that patients with stable  COPD were able to generate, on average, a 
MIF of 72 L/min with a range of 47-99L/min to 94.8 L/min (range, 52–133 L/min) and mean 
inhaled volumes (Vin) of 1.7L, range of 1 to 2.2 L (Pavkov et al., 2010, Chapman et al., 2011, 
Colthorpe et al., 2013). In-vitro dose emission studies focus on identifying the optimal 
inhalation flow rate for dose de-aggregation; however, this optimal flow may not be 
achievable in the real life use by the patient.  
The multivariate statistical approach study carried out by Buttini et al., (2016) demonstrate 
that the fine particle mass emitted from the single dose inhaler device had significantly 
decreased when a minimum inspiratory volume was used to operate the device (Buttini et al., 
2016b).  The information that is of most clinically relevant is to identify the type of dose 
emitted when low inhalation flows and inhaled volumes are used. This is very important for 
patients with COPD because these patients can only use low inhalation flows and low inhaled 
volumes (Azouz et al., 2015a, Azouz et al., 2015b).  
Therefore, the primary aim of this work was to investigate a range of inhalation flow rates 
(28.3, 60, 90 and 120 L/min) and volumes (500, 750, 1000, 1500 and 2000 mL) on the dose 
emission from 150 µg and 300 µg Indacaterol Onbrez Breezhaler® (Novartis Pharmaceuticals 
Ltd, UK) using two separate inhalations. Secondly, to determine the aerodynamic 
characteristics of indacaterol emitted dose using an ACI at a MIF of 28.3, 60 and 90 L/min 
and Vin of   1, 1.5, 2 and 4 L. 
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 Materials and Methods 
6.2.1 Material and instrumentation for DUSA 
The dose emission material and instrumentation used for in-vitro dose emission study were 
explained in Chapter 3 (see sections 3.1.2 and 3.1.4.1). A List of the material and other 
laboratory apparatus used in the study were listed in Chapter 3 (see section 3.1.1). 
6.2.2 Dose emission methodology 
The methodology and experimental set-up used for the determination of indacaterol 
Breezhaler® dose emission using dose unit sample apparatus (DUSA) in vitro was explained 
in the previous Chapter 4 (section 4.2.1 and 4.2.2). For dose strength study, dose emission 
experiment was carried out in triplicate (n=3) for each set of MIF and Vin. 
6.2.3 Determination of the aerodynamic characteristics of the emitted dose and 
collection of the residual amount of indacaterol 
Figure 6.1 shows schematic diagram of the method for the determination of aerodynamic dose 
emission characteristics of indacaterol 150 µg and 300 µg from an Onbrez Breezhaler® . 
 
Figure 6.1: Schematic diagram of a pharmacopeial compendial method of Andersen cascade 
impactor for DPIs testing 
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6.2.4 Characterisation of the indacaterol Onbrez Breezhaler® 150 and 300 µg powder 
formulations by Scanning Electron Microscope (SEM). 
SEM investigations of the shape, particle size and surface texture of indacaterol and the 
lactose in the Onbrez Breezhaler® 150 µg and 300 µg (Novartis Pharmaceuticals, CH) 
products was carried out using a Jeol 6060 LV SEM (Jeol Ltd., UK). A sample of the powder 
formulation was scattered onto the aluminium stage stub, by a gentle tapping motion to 
provide a thin layer that was suitable to view the particles. The movement of the sample was 
restricted by adhering the sample to a double-sided conductive carbon adhesive tape (Agar 
Scientific, UK). As the sample is non-conductive, it was required to coat the sample with a 
thin layer of gold (15 – 20 nm) (Quorum Technologies Ltd., UK) using a Quorum SC7620 
Sputter Coater (Quorum Technologies Ltd., UK). 
6.2.5 Characterisation of the indacaterol Onbrez Breezhaler® 150 and 300 µg powder 
formulations by differential scanning calorimetry (DSC) and thermogravimetric 
analysis (TGA). 
DSC experiments were conducted using a DSC 822e instrument (Mettler-Toledo, UK), with a 
refrigerated cooling system (RCS). Nitrogen was used as the purge gas, flowing at a rate of 50 
ml min−1 through the DSC cell and at 150 ml min−1 through the RCS units. Aluminium non-
hermetic DSC pans were used through the study. The mass of each empty sample pan was 
matched with the mass of the empty reference pan to ±0.1 mg. The instrument was calibrated 
using an indium standard; approximately 2.5 ± 0.2 mg of sample (Indacaterol 150, 300 µg or 
indacaterol powder) was used for each run. After sealing the pans, they were placed in the 
DSC furnace, which had been pre-equilibrated at 25 °C. Before each measurement, the 
samples were allowed to equilibrate for 5 min at 25°C and were then heated to 250°C at a 
heating rate of 10°C min−1. Each batch was analysed in duplicate. The DSC results were 
analysed using the STARe SW 9.01 version (Mettler-Toledo, Leicester, UK). 
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 Results  
6.3.1 Dose emission results for both dose strengths 150 and 300µg indacaterol 
Breezhaler®. 
The dose emission of indacaterol from Breezhaler® was investigated using a different range of 
MIFs and Vins. The dose emission was measured after first (ED1) and second (ED2) 
inhalation and the total emitted dose was the sum of ED1+ ED2. 
Table 6-1: Mean (SD) of Dose emission data of 150 µg indacaterol dose after two separate 
inhalations [n=3]. 
Vin (mL) ED1 (µg) ED2 (µg) TED (µg) TRA (µg) TRD (µg) 
a). Inhalation flow rate 28.3L/min 
500 96.26 (1.89) 22.68 (1.74) 118.94(2.72) 31.63 (2.51) 150.57 (0.37) 
750 104.90 (2.01) 18.40 (1.65) 123.30(0.76) 28.41(1.52) 151.71 (1.86) 
1000 114.98 (2.71) 9.72 (0.66) 124.70(3.27) 20.05(0.23) 144.75 (3.24) 
1500 121.23 (3.08) 6.58 (1.92) 127.81(1.16) 17.78(0.38) 145.59 (1.12) 
2000 123.13 (3.07) 4.44 (0.56) 127.57(2.68) 17.88(0.80) 145.45 (5.03) 
b). Inhalation flow rate 60L/min 
500 120.14 (5.26) 10.50(1.27) 130.64(6.46) 19.43(0.65) 150.07 (7.04) 
750 123.90 (2.41) 7.72(2.86) 131.62(1.57) 18.15(0.88) 149.77 (2.27) 
1000 129.16 (3.36) 4.75 (0.66) 133.91(3.11) 15.97(0.61) 149.88 (3.11) 
1500 131.73 (4.10) 3.72 (0.91) 135.45(4.65) 13.790.70) 149.24 (5.28) 
2000 134.27 (4.32) 2.50 (0.70) 136.77(3.96) 13.37(0.75) 150.14 (4.25) 
C). Inhalation flow rate 90L/min 
500 125.83 (4.58) 8.76 (2.02) 134.59(3.84) 14.76(1.54) 149.35 (2.97) 
750 128.16 (3.62) 7.19 (1.61) 135.35(5.23) 13.37(0.14) 148.72 (5.10) 
1000 133.87 (1.63) 3.07 (1.19) 136.94(2.38) 13.33(0.09) 150.27 (2.45) 
1500 136.08 (4.45) 2.13 (0.63) 138.21(3.92) 12.50(0.24) 150.71 (5.52) 
2000 137.15 (4.93) 1.92 (0.95) 139.07(5.76) 12.22(0.73) 151.29 (3.48) 
d). Inhalation flow rate 120 L/min 
500 130.18 (4.37) 6.24 (1.59) 136.42(5.32) 12.42(0.92) 148.84 (6.18) 
750 136.03 (4.77) 3.41 (0.94) 139.45(5.40) 11.33(1.80) 150.77 (7.12) 
1000 138.07 (7.98) 3.41(1.64) 141.48(3.39) 11.71(1.63) 153.19 (8.00) 
1500 140.42 (6.98) 2.76(0.47) 143.17(6.55) 9.94(0.54) 153.12 (6.62) 
2000 142.43 (1.94) 1.28(0.73) 143.71(1.74) 8.65(0.89) 152.36 (2.53) 
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Table 6-2: Mean (SD) of Dose emission data of 300 µg indacaterol dose after two separate 
inhalations [n=3]. 
 
Vin (mL) ED1 (µg) ED2 (µg) TED (µg) TRA (µg) TRD (µg) 
a). Inhalation flow rate 28.3L/min 
500 199.15(12.86) 35.07(5.51) 234.21(9.46) 57.20(1.40) 291.41 (13.84) 
750 214.89(12.81) 32.25(1.84) 247.14(14.20) 47.71(1.45) 294.85 (10.03) 
1000 242.03(11.55) 11.49(5.13) 253.52(11.00) 36.16(0.84) 289.68 (11.42) 
1500 244.82(12.01) 9.68(3.34) 254.51(10.47) 35.50(1.60) 290.01 (14.74) 
2000 249.43(11.15) 5.74(1.77) 255.17(11.98) 31.47(1.13) 286.63 (13.10) 
b). Inhalation flow rate 60L/min 
500 228.89 (9.28) 19.66 (8.79) 248.55(13.59) 42.94(1.40) 291.49 (12.91) 
750 242.91 (5.23) 9.34 (2.13) 252.25(6.91) 38.74(1.33) 290.99 (8.22) 
1000 253.20 (11.25) 5.17 (1.05) 258.37(10.25) 35.42(0.44) 293.79 (10.32) 
1500 255.77 (7.15) 4.03 (2.07) 259.80(15.83) 32.70(0.78) 292.50 (11.07) 
2000 259.17 (9.53) 3.40 (0.56) 262.57(9.61) 30.47(2.07) 293.04 (11.89) 
c). Inhalation flow rate 90L/min 
500 253.98 (3.46) 11.78 (2.44) 265.76(1.91) 33.07(1.17) 298.83 (7.84) 
750 264.76 (7.36) 8.75 (5.51) 273.51(8.65) 26.65(1.14) 300.16 (9.60) 
1000 270.32 (6.58) 5.04 (1.79) 275.36(4.79) 24.63(1.69) 299.99 (6.48) 
1500 274.72 (7.18) 2.81 (0.72) 277.53(6.73) 22.94(1.20) 300.47 (7.00) 
2000 276.45 (8.63) 2.83 (1.56) 279.28(7.19) 23.77(1.15) 303.05 (6.24) 
d). Inhalation flow rate 120 L/min 
500 261.25 (11.38) 8.84 (0.16) 270.10(19.22) 22.46(1.72) 292.55 (1.87) 
750 268.31 (4.21) 5.61 (0.64) 273.92(4.77) 19.82(1.71) 293.75 (6.44) 
1000 270.58 (3.57) 5.02 (0.37) 275.59(3.19) 19.02(0.80) 294.62 (2.99) 
1500 278.02 (12.89) 3.18 (0.98) 281.20(13.51) 15.60(1.90) 296.80 (10.69) 
2000 280.87 (12.04) 2.91 (0.99) 283.79(13.03) 12.80(1.17) 296.58 (13.20) 
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Figure 6.2: Mean of indacaterol 150µg (ED1) and (ED2) as % of the nominal dose [n=3]. 
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Figure 6.3: Mean of indacaterol 300µg emitted dose after first (ED1) and second (ED2) inhalation as % of the nominal dose [n=3].
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6.3.2 Aerodynamic dose emission characteristics of indacaterol Breezhaler® using Andersen cascade impactor.  
The aerodynamic characteristics of the emitted dose of indacaterol 150 and 300 µg dose strengths were investigated. The range of MIF and Vin 
used for the study was chosen to comply with the specification of the internal impactor volume (approximately 1L) and the clinical inhalation 
profiles data of patients with COPD (mild to very severe condition)  
Table 6-3: Mean (SD) of the aerodynamic characteristics of the indacaterol 150 µg dose emission at different MIF and Vin [n=3]. 
 
 
MIF = 28.3 L/min 
Vin (L) FPD (µg) TED (µg) %FPF EFPD (µg) RA(µg) %TRD MMAD (µm) GSD 
1.0 36.4(0.4) 105.7(1.5) 34.5(0.2) 20.1(0.1) 29.3(1.3) 90.0(1.4) 3.5(0.1) 1.8(0.1) 
1.5 40.5(0.2) 111.6(0.9) 36.3(0.4) 21.5(0.4) 22.3(0.8) 89.3(0.9) 3.4(0.0) 1.9(0.0) 
2.0 42.9(0.1) 115.4(1.3) 37.2(0.3) 25.2(0.1) 21.7(1.3) 91.4(1.1) 3.3(0.1) 1.8(0.1) 
4.0 46.8(0.5) 120.0(0.8) 39.1(0.1) 27.6(0.0) 18.9(0.4) 92.6(0.7) 3.2(0.1) 1.8(0.1) 
  MIF = 60 L/min 
1.0 43.2(0.5) 119.4(1.1) 36.2(0.7) 28.6(0.2) 21.7(2.1) 94.1(1.0) 2.9(0.1) 1.9(0.1) 
1.5 45.7(0.3) 120.4(0.7) 37.9(0.3) 30.7(0.3) 18.6(0.6) 92.7(0.6) 2.9(0.1) 2.0(0.1) 
2.0 47.7(0.9) 121.2(0.3) 39.4(0.5) 31.6(0.3) 18.1(0.7) 92.9(0.3) 2.9(0.0) 2.1(0.0) 
4.0 50.9(0.1) 123.9(0.4) 41.1(0.5) 34.1(0.1) 17.5(0.4) 94.3(1.2) 2.8(0.1) 2.0(0.1) 
  MIF =90 L/min 
1.0 45.7(0.2) 121.0(0.2) 37.8(0.6) 34.2(0.6) 17.8(0.6) 92.5(0.8) 2.8(0.1) 2.0(0.1) 
1.5 47.7(0.1) 123.8(0.8) 38.5(0.4) 35.1(0.3) 15.7(0.4) 93.0(1.2) 2.8(0.1) 2.1(0.1) 
2.0 53.9(0.4) 124.6(0.7) 43.2(0.6) 38.4(0.2) 13.3(0.3) 91.9(0.7) 2.7(0.0) 2.0(0.0) 
4.0 54.7(0.4) 126.2(0.3) 43.4(0.9) 39.1(0.9) 12.7(0.7) 92.6(1.5) 2.7(0.0) 2.0(0.0) 
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Table 6-4: Mean (SD) of the aerodynamic characteristics of the indacaterol 300 µg dose emission at different MIF and Vin [n=3]. 
 
MIF= 28.3 L/min 
Vin (L) FPD (µg) TED (µg) %FPF EFPD (µg) RA(µg) %TRD MMAD (µm) GSD 
1.0 72.9(1.2) 218.9(1.7) 33.3(1.2) 40.5(0.2) 49.7(0.9) 89.5(2.1) 3.3(0.0) 1.8(0.1) 
1.5 83.0(0.2) 231.0(1.4) 36.0(0.3) 45.3(0.5) 39.2(1.1) 90.0(0.9) 3.3(0.1) 1.9(0.1) 
2.0 86.3(0.4) 232.0(1.2) 37.2(0.2) 48.3(0.3) 38.1(0.7) 90.1(1.1) 3.2(0.0) 1.9(0.0) 
4.0 89.8(1.3) 236.1(1.0) 38.0(0.3) 50.0(0.1) 35.5(1.3) 90.5(1.6) 3.0(0.1) 1.8(0.0) 
  MIF = 60 L/min 
1.0 92.5(0.4) 240.9(2.0) 38.4(0.4) 62.6(0.5) 36.3(1.0) 92.4(2.0) 2.8(0.0) 2.0(0.1) 
1.5 96.0(0.5) 245.4(1.3) 39.1(0.6) 64.4(0.3) 33.1(1.2) 92.8(1.1) 2.8(0.1) 2.1(0.1) 
2.0 99.8(0.9) 247.8(1.5) 40.3(0.7) 66.1(0.3) 32.9(0.8) 93.6(1.3) 2.7(0.1) 2.0(0.1) 
4.0 106.4(0.6) 249.5(0.7) 42.7(0.5) 68.8(0.8) 31.5(0.6) 93.6(1.9) 2.7(0.0) 2.1(0.0) 
  MIF= 90 L/min 
1.0 95.5(1.2) 244.1(1.1) 39.1(0.8) 74.0(0.6) 34.6(0.9) 92.9(1.2) 2.7(0.1) 2.0(0.1) 
1.5 105.3(0.8) 246.5(0.9) 42.7(0.7) 79.0(0.3) 30.5(0.4) 92.3(1.0) 2.7(0.0) 1.8(0.0) 
2.0 108.5(0.4) 247.4(0.7) 43.9(0.6) 81.1(0.2) 31.1(0.8) 92.8(0.7) 2.6(0.1) 1.9(0.1) 
4.0 112.6(0.7) 252.1(1.0) 44.7(0.9) 82.1(0.9) 29.1(0.5) 93.7(0.8) 2.6(0.1) 1.9(0.1) 
FPD= Fine particle dose (≤5µm), TED= Total emitted dose, FPF= fine particle mass as % of the TED, EFPD= Extra fine particle dose (≤ 3µm), RA= Residual amount (retained in capsule and 
device), % TRD= Total recovery dose as % of the nominal dose 300 µg indacaterol, MMAD= Mass median aerodynamic diameter, GSD= Geometric standard deviation, MIF= maximum 
inhalation flow, Vin= Inhaled volume. 
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Figure 6.4: The fine particle dose (FPD) of indacaterol emitted from the Onbrez Breezhaler® at 
different MIF of (28.3, 60 and 90L/min) and Vin of (1, 1.5, 2 and 4L) for both A) 150µg dose 
strength B) 300 µg dose strength 
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Figure 6.5: The extra fine particle dose (EFPD) of indacaterol emitted from the Onbrez Breezhaler® as a function of the inhalation flow (MIF) and 
volume (Vin) used for both dose strengths 150 and 300 μg. 
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Figure 6.6: The Mass median aerodynamic diameter (MMAD) of indacaterol emitted particles 
at different inhalation flow (MIF) and inhalation volumes (Vin) for both A). 150 µg indacaterol 
dose strength. B). 300 µg indacaterol dose strength. 
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Figure 6.7: Scanning electron micrographs of indacaterol Onbrez Breezhaler 150 µg and 300 µg 
powder formulations. a) 150 µg general view, b) 300 µg general view, c) 150 µg close view, d) 300 
µg close view. 
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Figure 6.8: Differential scanning calorimetry (DSC) of indacaterol Onbrez Breezhaler: a) 150 µg 
and b) 300 µg and c) indacaterol powder. 
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 Discussion  
The Onbrez Breezhaler® formulation, like many DPI devices, contains a blend of the 
micronised drug with tomahawk shaped α-lactose monohydrate carrier (Figure 6.7 C and D).  
As shown from the DSC thermogram (Figure 6.8 A and B) the endothermic transition peaking 
at 147 oC corresponds to the loss of water of crystallisation whilst the endothermic peak at 
217 oC is due to the melting of α- lactose monohydrate (Lerk et al., 1984). A small exothermic 
transition is observed at around 172 oC corresponding to the small amount of amorphous 
content (Larhrib et al., 2003). Indacaterol showed a sharp endothermic melting peak (Figure 
6.8 C) which is not shown in the Onbrez Breezhaler formulation either because it was masked 
by lactose melting peak or it was not detected due to it comprise a smaller amount in the DPI 
formulation. Each capsule contains indacaterol maleate equivalent to 150 µg or 300 µg 
Indacaterol. Onbrez Breezhaler® 150 µg and 300 µg are formulated with similar amounts of 
carrier i.e., 24.8 mg for the 150 µg indacaterol and 24.6 mg for the 300 µg dose (Moen, 2010), 
corresponding to a 0.6% w/w and 1.2% w/w drug/lactose ratio for 150 µg and 300 µg 
indacaterol respectively. It can be seen from the scanning electron micrographs (Figure 6.7 A 
and B) that 150 µg indacaterol formulation has a higher concentration of fine carrier particles 
in comparison to 300 µg indacaterol formulation. The performance of DPIs is profoundly 
influenced by the physical properties of the carrier particularly their particle size and surface 
roughness (Larhrib et al., 1999). These morphological features of lactose carrier play a 
significant role in determining DPI performance by influencing the flow and hence drug 
content uniformity and influencing the adhesion and detachment of drug from the surface of 
the carrier. Kaialy et al., (2012) reported that reducing the particle size of the carrier improves 
the amount of respirable drug delivered from a DPI but has an adverse effect on drug content 
uniformity and result in more drug deposited in the oropharyngeal region (Kaialy et al., 2012). 
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Despite the difference observed in the carrier particle size, size distribution (SEM) and drug to 
carrier ratio yet both formulations produced a good drug content uniformity (% CV < 1.8%) 
and a % recovery of 100% (Table 6.5). 
Table 6-5: Mean, Percent recovery and % coefficient of variation (% CV) of indacaterol maleate 
content contained in 150 µg and 300 µg indacaterol Onbrez Breezhaler® (n =6). 
Indacaterol maleate 
dose strength 
Mean dose per 
capsule ± SD 
% CV 
150 µg 151.32 ± 2.68 1.77 
300 µg 301.46 ± 4.74 1.57 
Tables 6.1 and 6.2 summarise the dose emission results after the first (ED1) and after the 
second inhalation (ED2) as well as the total emitted dose (TED) for the 150 µg and 300 µg 
indacaterol products as a function of MIF and Vin. The ED1 significantly increased (p <0.05) 
whereas the ED2 decreased with increasing the MIF and VIN.  At the low inhalation flow rate 
(28.3 L/min), the first inhalation was not sufficient to withdraw most of the dose from the 
capsule and the second inhalation was necessary to empty the capsule (Figures 6.2 and 6.3). 
The results confirm the recommendation to make two separate inhalations from each dose to 
successfully empty the capsule (Laube et al., 2011) it is more important to make two separate 
inhalations when the only low flow rate is achieved by the patient.  The Vin contributed to the 
capsule emptying after the first inhalation. At the higher inhalation flow rate (120 L/min) 
most of the dose was emitted from the capsule after the first inhalation, and only small 
amount of the drug was left in the capsule for the second inhalation (Table 6.1 and 6.2). The 
impact of the inhaled volume with regard to dose emptying was more pronounced at the low 
MIFs than at high MIFs (Table 6.1 and 6.2). It is widely accepted that breath-activated DPIs 
are often associated with flow rate-dependent changes in the emitted dose (Hill and Slater, 
1998, Taylor and Gustafsson, 2005, Telko and Hickey, 2005, Johal et al., 2013). Increasing 
the MIF from 28.3 L/min to 120 L/min resulted in a significant (p < 0.05) increase in the total 
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emitted dose. Overall dose emission was reduced below a MIF of 60 L/min and Vin of 1 L 
(Table 6.1 and 6.2).  Since the reported MIF and Vin of some COPD patients were found to 
be below these values (Pavkov et al., 2010, Chapman et al., 2011, Colthorpe et al., 2013) this 
would suggest that not all patients will inhale the full prescribed dose when using the Onbrez 
breezhaler®. 
The resistance of a DPI can be classified with respect to the inhalation flow required to 
produce a pressure drop of 4 kPa. This value was chosen because it is the one recommended 
by pharmacopoeia (USP, 2014) for the in-vitro characterisation of the dose emitted from a 
DPI. A device that is characterised as having a low resistance requires an inspiratory flow of 
90 L/min to produce this pressure drop (Laube et al., 2011). We found that the flow rate 
required to achieve a 4 kPa pressure drop through the Breezhaler® was around 100 L/min 
which is in line with other authors results (Pavkov et al., 2010, Dederichs et al., 2015). This 
confirms that the Breezhaler® is a low resistance device. 
In the case of the Indacaterol Breezhaler®, irrespective of the sampling apparatus used (DUSA 
or ACI) the TED is almost doubled with increasing indacaterol dose from 150 µg to 300 µg 
(Tables 6.1- 6.2 DUSA and 6.3- 6.4 ACI), suggesting a linear relationship between inhaled 
dose and the delivered dose in-vitro. The TEDACI is equivalent to ED1 recovered from 
DUSA1. At the same MIF (90 L/min) and Vin (2 L), the TEDACI was generally smaller than 
ED1 (Table 6.1 and 6.3). The ACI is composed of many stages and its internal volume (1.155 
L) comfortably exceeds the volume of DUSA (0.1 L). As a result the washing of ACI for drug 
collection is time consuming, and the probability of losing some drug during the washing 
could be more for ACI than for DUSA.  The washing procedure of either DUSA or ACI was 
carefully conducted as shown from the total recovered dose (TRD) which was around 100% 
for DUSA (Tables 6.1  and 6.2) and > 92% for ACI (Table 6.3 and 6.4). 
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Capsule-based DPIs can be limited by powder retention in the capsule and device, which 
leads to a reduction in the emitted dose (Vidgren et al., 1988). The drug retention could be 
minimised by coating the drug capsule and delivery device with pharmaceutically acceptable 
force-control agents (Heng et al., 2013).  Irrespective of the dose strength, the residual amount 
in the capsule after two separate inhalations (RAcap), residual amount in the device (RADev) 
and the total residual amount in capsule and device (TRA is equal RAcap + RADev) were 
decreased with increasing the MIF  and Vin ( Table 6.1 and 6.2).  The RA (Cap) after two 
separate inhalations is much smaller than the RA (Dev). Thus, inhaling twice from the 
capsule, inhaling forcefully and prolonging the inhalation time contribute all to the reduction 
in the TRA.  The RA is about two-fold for 300 µg Indacaterol (Table 6.2) in comparison to 
150 µg using DUSA (Table 6.1) or ACI (Table 6.3 and 6.4). 
The inhaled volumes used to quantify the aerodynamic particle size distribution of inhaled 
indacaterol exceed the internal volume of the ACI ( 1.155 L) (Copley et al., 2005) to allow 
sufficient sampling time for the aerosol bolus transfer from the inhaler device to distal stages 
of the ACI. The ACI data illustrate the impact of the Vin and MIF increase on the 
aerodynamic characteristics of indacaterol emitted dose. The results of the FPD as a function 
of the Vin at different MIFs for both dose strengths 150 µg and 300 µg are shown in Figures 
6.4 A and B respectively. The FPD significantly (p < 0.05) increased with both the Vin and 
the MIF irrespective of the dose strength. The FPD was almost doubled when the dose 
strength increased from 150 µg to 300 µg (Figures 6.4 A and B) across all MIFs and Vins, 
however as a percentage of the nominal dose, the FPD would be almost the same for both 
dose strengths suggesting the reliability of the Breezhaler in delivering a consistent drug 
dosing in-vitro. Prolonging the Vin is more critical especially when low MIF is used. For 
example using an inhaled volume of 4 L at 28.3 L/min would provide similar FPD to 90 
L/min and 1 L inhaled volume (Figure 6.4). Thus, prolonging the Vin is essential when high 
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MIF cannot be achieved. The increase in FPD is more pronounced between 28.3 and 60 
L/min, and the rate of increase in the FPD between 60 and 90 L/min is generally reduced. 
Thus, 60 L/min could be considered as a threshold MIF to operate the Breezhaler, which can 
be achieved easily achieved in practice due to the low resistance of this device. For example, 
using the same patients, a mean peak inspiratory flow (PIF) of 72 L/min was generated with 
the Breezhaler® device compared with a mean PIF of only 36 L/min with the Handihaler® 
(Price and Chrystyn, 2015). The results of the EFPD (< 3um) for both dose strengths (150 µg 
and 300 µg) are shown in Figure 6.5, and a similar trend was observed for EFPD (< 3 µm) for 
both dose strengths with increasing the MIFs and Vins. The high proportion of EFPDs would 
improve the deposition in the peripheral airways in the lungs, and this is considered beneficial 
for the management of COPD (Heyder, 2004, De Boer et al., 2015). Our study showed that 
both the MIF and Vins are important in maximising the EFPD of indacaterol (Figure 6.5). 
GSD values are > 1.2 µm (Tables 6.3 and 6.4) suggesting polydispersity of the aerosol; this 
polydispersity is more likely to influence drug distribution in the airways.  This polydispersity 
contains substantial mass fractions of particles smaller than 5 µm (Figures 6.4 A and B).  The 
greatest decrease in MMAD was observed between 28.3 L/min and 60 L/min across all Vins 
used and increasing the MIF above 60 L/min did not make much difference in the MMAD 
(Figure 6.6 A and B), suggesting that 60 L/min is the minimum MIF to operate the 
Breezhaler. An MMAD < 5 µm is considered to be necessary for sufficient airway deposition 
(Roche et al., 2013). The difference in FPD < 5 µm between different flow rates and volumes 
are also strongly reflected in the differences in the EFPF (< 3 µm). The turbulent generated at 
high flow rates 60 and 90 L/min was able to generate sufficient shear forces between drug-
drug particles. Such phenomenon would be able to enhance particles dispersion leading to the 
formation of smaller particle size (Abadelah et al., 2017). Prolonging inhaled volume may 
have also provided particles with sufficient time of flight allowing drug-drug particles 
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detachment. The performance of Breezhaler is dependent on both inhalation flow rate and 
volume. The increase in FPD is more pronounced between 28.3 and 60 L/min. Prolonging the 
Vin is more critical especially when low MIF is used. Breezhaler was effective in producing 
respirable particles with an MMAD < 5 µm irrespective of the inhalation flow rate, but the 
mass fraction of particles with an aerodynamic diameter < 3 µm is more pronounced between 
60 and 90 L/min as shown in Figure 6.5. The difference in the drug particle size distribution 
as a function of the flow rate and volume is more likely to influence drug distribution in the 
airways. 
 Conclusions  
Although the difference in particle size of lactose carrier both indacaterol formulations 150 µg 
and 300 µg provided an excellent drug content uniformity with a % CV < 1.8. The indacaterol 
dose emission from the capsule based Onbrez Breezhaler® for both dose strengths 150 and 
300 µg demonstrated inhalation flow dependent dose emission. Furthermore, the inhaled 
volume (Vin) was important when low MIF was used. The aerodynamic characteristics of 
indacaterol showed that Breezhaler® was effective in producing respirable particles with an 
MMAD < 5 µm irrespective of the inhalation flow rate, but the mass fraction of particles with 
an aerodynamic diameter <3 µm is more pronounced between 60 and 90 L/min. The 
difference in the drug particle size distribution as a function of the flow rate and volume is 
more likely to influence drug distribution in the airways. 
This chapter results showed that a minimum MIF of 60 L/min and inhaled volume of 1L is 
required when using the indacaterol Breezhaler®. Finally, the results confirm the 
recommendation of using two separate inhalations for each dose when high MIF is not 
achieved through Onbrez Breezhaler®. 
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Breezhaler® using real life recorded and 
simulated COPD patients’ inhalation profiles 
 
 
 
 
 
 
  
 
 
 
 
 
 
191 
 
 Chapter overview 
It is obvious that the square wave profiles generated by the vacuum pump are by no mean a 
precise simulation to the patients’ IP. It has been argued that this method fails to reliably 
assess how a DPI would perform for weak patients such as those with severe impaired lung 
function and very severe COPD (Al-Showair et al., 2007b, Copley et al., 2014). Patient IP is 
bell shaped with a gradual increase in the ACIM to reach the maximum inspiratory flow 
(Chrystyn and Price, 2009). In real life COPD patients’ IP,  the inspiratory parameters MIF, 
Vin and ACIM act all together during the inhalation manoeuvre, but the extent of each 
parameter in the overall dose emission and aerodynamic characteristics of indacaterol 
Breezhaler® is not known in the literature. The present chapter assess the performace of 
indacaterol Breezhaler® (150 µg) using real life COPD patients’ IP, in addition to the impact 
of each parameter of the inhalation manouever on the aerodynamic dose emission 
characterisitcs of indacaterol Breezhaler using simulated COPD patients’ IP.   
The patient inability to achieve the required optimum inhalation effort will result in poor drug 
delivery to the lungs (Haidl et al., 2016). The patient IP comprises of different parameters 
namely MIF, Vin and ACIM (Olsson and Asking, 1994, Chrystyn et al., 2015, 
Bagherisadeghi et al., 2017).The IP characteristics depend on the patient body mass index 
(BMI), gender, age and disease status (Chrystyn and Price, 2009), which makes the inhalation 
manoeuvre parameters differ from one patient to another when inhaling through the same DPI 
device. The difference in the inhalation manoeuvre parameters between patients results in a 
different dose delivered to the lungs (Pasquali et al., 2015, Buttini et al., 2016a). The square 
wave IP generated by the vacuum pump applies a constant flow rate which is maintained for a 
specific period of time during aerosolisation in-vitro testing to represent the inhalation time. 
Furthermore, results in a rapid ACIM through the DPI beyond the capability of a typical 
patient (Copley et al., 2014). 
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Recently, researchers have adapted a new methodology to replace the use of the vacuum 
pump with in-vivo generated patients’ IPs using breath simulator (BRS) (Olsson et al., 2013). 
This methodology is more representative than the electronic lung methodology (Brindley et 
al., 1994). The ex-vivo methodology has been extensively used to determine the difference in 
aerodynamic characteristics when patient IPs are used instead of compendial vacuum pump 
(Chrystyn et al., 2015, Bagherisadeghi et al., 2017). Breath simulator has opened up the 
opportunity to improve the clinical relevance of in-vitro orally inhaled product (OIP) testing 
techniques (Copley et al., 2014). Rather than using a BRS to generate and apply inhalation 
/exhalation profile that mimics human subject researcher have started to work with real 
patients’ IPs to scope product performance. 
The present chapter was designed to study the effect using in-vivo generated COPD patients’ 
IP on the dose emission of indacaterol Breezhaler®. The only difference between our study 
and the above-mentioned study (Chrystyn et al., 2015) was that the ACI was used instead of 
NGI to determine inhaled indacaterol aerodynamic particle distribution. Furthermore, effect 
of each inspiratory parameter (MIF, Vin and ACIM) was determined using simulated COPD 
patients’ IPs. These simulated IPs were produced by altering the raw profiles to change only 
one parameter at a time. The ranges of MIF ( 40  L/min, 65 L/min and 85 L/min), Vin ( 1 L, 2 
L and 3 L), ACIM ( 2 L/s2, 4 L/s2 and 8 L/s2) were chosen to be of clinical relevance based on 
previous in-vivo studies (Pavkov et al., 2010, Chapman et al., 2011, Colthorpe et al., 2013), 
and also to be within the specifications of both ACI and BRS. 
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 Inhalation profiles  
7.2.1 Calculation of the inhalation profiles parameters 
The MIF for each profile was the maximum flow point achieved by the patient. The Vin was 
calculated from the area under the curve of each profile where the inhalation MIF is 
represented in y-axis versus time in x-axis. The IP time was calculated from the zero starting 
point of the profile, then reaching the maximum flow and finally returned to zero. 
The ACIM was calculated from the patient profile data. Whereas linear regression was 
calculated for each 0.1 second interval between the inhalation flow and time, then highest 
slope with Square regression close to 1 was chosen as the ACIM for each profile. 
The flow rates values were then changed into (mL/s) to be replayed using the breath 
simulator. Only TXT files format are accepted to be used with the simulator.  
Table 7-1: illustrates the calculation of the inhalation profile parameters. 
T(s) Q (L/min) ACC (L/s2) R2 IV(L) Q (mL/s) 
0 0 0.722684 1 0.001 0.000 
0.05 2.168052 0.639054 1 0.003 36.134 
0.1 4.085213 1.918357 1 0.006 68.087 
0.15 9.840283 2.512637 1 0.011 164.005 
0.2 17.378193 2.938076 1 0.018 289.637 
0.25 26.192422 1.909365 1 0.024 436.540 
0.3 31.920518 1.699543 1 0.029 532.009 
0.35 37.019147 1.445895 1 0.033 616.986 
0.4 41.356833 1.209125 1 0.036 689.281 
0.45 44.984207 0.992193 1 0.039 749.737 
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7.2.2 Recorded COPD inhalation profiles  
 The IPs of 38 patients with different COPD severity aged 55-79 with a mean age of 66 were 
recorded using an inhalation profile recorder. The profiles were recorded using an empty 
(Placebo) Onbrez Breezhaler® inhaler device, and the patients were able to generate an 
average MIF of 88 L/min. The patients were given the patient information leaflet (PIL) to 
read and trained to inhale as hard and fast as they can from the start of the inhalation 
manoeuvre and for as long as they could.(COPD profiles were generated in previous in-vivo 
study (Azouz et al., 2015b). [see appendix for profiles’ figures] 
Table 7-2: Patient’s demographic details and inhalation parameters.[ Patients’ inspiratory 
parameters were highlighted] 
Volunteer 
code 
Age BMI SEX 
PEF FEV1 
MIF Vin 
(ml) 
ACIM 
Time(s) 
(yrs) (kg/m2) (M/F) (L/min) (L/sec2) 
1 71 48.6 F 180 1 28.3 0.7 1.9 2.4 
2 61 29.4 M 160 1.1 36.0 1.2 2.1 4.1 
3 73 39.5 M 305 1.8 39.2 2.0 5.1 4.4 
4 62 32.1 F 205 1 43.8 1.6 2.2 3.5 
5 55 19.8 M 220 1.65 51.8 1.6 3.9 3.7 
6 74 22.1 M 255 1.6 53.5 2.6 3.8 4.6 
7 69 30 M 200 1.15 54.8 2.0 3.6 3.3 
8 53 26.4 F 235 1.75 54.9 2.5 2.9 5.3 
9 74 18.4 F 65 0.8 66.0 1.0 4.7 1.7 
10 73 24.2 M 185 1.2 71.0 2.4 4.4 3.4 
11 63 20.2 M 160 1.25 76.3 2.6 6.3 4.3 
12 69 21.5 F 160 1.3 78.4 1.9 4.1 2.5 
13 73 32.3 M 130 0.5 80.9 3.0 5.2 3.3 
14 67 24.8 M 190 1.15 81.3 2.5 2.8 3.1 
15 69 33.2 M 170 0.85 83.7 1.8 5.2 2.3 
16 78 21.2 M 290 1.5 87.8 3.0 5.1 4.0 
BMI= body mass index, PEF= peak expiratory flow, FEV1= forced expiratory volume in 1 seconds, MIF= maximum 
inspiratory flow, Vin= Inhaled volume, ACIM= initial acceleration of the inhalation manoeuvre, Ti=inhalation time in 
seconds. 
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7.2.3 Simulated COPD patients’ inhalation profiles  
The inspiratory parameters (e.g., MIF, ACIM and Vin) were measured for each profile; the 
MIF for each profile is the highest flow the patient can achieve from the start to the finish of 
the inhalation time. The Vin was calculated from the area under the curve of the inhalation 
flow against the time profile. While, ACIM was determined by firstly calculating the slope of 
the flow values against the inhalation time, then the value with a high linear regression (r2) 
was chosen. In the case of Onbrez Breezhaler the linear regression was almost r2=1 for all the 
values. Therefore ACIM was determined as the values with high slope. 
The IPs were classified into three main groups depending on the MIF that was generated by 
the COPD patient’s low (40 L/min) medium (65L/min) and high (85L/min). Then, both 
ACIM and Vin of these profiles were altered to obtain Vin values of 1, 2 and 3 L and ACIM 
values of 2, 4 and 8 L/s2. The Vin was altered by increasing or decreasing the inhalation time 
(Ti) after the MIF of the profile. The ACIM was altered for chosen profiles by increasing or 
decreasing the steepness of the initial slope of the profile. The patients were able to achieve a 
MIF of 88.93 L/min (29.48), Vin of 2.13 L (0.60) and ACIM of 6.18 L/s2 (4.23) when 
inhaling through Onbrez Breezhaler®. Therefore, the parameters for simulated IPs were 
designed to mimic these values. [Summary of the simulated patients’ IP (n=27) used in the 
study are provided in the appendix] 
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 Materials and methods  
7.3.1 Materials  and HPLC method  
The materials used for the determination of aerodynamic dose emission of indacaterol 
Breezhaler® were discussed in Chapter 3 (section 3.1.3). A validated HPLC method for the 
quantification of the indacaterol was explained in Chapter 3 (section 3.2.5). 
7.3.2 Measurement of the dose emission aerodynamic characteristics using inhalation 
profiles.  
The ex-vivo methodology was used to replay the patients’ IPs using breath simulator; a 
mixing inlet was used to enable the measurement of the aerosolised dose with breath 
simulator ( Nadarassan, 2010; Olsson, 2013; Chrystyn et al. 2015). The principle of using the 
breath simulator (BRS) with Andersen cascade impactor (ACI) was achieved by introducing a 
mixing inlet in between the pre-separator of the cascade impactor and the Alberta Idealised 
Throat (IAT) see Figure 7.1. The role of the mixing inlet is enabling the ACI to work at 
constant flow rate ( e.g., 90 L/min) and therefore, not affecting the principle of ACI mode of 
work. An inhalation flow generated by the breath simulator will pass through the inhaler 
device, and it is the one responsible for dose de-aggregation. The ACI was connected to the 
vacuum pump by the mean of a critical flow controller; then the mixing inlet was connected 
to the breath simulator. The supplementary air cylinder was connected to the breath simulator 
and mixing inlet via controlled valve connection. The controlled valve was opened to 
introduce the supplementary air to the mixing inlet. The flow rate was monitored to ensure 
that flow rate at the mouthpiece is constant at 0 L/min before dose actuation. 
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Figure 7.1: Breath simulator, ACI and AIT experimental set-up  
7.3.3 Measurement of dose content uniformity using dose unit sampling apparatus 
DUSA. 
For DPIs, the dose emptying as well as the aerodynamic particle size distribution (APSD) is 
defined by the inhalation manoeuvre. Therefore, the IPs should be applied using both DUSA 
and ACI in order to scope performance of the inhaler device using breath simulator fully. The 
investigation of dose delivery uniformity (DDU) is usually carried out using DUSA, which 
capture the entire dose delivered by the orally inhaled product (OIP). 
The experimental set-up is similar to that applied with ACI (Section 7.3.2) instead of using 
ACI; DUSA was used to measure dose emission uniformity of the inhaler device. All profiles 
(Table 7.2) were used to aerosolise the dose of 150 µg indacaterol into the DUSA. Three 
determination of each profile was carried out using 3 capsules, then total emitted dose 
(TEDDUSA) and total residual amount (TRADUSA) were determined after recovering the dose 
emitted into the DUSA and amount retained in the capsule and device. 
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 Experimental set-up 
7.4.1 Andersen cascade impactor set-up  
The manufacturing protocol was carried out to ensure that all ACI stages, the pre-separator, 
the mixing inlet and the Alberta idealised throat (AIT) are washed, cleaned and dried before 
use. An oven (Memmert Ltd, Germany) was used for drying. However, appropriate time was 
given for all the washed parts to cool at room temperature in order to ensure that no 
electrostatic charge would affect the aerosolised drug powder. The collection plates were 
cleaned with acetone, and thereafter sprayed with a silicone lubricant and left to dry for 20 
mins to avoid particle bouncing when hitting the plate during the experiment. The inner face 
of the AIT was sprayed with a silicone lubricant to maintain a condition which would be a 
realistic representation to the patient’s throat and to prevent particles bouncing off the surface 
(Zhou et al., 2011). 
The ACI was set to operate at either 60 or 90 L/min. When 60 L/min was used stages 0 and 7 
of the ACI were replaced by stages -1 and -0, while stages -1 and 6 were replaced by the 
stages -2A and -1A when 90 L/min was used. The pre-separator was chosen for each 
operating flow rate. The pre-separator was filled with 10 mL of a washing solution ( MeOH: 
water 60:40 % v/v) to prevent large particles from bouncing into the stages of the ACI and 
thereby affecting the deposition results (USP, 2014, Copley, 2015). The ACI stages were 
assembled in order, and a 82mm filter (Whatman®, UK) was then placed in the filter stage to 
collect the remaining particles in the air stream. The mixing inlet was positioned between the 
pre-separator and the AIT to introduce supplementary air through the side arm (Figure 7.1). 
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7.4.2 Breath Simulator- ACI set-up 
Figure 7.2 shows the experimental set-up of the breath simulator (BRS 3000) with ACI. The 
breath simulator warming profile was carried out (20 cycles) prior to the experiment run.The 
system warm- up procedure was recommended by the manufacturer (Copley, 2015). 
 
Figure 7.2: Schematic diagram of the methodology set-up. 
 The ACI was connected to the vacuum pump by using the critical flow controller (TPK 2000, 
Copley Scientific Ltd, UK). Then, the ACI was connected to the breath simulator using the 
mixing inlet side arm. The supplementary air cylinder was connected to the breath simulator 
using a regulatory flow valve. The vacuum pump was switched on 20 minutes  before the first 
determination to ensure flow stability. The airflow through the ACI was set either at 60L/min 
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or 90L/min in accordance with the chosen IPs. The flow from the vacuum pump was set while 
the regulatory flow valve remained closed.The flow meter (DFM 2000, Copley Scientific Ltd, 
UK) was used to measure the flow through ACI ( flow stability P3/P2 ≤ 0.5). When the 
required flow was displayed on the meter’s screen and set, the regulatory valve was then 
opened to introduce the supplementary air through the mixing inlet side arm. The flow meter 
screen was then monitored to ensure that the supplementary air introduced is equal to that 
introduced by the vacuum pump, and the flow at the mouthpiece is  0 L/min. 
Then, the run button on the screen of the BRS was pressed in order to replay the IPs which are 
programmed to be used with BRS 3000. The IP flow condition was withdrawn from the 
supplementary air. Therefore, the inhalation profiles’ MIF should be 5 L/min below the 
operating flow rate.The flow rate was kept constant through the ACI using the vacuum pump. 
For IPs below 60 L/min, an operating flow rate of 60 L/min was used, while an operation 
flow rate of 90 L/min was used for IPs above 60 L/min.  ACI stages and collection plates 
(including the holo plates) were assembles depending on the flow rate of set-up (Discussed in 
Chapter 3- section 3.2.1). 
The indacaterol dose emission was carried out by using three capsules for each IP following 
the recommendations and the dose preparation instructions in patient information leaflet (PIL) 
of the Onbrez Breezhaler® (Novartis Pharmaceuticals Ltd, UK). Once the three capsules were 
aerosolised into the impactor, the residual amount (RA) left in the capsules and device was 
recovered. For each IP, three determinations were made in order to ensure that dose emission 
procedure is reproducible. 
After dose aerosolisation and before starting the washing procedure the AIT, the mouthpiece 
and the mixing inlet side arm were sealed with parafilm to ensure that no drug powder was 
wasted during the ACI disassemble  procedure. 
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The washing procedure was undertaken once the run was finished and the three capsules of 
150 µg indacaterol were aerosolised into the ACI. The washing solution was MeOH:water 
60:40 % v/v with dexamethasone (1µg/mL) as an internal standard. Appropriate volumes 
were added to the mouthpiece, the AIT, the pre-separator, the ACI stages, the capsule, the 
device and the filter to recover the drug dose from each part of the experiment. The samples 
were transferred into 20 mL vials and then sonicated for 15 minutes to facilitate drug particle 
solubility. Thereafter, all samples were transferred into 2 mL HPLC amber vials by using a 
plastic syringe and 0.45 filter tips (Thermo Scientific Ltd, UK) and sealed properly with a vial 
cap. The indacaterol amounts in each sample were then quantified using a validated HPLC 
method (HPLC method validation discussed in Chapter 4 – Section 4.4).  
Table 7-3: Volumes of washing solution used to collect the emitted dose from different 
experiment parts. 
Experiment part Washing solution volume 
Idealised Alberta Throat (AIT) 10 mL 
Mouthpiece (MP) 5 mL 
Pre-separator (PS) 20 mL 
ACI stages 10 mL 
Filter 10 mL 
Capsules (n=3) (Cap) 10 mL 
Device (Dev) 10 mL 
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7.4.3 Data analysis  
The Copley Inhaler Testing Data Analysis Software (CITDAS version 2.0, Copley Scientific 
Ltd, UK) was used to calculate the aerodynamic dose emission parameters.  
The aerodynamic particle size distribution (APSD) characteristics of the emitted dose were 
calculated. The total emitted dose (TED) was obtained from the cumulative amounts of 
indacaterol maleate deposited in the Alberta idealised throat (IAT), the pre-separator (PS) and 
all the stages of the ACI. The fine particle dose (FPD) was the mass associated with particles 
< 5 µm, and the extra-fine particle dose (EFPD) was the mass of powder associated with 
particles < 3 µm.The fine particle fraction (FPF) was the FPD divided by the TED. The mass 
median aerodynamic diameter (MMAD) was the size corresponding to the 50th percentile of 
the cumulative mass-weighed distribution of the amount deposited in the ACI. The geometric 
standard deviation (GSD) is the square root of the size corresponding to 15.87 % divided by 
square root of the size for 84.13%. The residual amount (RA) was obtained as the sum of the 
dose retained in the capsule and device after aerosolisation.  The total recovered dose (TRD) 
was calculated as the sum of the total emitted dose (TED) and the residual amount (RA).  
A one-way and Two-way ANOVA were used to determine the difference in the TED, FPD, 
RA, etc. Tuckey test was used to determine the difference between the different parameters 
used. The hypothesis of (p < 0.05) was used to determine the significant difference.  
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 Results  
7.5.1 Dose emission aerodynamic characteristics of indacaterol Breezhaler® using 
COPD patients’ IP 
The mean inhalation parameters of the selected profiles MIF, Vin, ACIM and Ti were 64.9 
L/min, 2.1 L, 4.2 L/s2 and 3.4 s respectively (Table 7.2). A summary of indacaterol 
aerodynamic dose emission characteristics results of all IPs selected is shown in Table 7.4. 
The results were arranged according to the profiles’ MIF, and the results of TED, FPD and 
MMAD of 150 µg indacaterol emitted from Onbrez Breezhaler® for all the profiles are shown 
in Figures 7.3, 7.4 and 7.6. 
Table 7-4: Mean (SD) of Indacaterol aerodynamic dose emission characteristics of 18 COPD 
patient profiles from Onbrez Breezhaler® [3 Capsules of 150 µg indacaterol dose per 
determination, 3 determinations for each profile] 
Profile 
Number FPD (µg) TED (µg) % FPF RA(µg) TRD 
MMAD 
(µm) GSD 
1 28.7 (1.6) 92.0 (4.2) 31.2 (0.3) 45.3 (3.8) 137.3 (1.3) 3.7 (0.1) 1.8 (0.0) 
2 34.5 (1.7) 103.6 (5.2) 33.3 (0.1) 33.2 (2.6) 136.8 (0.8) 3.4 (0.1) 1.7 (0.1) 
3 31.7 (0.8) 100.1 (0.6) 31.6 (0.8) 34.4 (2.7) 134.5 (4.3) 3.2 (0.1) 1.7 (0.1) 
4 37.1 (0.8) 105.4 (3.2) 35.2 (0.3) 28.6 (3.2) 134.0 (2.5) 3.3 (0.1) 1.7 (0.0) 
5 39.7 (1.4) 109.2 (6.5) 36.4 (0.9) 29.0 (1.3) 138.2 (5.2) 3.1 (0.1) 1.7 (0.1) 
6 40.4 (2.1) 111.1 (2.3) 36.4 (0.2) 29.6 (2.2) 140.6 (1.1) 2.9 (0.1) 1.7 (0.1) 
7 39.2 (2.5) 108.1 (6.1) 36.3 (0.3) 29.6 (2.1) 137.7 (3.9) 3.0 (0.0) 1.7 (0.0) 
8 43.2 (1.1) 116.1 (2.5) 37.2 (0.7) 27.4 (0.6) 143.5 (2.3) 3.1 (0.0) 1.7 (0.0) 
9 37.6 (1.2) 113.8 (1.2) 33.0 (0.5) 22.3 (3.2) 136.1 (1.2) 2.5 (0.1) 2.0 (0.1) 
10 39.8 (0.9) 116.5 (1.0) 34.2 (0.3) 19.9 (2.8) 136.4 (1.0) 2.4 (0.0) 2.0 (0.1) 
11 40.6 (1.2) 120.6 (2.7) 33.7 (0.2) 15.4 (1.4) 136.1 (2.7) 2.2 (0.0) 2.0 (0.1) 
12 41.1 (0.4) 114.0 (1.0) 36.0 (0.1) 15.7 (1.12) 129.7 (5.3) 2.4 (0.0) 2.0 (0.0) 
13 43.5 (0.7) 125.2 (1.1) 34.8 (0.2) 16.2 (0.35) 141.4 (1.1) 2.2 (0.0) 2.1 (0.1) 
14 37.8 (1.8) 119.7 (1.5) 31.6 (0.1) 17.3 (2.1) 137.0 (1.1) 2.6 (0.0) 2.0 (0.1) 
15 37.4 (0.6) 114.5 (1.2) 32.7 (0.3) 18.9 (1.5) 133.4 (1.2) 2.4 (0.1) 2.0 (0.1) 
16 45.6 (0.8) 125.1 (1.4) 36.5 (0.7) 11.4 (1.1) 136.5 (0.4) 2.3 (0.1) 2.0 (0.0) 
Mean(SD) 39.7 (5.0) 113.4 (8.9) 34.9 (2.4) 23.4 (8.9) 136.8 (3.1) 2.7 (0.5) 1.9 (0.2) 
FPD = fine particle dose, TED = Total emitted dose, %FPF = fine particle dose as % of the emitted 
dose, RA = Residual amount, TRD =Total recovered dose, MMAD = Mass median aerodynamic 
diameter, GSD = Geometric standard deviation. 
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The results of dose emission uniformity of Breezhaler® using DUSA are presented in Table 
7.5. In contrast to the dose emitted with ACI more indacaterol dose was found to be recovered 
using DUSA.  
Table 7-5: Mean (SD) of the DUSA results of all IPs used in the study. 
Profile 
number 
TED TRA TRD %TRD 
1 96.35 (2.16) 52.17 (1.96) 148.52 (2.06) 99.01 (1.37) 
2 107.46 (2.79) 43.60 (4.17) 151.05 (3.38) 100.70 (2.25) 
3 121.99 (4.17) 28.63 (2.26) 150.63 (6.43) 100.42 (4.29) 
4 123.55 (2.66) 26.80 (2.80) 150.35 (1.14) 100.23 (0.76) 
5 135.79 (4.93) 17.44 (1.29) 153.23 (3.64) 102.15 (2.43) 
6 120.14 (1.50) 30.04 (1.01) 150.18 (2.51) 100.12 (1.67) 
7 134.01(1.22) 19.08 (2.97) 153.08 (1.75) 102.05 (1.17) 
8 127.22 (3.88) 24.02 (0.73) 151.24 (4.62) 100.83 (3.08) 
9 111.13 (3.28) 39.98 (3.39) 151.12 (6.68) 100.74 (4.45) 
10 133.18 (2.12) 18.41(1.71) 151.58 (1.59) 101.06 (1.06) 
11 132.95 (5.09) 20.93 (1.41) 153.87 (5.50) 102.58 (3.67) 
12 122.46 (3.69) 28.25 (2.36) 150.71 (2.33) 100.47 (1.56) 
13 128.99 (4.33) 19.17 (3.70) 148.15 (2.63) 98.77 (1.76) 
14 124.34 (1.29) 25.78 (1.14) 150.12 (1.85) 100.08 (1.24) 
15 127.33 (5.28) 25.54 (2.03) 152.87 (3.25) 101.91 (2.16) 
16 120.53 (6.35) 28.67 (4.07) 149.20 (2.28) 99.47 (1.52) 
Mean (SD) 123.07 (1.49) 28.05 (1.17) 151.13 (1.65) 100.75 (1.10) 
TED = Total emitted dose; dose trapped inside the sampling unit; TRA = Total residual amount; dose 
retained in the capsule and device; TRD = Total recovered dose; delivered dose in relation to the 
nominal dose 150 µg 
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Figure 7.3: Mean (SD) of the Total emitted dose (TED) for 16 COPD inhalation profiles. 
 
Figure 7.4: Mean (SD) of the fine particle dose (FPD) for 16 COPD inhalation profiles. 
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Figure 7.5: Mean (SD) of the residual amount (RA) retained in both device and capsule for 16 
COPD inhalation profiles. 
 
Figure 7.6: Mean (SD) of the MMAD results for 16 COPD inhalation profiles. 
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Figure 7.7: Total recovered dose (TRD) of 16 COPD patient profiles. 
The results of the aerodynamic dose emission of indacaterol Breezhaler® using recorded 
COPD patients’ IP showed that TED (as % of 150 µg indacaterol nominal dose) was ranging 
from 61% to 83% with a mean (SD) 113.4 µg (8.9) (Figure 7.3). The fine particle dose (FPD) 
of indacaterol was ranging from 19% and 30% of with a mean (SD) of 39.7 µg (5.0) (Figure 
7.4). The MMAD results show that marked reduction in the particle size with the increase of 
profiles MIF from 3.7 µm to 2.3 µm (Figure 7.6). The dose emission from Breezhaler was 
consistent with almost 93% dose recovery with ACI (Figure 7.7) and 99% with DUSA (Table 
7.5). The present performance study results demonstrate that TED, FPD increased 
significantly (p < 0.05) when the MIF of the IPs increased (Figures 7.3 and 7.4). In contrary, 
TRA an MMAD decreased significantly (Figures 7.5 and 7.6). 
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7.5.2 Dose emission aerodynamic characteristics of indacaterol Breezhaler® using 
simulated COPD patients’ IP 
The results of the aerodynamic characteristics of profiles divided into three categories depending 
on the MIF value (Low 40 L/min – Medium 65 L/min and high 85 L/min). A summary of the data 
is presented in Tables 7.6, 7.7 and 7.8 respectively. Furthermore, DUSA results of the dose 
emission of all the profiles using breath simulator are also shown in Table 7.9 
Table 7-6: Mean (SD) Indacaterol dose emission aerodynamic characteristics (150µg nominal 
dose) for low MIF profiles (n= 3) using 3 doses for each determination. 
 
Vin ~ 1L 
40 L/min ACIM ~ 2.0 ACIM ~ 4.0 ACIM ~ 8.0 
FPD 29.4 (0.7) 31.6 (0.2) 34.7 (0.7) 
TED 113.5 (2.8) 114.8 (1.2) 120.4 (1.1) 
FPF% 25.9 (3.2) 27.6 (1.9) 28.8 (2.3) 
LPM 70.2 (1.6) 68.3 (1.2) 72.8 (1.4) 
%EFPD 13.1(1.1) 15.9 (1.0) 16.8 (0.3) 
RA 24.8 (2.4) 22.6 (2.6) 22.4 (3.4) 
TRD 138.3 (1.2) 137.5 (2.4) 142.8 (3.0) 
MMAD 3.4 (0.1) 3.2 (0.1) 3.1 (0.0) 
GSD 1.8 (0.0) 1.8 (0.0) 1.9 (0.0) 
 
Vin ~ 2L 
 
2.0 4.0 8.0 
FPD 33.3 (1.8) 35.8 (1.9) 38.3 (0.5) 
TED 117.7 (1.2) 118.1(4.6) 122.1 (2.9) 
FPF% 28.3 (0.8) 30.3 (3.0) 31.4 (1.2) 
LPM 70.4 (1.9) 69.7 (2.8) 70.5 (2.5) 
%EFPD 14.1 (0.1) 14.5 (0.9) 15.7 (0.4) 
RA 22.9 (1.8) 21.1 (1.0) 18.9 (0.9) 
TRD 140.5 (2.2) 139.2 (1.0) 141.0 (3.7) 
MMAD 3.3 (0.1) 3.3 (0.1) 3.4 (0.1) 
GSD 1.8 (0.1) 1.8 (0.1) 1.8 (0.0) 
 
Vin ~ 3L 
 
2.0 4.0 8.0 
FPD 36.5 (0.7) 38.8 (1.1) 40.3 (0.7) 
TED 120.4 (1.8) 121.7 (1.4) 123.0 (0.6) 
FPF% 30.3 (1.2) 31.9 (3.0) 32.7 (0.9) 
LPM 70.7 (2.8) 71.4 (2.5) 71.8 (3.2) 
%EFPD 17.1 (0.2) 17.7 (0.3) 17.9 (0.5) 
RA 21.7 (1.0) 19.9 (0.7) 17.2 (0.9) 
TRD 142.1 (3.8) 141.6 (2.7) 140.2 (2.3) 
MMAD 3.1 (0.0) 3.1 (0.1) 3.2 (0.1) 
GSD 1.9 (0.0) 2.0 (0.0) 1.9 (0.1) 
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Table 7-7: Mean (SD) Indacaterol dose emission aerodynamic characteristics (150µg nominal 
dose) for medium MIF profiles (n= 3) using 3 doses for each determination. 
 
Vin ~ 1L 
65L/min ACIM ~ 2.0 ACIM ~ 4.0 ACIM ~ 8.0 
FPD 37.9 (1.3) 38.1 (0.6) 40.5 (0.4) 
TED 115.9 (2.4) 116.0 (1.4) 123.2 (3.1) 
FPF% 32.7 (3.0) 32.9 (1.2) 32.9 (3.2) 
LPM 67.9 (4.4) 66.8 (0.9) 69.4 (2.2) 
%EFPD 20.7 (0.8) 20.3 (0.2) 21.9 (0.7) 
RA 21.9 (0.9) 21.3 (1.7) 19.9 (2.2) 
TRD 137.8 (1.4) 137.2 (0.9) 143.0 (2.5) 
MMAD 2.9 (0.1) 2.9 (0.1) 2.8 (0.0) 
GSD 2.0 (0.0) 1.9 (0.1) 2.1 (0.0) 
 
Vin ~ 2L 
 
2.0 4.0 8.0 
FPD 39.0 (0.4) 39.9 (0.5) 42.5 (1.6) 
TED 118.4 (2.0) 119.0 (2.0) 124.2 (1.6) 
FPF% 33.0 (2.2) 33.5 (0.8) 34.2 (1.7) 
LPM 73.6 (0.9) 68.7 (1.6) 70.7 (2.3) 
%EFPD 18.6 (1.3) 21.4 (0.6) 23.2 (1.0) 
RA 20.9 (0.7) 19.0 (3.3) 17.9 (0.6) 
TRD 139.4 (4.1) 138.0 (3.8) 142.1 (2.4) 
MMAD 3.0 (0.1) 2.9 (0.1) 2.9 (0.1) 
GSD 2.2 (0.1) 2.0 (0.0) 2.0 (0.0) 
 
Vin ~ 3L 
 
2.0 4.0 8.0 
FPD 40.3 (0.3) 41.7 (0.8) 43 (0.3) 
TED 121.6 (2.2) 122.8 (3.8) 125.9 (1.6) 
FPF% 33.2 (2.3) 34.0 (1.9) 34.2 (3.2) 
LPM 66.1 (1.2) 70.6 (2.8) 72.4 (2.2) 
%EFPD 22.0 (0.9) 22.6 (0.6) 24.1 (0.9) 
RA 18.5 (0.9) 16.2 (1.1) 15.2 (0.7) 
TRD 140.1 (0.7) 139.1 (1.1) 141.0 (2.8) 
MMAD 2.9 (0.0) 2.8 (0.1) 2.7 (0.0) 
GSD 2.0 (0.0) 1.9 (0.0) 2.1 (0.1) 
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Table 7-8: Mean (SD) Indacaterol dose emission aerodynamic characteristics (150µg nominal 
dose) for high MIF profiles (n= 3) using 3 doses for each determination. 
 
Vin ~ 1L 
85 L/min ACIM ~ 2.0 ACIM ~ 4.0 ACIM ~ 8.0 
FPD 40.7 (1.1) 42.0 (1.0) 43.7 (0.2) 
TED 118.8 (1.7) 119.4 (1.0) 124.0 (1.2) 
FPF% 34.3 (1.1) 35.4 (0.6) 35.8 (1.9) 
LPM 67.9 (2.7) 71.0 (1.9) 73.1 (2.9) 
%EFPD 22.2 (0.5) 20.6 (0.3) 21.9 (1.2) 
RA 18.9 (3.0) 18.7 (2.1) 17.3 (0.7) 
TRD 137.7 (0.8) 138.1(1.3) 141.2 (3.9) 
MMAD 3.0 (0.1) 2.9 (0.0) 2.8 (0.1) 
GSD 2.0 (0.1) 2.0 (0.0) 2.1 (0.1) 
 
Vin ~ 2L 
 
2.0 4.0 8.0 
FPD 41.8 (0.2) 43.4 (0.3) 44.8 (1.5) 
TED 120.4 (0.8) 121.0 (0.4) 125.9 (0.8) 
FPF% 34.7 (0.5) 35.8 (1.8) 36.2 (0.5) 
LPM 72.4 (1.6) 72.6 (1.0) 74.1 (3.5) 
%EFPD 20.2 (0.8) 21.5 (0.4) 23.0 (0.2) 
RA 18.2 (0.6) 17.4 (1.2) 14.8 (0.7) 
TRD 138.6 (0.9) 138.4 (1.3) 140.7 (0.6) 
MMAD 2.9 (0.0) 2.8 (0.0) 2.7 (0.0) 
GSD 2.1 (0.0) 2.0 (0.0) 2.0 (0.0) 
 
Vin ~ 3L 
 
2.0 4.0 8.0 
FPD 44.1 (1.0) 46.8 (0.5) 49.8 (1.0) 
TED 123.1 (1.9) 123.9 (1.0) 127.5(1.0) 
FPF% 35.9 (1.7) 37.8 (1.3) 38.7 (2.0) 
LPM 73.5 (2.4) 71.8 (3.0) 73.0 (2.6) 
%EFPD 21.6 (0.8) 23.4 (0.2) 26.1 (0.2) 
RA 17.6 (0.8) 14.0 (1.6) 12.2 (0.6) 
TRD 140.6 (0.9) 137.9 (2.1) 139.7 (3.1) 
MMAD 2.9 (0.0) 2.8 (0.1) 2.6 (0.0) 
GSD 2.0 (0.0) 2.0 (0.0) 2.1 (0.0) 
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Table 7-9: Mean (SD) Indacaterol dose emission data using DUSA (150µg nominal dose) for all 
profiles (n= 3) using 1 dose for each determination. 
 40 L/min 65 L/min 85 L/min 
 Mean  SD Mean  SD Mean  SD 
 1L -2ACIM 
TED 116.80 (1.25) 121.84 (0.11) 125.41 (0.73) 
RA 33.51 (1.00) 25.36 (1.04) 22.76 (0.54) 
TRD 150.32 (0.25) 147.21 (0.93) 148.17 (0.19) 
 1L -4ACIM 
TED 117.96 (2.08) 122.99 (3.50) 126.27 (3.50) 
RA 30.58 (0.73) 24.92 (3.18) 22.32 (3.71) 
TRD 148.54 (1.35) 147.92 (0.32) 148.59 (0.21) 
 1L-8ACIM 
TED 121.31 (0.16) 125.39 (1.06) 129.40 (1.68) 
RA 27.98 (2.77) 21.19 (1.49) 19.70 (0.62) 
TRD 149.29 (2.93) 146.58 (0.43) 149.11 (1.06) 
 2L/-2ACIM 
TED 118.32 (1.26) 125.50 (0.05) 129.37 (2.99) 
RA 29.38 (4.48) 21.84 (1.90) 20.24 (1.74) 
TRD 147.70 (1.22) 147.34 (1.85) 149.61(1.25) 
 2L-4ACIM 
TED 119.48 (0.28) 126.19 (2.38) 130.06 (1.12) 
RA 27.74 (0.53) 21.16 (0.35) 21.16 (0.35) 
TRD 147.22 (0.81) 147.35 (2.73) 151.22 (1.47) 
 2L-8ACIM 
TED 122.81 (0.79) 128.26 (1.11) 131.83 (1.95) 
RA 24.75 (1.39) 20.42 (1.19) 20.42 (1.19) 
TRD 147.56 (0.61) 148.68 (0.08) 152.25 (0.76) 
 3L-2ACIM 
TED 123.98 (0.44) 126.83 (1.47) 131.29 (0.64) 
RA 24.05 (1.01) 19.31 (0.77) 18.20 (0.80) 
TRD 148.03 (0.57) 146.14 (0.69) 149.49 (0.17) 
 3L-4ACIM 
TED 124.61 (2.65) 128.73 (1.36) 132.30 (1.78) 
RA 23.53 (2.00) 19.49 (0.55) 16.51 (1.56) 
TRD 148.14 (0.65) 148.22 (1.91) 148.82 (0.22) 
 3L-8ACIM 
TED 127.30 (3.35) 129.47 (0.31) 134.83 (1.58) 
RA 20.43 (1.42) 17.93 (0.20) 14.58 (2.44) 
TRD 147.73 (4.77) 147.40 (0.51) 149.41 (0.86) 
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Figure 7.8: Mean (SD) of indacaterol TED for all inhalation profiles at different MIF, Vin and ACIM (n=3).  
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Figure 7.9: Mean (SD) of indacaterol FPD for all inhalation profiles at different MIF, Vin and ACIM (n=3).  
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Figure 7.10: Mean (SD) of indacaterol MMAD for all inhalation profiles at different MIF, Vin and ACIM (n=3). 
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Figure 7.11: EFPD for all inhalation profiles used at different MIF, Vin and ACIM (n=3).  
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Figure 7.12: Mean (SD) of indacaterol RA for all inhalation profiles at different MIF, Vin and ACIM (n=3). 
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The profiles were classified into three different categories depending on the MIF value of the 
profiles (40, 65 and 85 L/min). For each group the profiles were simulated to changes one 
parameter at a time, therefore ACIM and Vin effect on the aerodynamic dose emission 
characteristics of indacaterol can be studied [see appendix for simulated IPs figures].  
The results show the both FPD and TED increased significantly (p < 0.05) with the increase 
of the Vin and ACIM at each category of the MIF values low, medium and high (Tables 7.6 
7.7 and 7.8). The FPD and TED were increased from 29.4µg to 49.9µg and 113.5µg to 
127.5µg respectively. The MMAD decreased significantly (p < 0.05) with increasing the MIF 
from 40 L/min to 85 L/min; furthermore, ACIM and Vin have shown an impact on the 
MMAD especially when combined with high flow rate (Figure 7.10). The EFPD results 
showed no significant change at low and medium MIF when ACIM and Vin increased, 
However at high MIF the increase of Vin and ACIM show a significant (p <0.05) on the 
EFPD of indacaterol dose emitted from Breezhaler (Figure 7.11).  The residual amount (RA) 
left in the device and capsule showed a significant decrease (p <0.05) with increasing the Vin, 
especially at low and medium MIF profiles, at high profiles small change was observed. The 
ACIM also shows a slight effect on the RA (7.12). 
 
 
 
 
 
 
218 
 
 Discussion  
The performance of 150µg indacaterol Breezhaler® was determined using real life recorded 
patients’ IPs (7.2.2). Furthermore, the effect of each inspiratory parameter was assessed using 
simulated patients’ IPs.  
The ex-vivo methodology used is describing the process of generating dose emission data for 
inhaler devices by replaying in-vivo recorded patients’ IPs using analytical technique coupled 
with breath simulator as shown in Figure 7.1. This technique is widely used to determine the 
APSD as well as the dose delivered uniformity providing an approximation to the dose patient 
would receive when using the inhaler device (Nadarassan et al., 2010, Olsson et al., 2013, 
Chrystyn et al., 2015). The method set-up used in this study was similar to that reported by 
(Bagherisadeghi et al., 2017).The benefits of using ACI over NGI when studying the 
aerodynamic characteristics of inhaler devices are that the ACI stages and pre-separator can 
be changed when different inhalation flow used (28.3, 60 and 90 L/min). While with NGI 
changes in the applied flow rate is accompanied with an adjustment to stages cut-off diameter. 
Therefore, using ACI enables direct comparison between the amounts of inhaled drug 
particles deposited on each stage (Copley, 2015). The internal dead volume of ACI (1.155 L) 
is smaller when compared to NGI (2.025 L), the use of ACI enables the determination of low 
volume profiles (Mohammed et al., 2012). For these reasons, our study was conducted using 
ACI rather than NGI to investigate the performance of Onbrez Breezhaler® using in-vivo 
recorded COPD patients’ IPs. The  recorded patients’ IPs (Table 7.2) show that most of the 
patient with COPD are not able to generate a pressure drop corresponding 4kPa and inhaled 
volume of 4 L when recommended by the pharmacopoeia (USP, 2014) when they have 
inhaled through Breezhaler®. The Breezhaler® is a low resistance (0.017 kPa0.5 min/L) and an 
inhalation effort exceeding 100 L/min is required to generate the 4 kPa inside the inhalers 
(Explained in Chapter 2, section 2.6.4.1).  
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DPI formulation de-aggregation, dispersion and emission are dependent on the inhalation 
manoeuvre characteristics MIF, Vin and ACIM (Chrystyn et al., 2015, Bagherisadeghi et al., 
2017). The inspiratory effort generated by the patient during the inhalation manoeuvre creates 
a pressure drop inside the device that releases the dose from the DPI. The latter pressure drops 
is directly related to the inspiratory effort generated by the patient (Clark and Hollingworth, 
1993). DPIs are breath actuated devices and it has been reported that MIF has an effect on the 
dose emission as well as lung deposition of all DPIs, especially those with low resistance 
devices such as Aerolizer® and Breezhaler® where dose emission is mainly dependent on the 
generated MIF (Nielsen et al., 1997, Chew and Chan, 2001, Weuthen et al., 2002, Meyer et 
al., 2004, Alaboud et al., 2010, Colthorpe et al., 2013). 
7.6.1 COPD patients’ IPs  
The inspiratory parameters of inhalation manoeuvre MIF, Vin and ACIM have shown an 
effect on the dose emission as well as aerodynamic particle size distribution of indacaterol 
Breezhaler®. However, the impact of the MIF was more observable when compared to the 
effect of ACIM and Vin, due to that all the parameters act together and it was difficult to 
differentiate the effect of ACIM and Vin. The results show that increasing the MIF result in a 
significant (p < 0.05) increase in TED (92.0 µg to 125.1 µg) and FPD (28.7 µg to 45.6 µg) of 
indacaterol 150 µg dose (Figures 7.3 and 7.4). In contrast, the MMAD and TRA decreased 
significantly (p < 0.05) with increasing of MIF (Figures 7.5 and 7.6). Suggesting that 
increasing the MIF of the profiles lead to a subsequent increase in the turbulent energy inside 
the device, which therefore results in more dose being delivered from Breezhaler®. The 
results again demonstrate the flow rate dependency of Onbrez Breezhaler® as shown in 
previous chapters (4 and 6). Furthermore, the particle size distribution of the inhaled bolus is 
obvious from MMAD of all profiles ranging from 3.7 µm to 2.3 µm (Figure 7.6). 
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Drug retention inside the inhaler continues to be a factor plaguing the performance of novel 
inhalers (Tajber et al., 2009). Drug retention varies between inhaler devices in that some 
studies have reported between 30 and 50% of the nominal dose is retained within the device. 
It is important that the complete dose is released from the inhaler so as to maximise the 
therapeutic effect, minimising drug wastage and avoiding potential dosage errors during the 
next inhalation (Abadelah et al., 2017). Irrespective of the MIF for all profiles used there was 
always some indacaterol retained in the capsule/ device (Table 7.4). However, the TRA is 
reduced with the MIF from 45% to 11% of the total nominal dose for profile 1 and 16 
respectively. The length of device inhalation channel, as well as coating material, affect the 
residual amount of drug retained in the capsule and device. For instance, Easyhaler has short 
inhalation channel and reported to have less residual amount comparing to a device with 
longer inhalation channel such as Aerolizer® (Coates et al., 2004, Azouz and Chrystyn, 2012). 
The dose emission uniformity of all profiles chosen in this study was determined using DUSA 
instead of ACI in the experimental – setup (Figure 7.1). The recovered dose from the DUSA 
representing the TED, while dose retained in the capsule/device represent TRA. A good 
correlation was observed between both ACI and DUSA results. The increase of MIF leads to 
an increase in TED DUSA and a reduction in total residual amount TRADUSA (Tables 7.4 and 
7.5). The TEDDUSA was higher than TED using ACI and the reasons for that difference are 
higher dead volume and inter-stage particle loss of ACI (Byron et al., 2004, Kamiya et al., 
2009). Therefore, the washing procedure for DUSA is simple comparing to that for ACI and 
less chance of losing drug during the washing procedure. The consistency of washing 
procedure can be seen from the TRD for ACI, which was almost 92 % of the nominal dose 
(Figure 7.7), and for DUSA was almost 99% (Table 7.5). 
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7.6.2 Simulated patients’ IPs 
The effect of each inspiratory parameter MIF, Vin and ACIM was determined using simulated 
patients’ IPs where only one parameter was changed at a time. when we varied the MIF we 
maintained both the ACIM and Vin fixed using 3 levels, i.e., Vin (1 L, 2 L and 3L), ACIM (2 
L/s2,  4 L/s2, 8 L/s2)  (Tables 7.6, 7.7 and 7.8). For all the three levels, increasing the MIF 
from 40 L/min to 85 L/min resulted in a significant (p < 0.05) increase in both TED and FPD 
of indacaterol from Onbrez Breezhaler (Figure 7.8 and 7.9). At a fixed high Vin (3 L) and 
high ACIM (8 L/s2), the impact of the flow rate on the TED and FPD was the greatest as 
reported in ERS/ISAM task force report (Laube et al., 2011). The increase of the MIF was 
associated with both an increase in both TED and FPD, which is in agreement with (Laube et 
al., 2011, Chrystyn et al., 2015). Particles with an MMAD < 5 µm are considered as the 
respirable dose and are suitable for targeting the peripheral airways (Heyder, 2004, Roche et 
al., 2013). Irrespective of the MIF, the Onbrez Breezhaler was able to generate particles of 
clinical relevance with an MMAD <5µm. Moreover, at medium (65 L/min) and high (85 
L/min) MIFs, an increase in the extrafine particles with an MMAD <3 µm were obtained 
(Figure 7.10). The latter is considered important in targeting smaller airways, and they found 
to be useful in the management of respiratory diseases (De Boer et al., 2015, Scichilone, 
2015). 
The Vin is another inhalation parameter to be considered when evaluating the performance of 
DPIs. The pharmacopeial DPIs testing in-vitro suggested that a Vin of 4 L should be drawn 
through the inhaler. However, most of the patients with asthma and COPD were unable to 
achieve this value, and only a few patients were able to exceed 2 L Vin with a mean value ≥ 2 
L (Broeders et al., 2003, Azouz et al., 2015b). The inhaled volumes used to quantify the 
aerodynamic particle size distribution of inhaled indacaterol exceeds the internal volume of 
the ACI ( 1.155 L) (Copley et al., 2005) to allow sufficient sampling time for the aerosol 
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bolus transfer from the inhaler device to distal stages of the ACI (Mohammed et al., 2012, 
Mohammed et al., 2014). In the previous section (7.2.2), the patient using Breezhaler® 
achieved a Vin ranging from 0.7 L to 3.3 L. 
The present chapter shows that TED increased significantly (p < 0.05) with increasing the Vin 
especially when low MIF and ACIM were used (Figure 7.8). For instance, at a fixed MIF of 
(40 L/min) and ACIM (2 L/s2) the increase of the Vin from 1 L to 3 L resulted in an increase 
in the TED from 113.5 (2.8) µg to 120.4 (1.8) µg (Table 7.6) suggesting that when the MIF is 
not sufficient to de-aggregate the dose the Vin can play an important role to promote the de-
aggregation of the powder formulation. (Kamin et al., 2002) reported the effect of the Vin on 
the total mass output and FPD which is in agreement with the present chapter. At low MIF 
(40 L/min) and ACIM (2 L/s2) increasing the Vin from 1 L to 3 L subsequently increase FPD 
of indacaterol from 29.4 (0.7) µg at 1L Vin to 36.5 (0.7) µg at 3L Vin (Table 7.6) suggesting 
that more aerosol was pulled to distal part of the impactor. At medium and high MIF values 
65 and 85 L/min, increasing the Vin resulted in a less pronounced effect on the TED and FPD 
of indacaterol Breezhaler® (Figures 7.8 and 7.9). The β-receptors are abundant in the alveolar 
wall a region where no smooth muscle exists and whose functional configuration is unknown. 
The location of β-receptors in the lungs suggests that drug targeting is important for 
maximum therapeutics effect for example salbutamol require a more peripheral delivery to the 
medium and small airways to produce a therapeutic effect (Labiris and Dolovich, 2003). Thus 
particle size affects the lung deposition of an aerosol and influence the clinical effectiveness 
Zanen et al., (1996) reported that “in patients with mild to moderate asthma, particles with an 
MMAD of approximately 3 µm were more effective than larger particle size aerosol in 
producing bronchodilation since it has the best penetration and retention in the lungs in the 
presence of airways narrowing” (Zanen et al., 1996). Breezhaler® was effective in producing 
particles with an MMAD of around 3 µm, and the Vin has less effect on MMAD than MIF 
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suggesting that Vin is involved more in mass transfer rather than aerosol dispersion to cause a 
further decrease in the MMAD as shown from the present results (Figure 7.10). 
The ACIM has been reported to be very important in dose emission of the inhaled aerosol 
(Everard et al., 1997, Chrystyn, 2007, Chrystyn et al., 2015, Bagherisadeghi et al., 2017). 
Patients may achieve the same peak flow but with different accelerations. The one inhaling 
fast through DPIs would benefit more from the inhaled dose because the latter may leave the 
device before even the peak flow is reached as shown by the schematic diagram (Figure 7.13) 
reported by Chrystyn and Price (2009). 
 
Figure 7.13: The inhalation profiles for different types of DPIs. 
 ACIM was found to significantly (p < 0.05) affect the TED and FPD (Figure 7.8 and 7.9), 
whereas only a marginal decrease in the MMAD was observed mainly at high MIF (Figure 
7.10). The increase of ACIM form 2 L/s2 to 8 L/s2  at fixed MIF (40 L/min) and Vin (1 L) 
resulted in an increase in the TED from 113.5  (2.8) µg to 120.4  (1.1) µg  and FPD from 29.4  
(0.7) µg to 34.7  (0.7) µg respectively (Table 7.7).  
The ACIM had the almost similar effect to the Vin with regards to TED and FPD. Thus, the 
greater the ACIM, the greater is the TED and the greater the mass transfer to the lower stages 
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of the impactor. Achieving a high peak flow faster would not only promote high emission of 
the dose, but also increases the amount of the drug reaching the lower stages of the impactor 
with more particles in the extrafine range with high tendency for peripheral deposition as 
shown from the values of the MMAD at high flow rate (85 L/min) and ACIM (8 L/s2). This 
study showed that approximately 50% of the emitted dose deposited in the upper parts of the 
impactor (Alberta throat, mixing inlet and the pre-separator) as a large particle mass (LPM) 
irrespective of the inhalation manoeuvre.  
The RA amount of ACI study of Indacaterol left in the capsule and device was affected by all 
the inhalation parameters (Tables 7.6, 7.7 and 7.8). Increasing the MIF whilst keeping both 
the Vin and ACIM fixed, resulted in a significant decrease in the RA. For example, increasing 
the MIF from 40 L/min to 85 L/min at Vin (1 L) and ACIM (2 L/s2) resulted in a significant 
decrease (p < 0.05) in the RA from 24.8 (2.4) µg to 18.9 (3.0) µg (Tables 7.6 and 7.8). At a 
fixed MIF (65 L/min) and ACIM (4 L/s2) and increasing the Vin from 1 to 3 L caused a 
significant decrease in the RA from 21.3 (1.7) µg to 16.2 (1.1) µg (Table 7.7). At a fixed MIF 
(40 L/min) and Vin (3 L) but increasing the ACIM from 2 to 8 L/s2, resulted in a significant 
decrease in the RA from 21.7 (1.0) µg to 17.2 (0.9) µg (Table 7.6 and Figure 7.12). The 
residual amount was reduced by 50 % by combining all the inhalation manoeuvre parameters 
to their optimal values (i.e., increasing the MIF from 40 L/min to 85 L/min; ACIM from 2 
L/s2 to 8 L/s2; Vin from 1 L to 3 L). It is interesting to note that complete emptying of the 
capsule and device is still a challenge irrespective of the inhalation manoeuvre. The amount 
left in the device and capsule could be due to intrinsic and / or extrinsic factors such as the 
material composing the coat (intrinsic) of the inhaler device and moisture (extrinsic). The 
EFPD (% nominal dose) increased with increasing the ACIM and Vin, however, the major 
parameter affecting the EFPD was found to be the MIF.  The combined effect of  MIF, Vin 
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and ACIM result in an increase in the EFPD from 13.1% at low level to 26.2% at high level 
(Figure 7.11). 
The dose emission of all profiles using DUSA attached to Breath simulator was determined. 
For all Vins and ACIMs, increasing the MIF from 40 L/min to 85 L/min resulted in an 
increase in the TED. For example,  at a fixed Vin (1 L) and ACIM (2 L/s2), increasing the 
MIF from 40 L/min to 85 L/min resulted in a significant increase in the dose emission from 
116.80 (1.25) µg to 125.41 (0.73) µg (Table 7.9) suggesting dose emission flow rate 
dependency of the Onbrez Breezhaler as discussed in the previous chapters (4 and 6). 
Similarly, for all MIFs and ACIMs, increasing the Vin resulted in a significant (p <0.05) 
increase in the TED. The impact of the Vin was not extensively studied, but this study shows 
the dose emission Vin dependency. For example, at a fixed MIF (40 L/min) and (ACIM 2 
L/s2), increasing the Vin from 1 L to 3 L, the TED increased from 116.80 (1.25) µg to 123.98 
(0.44) µg (Table 7.9). It is interesting to note that varying the MIF or the Vin have almost the 
same impact on the TED suggesting the importance of the Vin in the dose emission from 
capsule based devices as we reported earlier in chapter 8. Equally, ACIM also showed an 
impact on the TED but with less effect than the MIF and Vin (Table 7.9). The dose emission 
study using DUSA follows the same trend to the results obtained with the ACI. However, 
more dose was recovered from the DUSA (Table 7.9) in comparison to the ACI for the 
reasons explained in the previous section (7.6.1). The TRD approached the nominal dose of 
150 µg irrespective of the MIF, Vin or ACIM and all the TRD values fall in the range of 85%-
125% of drug content uniformity for DPIs as described in the Pharmacopeia (CDER, 1998). 
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 Conclusion  
In present ex-vivo aerodynamic characteristics of indacaterol Breezhaler®, dose emission was 
investigated using both recorded real life and simulated COPD patients’ IPs. The use of ex-
vivo methodology provides more realistic representation to the way patient use the inhaler and 
dose they would receive in real life use. Indacaterol Breezhaler® have demonstrated a flow 
dependent dose emission, which is in line with previous chapter (4 and 6) finding using real 
life, generated COPD IPs.  
The use of simulated IPs enables us to assess the effect of each parameters (MIF, Vin and 
ACIM) in the inhalation manoeuvres. All inhalation parameters have shown an impact on the 
dose emission. However, the impact of the MIF was more pronounced than the Vin and 
ACIM by affecting all the aerodynamic dose emission characteristics (i.e., TED, FPD, and 
MMAD).  By combining high MIF, Vin and ACIM, the quality of the inhaled particles was 
improved. The profiles dose delivery uniformity using DUSA have demonstrated a consistent 
dose delivery of indacatrerol from Onbrez Breezhaler® 
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 General discussion  
In-vitro studies were introduced to evaluate product performance directly with a reduced cost 
and offer benefits in terms of ethical consideration when compared to in-vivo studies (Meyer 
et al., 2004). The dose and its particle size distribution emitted from a DPI is determined by 
the patient, the inhaler device and formulation (Abadelah et al., 2017). Most DPIs are breath 
actuated and are highly dependent on the patient’s inhalation flow. The threshold inhalation 
flow required to de-aggregate and disperse the drug powder is not determined for each DPI, 
and more effort is needed to shade the light on the minimum flow required to operate each 
DPI more efficiently to benefit the patients (Scichilone, 2015, Haidl et al., 2016). The 
inhalation manoeuvre is affected by a wide variety of factors namely MIF, Vin and ACIM. 
All of which have shown an impact on the dose emission and aerodynamic characteristics of 
emitted dose form a DPI (Bagherisadeghi et al., 2017). The pharmacopeial DPIs testing in-
vitro suggested that a Vin of 4 L should be drawn through the inhaler. However, most of the 
patients with asthma and COPD were unable to achieve this value, and only a few patients 
were able to exceed 2 L Vin with a mean value ≥ 2 L (Broeders et al., 2003, Azouz et al., 
2015b). The inhaled volumes used to quantify the aerodynamic particle size distribution of 
inhaled indacaterol exceeds the internal volume of the ACI ( 1.155 L) (Copley et al., 2005) to 
allow sufficient sampling time for the aerosol bolus transfer from the inhaler device to distal 
stages of the ACI (Mohammed et al., 2012, Mohammed et al., 2014). The compendial method 
of testing the inhalers using the vacuum pump clearly does not reflect the capabilities of a 
typical patient. The applied inhalation profile is a square wave taking the flow rate from 0 
L/min to a pre-determined constant value (X L/min) for short duration of time and then back 
to 0 L/min. This profile is by no mean achievable by healthy subject never mind an asthmatic 
patient (Copley, 2015).  
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The dose emission results of indacaterol and formoterol ( Chapter -4) showed that the impact 
or Vin on the dose emptying become less significant if the patient achieve high MIF. 
Suggesting that proper dose de-aggregation taken place when high MIF was achieved due to 
the increase in the turbulence force generated inside the device, which in turn depend on the 
intrinsic resistance of the DPI. The dose emission is flow dependent on the MIF generated by 
the patients however, patients who are unable to achieve minimum flow of 60 L/min when 
using Foradil Aerolizer® or Onbrez Breezhaler® should be encouraged to inhale twice for 
each single dose. The present chapter showed that MIF impact is enhanced with increasing the 
Vin. In case of high resistance device such as Easyhaler® used in the present work (Chapter -
5) low volume of 750 mL was found to be efficient to empty the dose, the reason for that is 
the small metering chamber in the design of the Easyhaler®. The results showed that 
increasing the Vin above 750 mL does not bring much improvement in the dose emission 
characteristics of formoterol from an Easyhaler®. It is a high resistance device, therefore,  the 
force generated at MIF of 30 L/min is corresponding to the same turbulent force when 60 
L/min is generated through low resistance devices such as Aerolizer® and Breezhaler®, 
because the turbulence energy generated upon inhalation is a function of both device 
resistance (R) and MIF (Q) (Clark and Hollingworth, 1993). The increase in MIF from 30 
L/min to 60 L/min and finally 90 L/min was accompanied with an increase in the dose 
emission characteristics of formoterol Easyhaler®, suggesting that more force was generated 
inside the device when the MIF was increased. However, that increase was less pronounced 
when MIF value of 60 L/min or above was achieved.  The dose emission of indacaterol 
Breezhaler® was found to be not affected by difference in the dose strength 150µg and 300µg. 
It has been seen from scanning electron micrographs that 150 µg indacaterol formulation has 
a higher concentration of fine carrier particles in comparison to 300 µg indacaterol 
formulation. Despite the difference observed in the carrier particle size, size distribution 
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(SEM) and drug to carrier ratio yet both formulations produced a good drug content 
uniformity (% CV < 1.8%) and a % recovery of 100%. A similar dose emission pattern to that 
seen in Chapter 4 was observed for both dose strengths. The increase in the MIF resulted in a 
significant increase (p < 0.05) in the ED1 and TED, while reverse trend was seen with ED2 
and TRA, as discussed before the resulted turbulent force was increased when the MIF 
increased and therefore, an adequate dose de-aggregation has occurred inside the device. The 
Vin also shown an important effect in dose emptying especially when low MIF 28.3 L/min 
and 60 L/min were achieved, suggesting that at low MIF dose de-aggregation was incomplete 
and consequently second inhalation was needed to successfully empty the dose. Breath 
simulator-based methods (BRS) have been recently introduced to study the aerodynamic 
characteristics of the inhaled products using previously recorded patient inhalation profile. 
They enable replay of patient-generated or standardised inhalation profiles thereby replacing 
the pharmacopeial method using the vacuum pump.This ex-vivo methodology, using patients’ 
IPs instead of the vacuum pump, provided a more realistic assessment of the aerodynamic 
properties of the inhaled medication that a patient would likely inhale compared with 
corresponding data obtained using compendial methodology. The inspiratory parameters 
namely MIF, Vin and ACIM of the COPD patients’ IP act together, therefore, the use of 
simulated IPs where one parameter was changed at time was important to assess the effect of 
each parameter on its own. The use of both COPD recorded and simulated profiles showed 
that indacaterol dose emission from Onbrez Breezhaler® was mainly affected by the MIF, but 
when the high MIF was not achieved then, ACIM and Vin showed an important role to 
maximise dose emission. In other words, MIF can be considered as the main factor, but 
ACIM  and Vin are also important to maximise both dose emptying and the aerodynamic 
characteristics of indacaterol Breezhaler®. In conclusion, the results of the dose emission 
showed that a minimum MIF and Vin is required for an adequate dose de-aggregation from 
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formoterol Aerolizer® (60 L/min with 1L), Easyhaler® (30 L/min with 0.75 L) and the 
indacaterol Breezhaler® (60 L/min with 1L). Patients with asthma and COPD are not able to 
generate the pharmacopeial recommendations inhalation parameters for DPIs in-vitro testing, 
i.e., Vin of 4 L and MIF corresponding to 4kPa pressure drop. Therefore, when testing DPIs 
in-vitro a range of MIF and Vin of clinical relevance to the inhalation parameters achieved the 
inhaler device should be used. The square wave profile generated by the vacuum pump is not 
representative to the typical inhalation profiles, the profile generated by the pump 
exacerbating the ACIM where no patient or even health volunteers were able to achieve 
maximum MIF at the start of the inhalation manoeuvre. Consequently, recently introduced ex-
vivo methodology is recommended to the performance of the DPIs and provides a more 
realistic data on the dose patient would inhale in real life when using the inhaler device.  The 
ex-vivo methodology provides a realistic representation of the patient’s inhalation manoeuvre 
parameters MIF, Vin and ACIM. The ex-vivo methodology has been used to study the dose 
emission aerodynamic characteristics of the indacaterol Breezhaler® using both COPD 
patients’ IPs and simulated patients’ IPs. The effect of MIF was more pronounced on the 
aerodynamic dose emission characteristics of indacaterol Breezhaler® than Vin and ACIM 
using ex-vivo methodology with both unaltered and simulated COPD patients’ IPs. The 
minimum inspiratory conditions to operate DPIs should be considered taking into account the 
maximum MIF, Vin and ACIM patients could generate in real life.   
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 Summary and future work 
In the present work, the effect of the inspiratory parameters MIF, Vin and ACIM on the dose 
emission and the aerodynamic characteristics of the dose emitted from three different DPIs 
Foradil Aerolizer®, Easyhaler® and Onbrez Breezhaler® was determined using both in-vitro 
and in-vivo techniques. 
The pharmacopoeia methods for the in-vitro dose emission testing of DPIs involve using a 
vacuum pump to generate an inhalation with a constant MIF which corresponds to a 4 kPa 
pressure drop with an inhaled volume of either 2 L (FDA, 1998) or 4 L (EP, 2013, USP, 
2014). Several studies have shown that most patients with asthma and COPD are unable to 
produce a pressure drop of 4 kPa when using DPIs neither they can generate a Vin  of 4 L 
(Nielsen et al., 1997, Pavkov et al., 2010, Azouz et al., 2015b).The airflow square waved 
profile generated by the vacuum pump cannot be replicated by a human and is not 
representative of the bell-shaped patient IPs in real life use (Copley et al., 2014).  
Recently, researchers have developed an ex-vivo methodology using patients’ IPs rather than 
the compendial vacuum pump square wave profiles.The ex-vivo methodology set-up was 
adapted by connecting an inertial impactor (i.e., ACI or NGI) with BRS using the mixing inlet 
side arm. The BRS was used in the procedure to replay the in-vivo recorded IPs through the 
inhaler device. The use of the mixing inlet allows a constant airflow to be drawn through the 
cascade impactor. This is achieved by balancing the air drawn through the impactor with a 
supplementary flow into the mixing inlet such that the airflow through the inhaler in-situ at 
the induction port is maintained at zero before dose aerosolisation. Therefore, the dose 
emission from the inhaler device occurs when a programmed IP is withdrawn from the 
supplementary flow and replayed at the mouthpiece of the inhaler using BRS. 
In the present work, instead of using the pharmacopoeia recommended MIF which 
corresponding to a 4 kPa pressure drop with a Vin  of 4L. The dose emission and 
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aerodynamic characteristics were determined using a wide range of MIFs and Vins to mimic 
the inspiratory parameters that the patient had achieved when they inhaled through the inhaler 
during the routine use. Furthermore, an ex-vivo methodology similar to that reported by 
(Bagherisadeghi et al., 2017) was used to determine the effect of the IP characteristics MIF, 
Vin and ACIM on the aerodynamic dose emission characteristics of the indacaterol 
Breezhaler® using previously recorded COPD patients’ IPs  (Azouz et al., 2015b).  
Chapter 2 provides a review on respiratory system physiological and pathological features, in 
addition to a review of the previous studies carried out using different inspiratory conditions 
and techniques. The development and validation of two HPLC methods for the quantification 
of indacaterol and formoterol was explained in details in chapter 3 with the material and 
laboratory instrumentation used to study the in-vitro and ex-vivo dose emission of indacaterol 
and formoterol from three marketed inhaler products Easyhaler®, Onbrez Breezhaler® and 
Foradil Aerolizer®.  
The dose emission performance of indacaterol Breezhaler® and formoterol Aeroliser® was 
determined using wide range of MIF (28.3 L/min to 120 L/min) and Vin (0.5 L to 2 L) after 
two separate inhalations in Chapter 4. Equally data form both devices showed that ED1 
significantly (p < 0.05) increased with increasing the MIF for all Vin used, while ED2 and 
TRA showed a reverse trend. The impact of the Vin on the dose emission of was more 
pronounced at low MIFs 28.3 L/min and 60 L/min, suggesting that dose de-aggregation was 
incomplete at low MIF 28.3 L/min and 60 L/min and in this case, a high volume was required 
to empty the capsule. While at high MIF 90 L/min and 120 L/min, most of the dose was 
emitted after one inhalation. The results of this chapter suggest that a minimum MIF of 60 
L/min and Vin of 1 L would be required to efficiently operate both devices.  
The effect of the MIF and Vin on the dose emission and aerodynamic dose emission 
characteristics of the formoterol Easyhaler® using a wide range of MIF and Vin was 
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determined in Chapter 5. The results showed that TED, FPD and % FPF significantly 
increased (p < 0.05) with the increasing the MIF from 28.3 L/min to 90 L/min. In contrast, 
MMAD significantly decreased (p < 0.05) with increasing MIF, suggesting increase in the 
turbulent energy with increasing the MIF and therefore, more efficient dose de-aggregation 
and dose dispersion. The increase in the Vin above 750 mL does not bring much difference in 
the aerodynamic characteristics of formoterol from Easyhaler®.  The in-vitro ACI and DUSA 
results suggest that although the Easyhaler® demonstrated some flow dependent dose 
emission, it was effective at low inhalation MIF and Vin and thereby can be used by patients 
with different degree of airway’s obstruction. 
The effect of the dose strength on the dose emission of indacaterol Breezhaler® 150 µg and 
300 µg in-vitro using different MIFs and Vins was studied in Chapter 6. The results showed 
that despite the difference in particle size of lactose carrier both indacaterol formulations 150 
µg and 300 µg provided an excellent drug content uniformity with a % CV < 1.8. The results 
indacaterol dose emission from the capsule based Onbrez Breezhaler® for both dose strengths 
(Tables 6.1 and 6.2) for DUSA and (Tables 6.3 and 6.4) for ACI demonstrated inhalation flow 
dependent dose emission as discussed in the previous chapter, the inhaled volume (Vin) was 
important when low MIFs 28.3 and 60 L/min were used. The aerodynamic characteristics of 
indacaterol showed that Breezhaler® was effective in producing respirable particles with an 
MMAD < 5 µm over the range of the MIFs used in the study. However, the mass fraction of 
particles with an aerodynamic diameter < 3 µm is more pronounced between 60 and 90 
L/min. The difference in the drug particle size distribution as a function of the flow rate and 
volume was noticed, and it is more likely to influence drug distribution in the airways. It is 
clear from the results that a minimum MIF of 60L/min and a Vin of 1L were required when 
using the indacaterol Breezhaler®. Finally, the results confirm the recommendation of using 
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two separate inhalations for each dose when a high MIF through an Onbrez Breezhaler® is not 
achieved. 
The aerodynamic dose emission characteristics of indacaterol Breezhaler using real life 
recorded patients’ IPs and simulated IPs have been investigated (Chapter – 7). The results 
showed flow rate dependent dose emission of indacaterol Breezhaler®, the aerodynamic 
parameters TED, FPD increased and MMAD decreased significantly (P < 0.05) with 
increasing the profile’s MIF. The inspiratory parameters in the IPs acting together and the 
extent of each parameter effect was not determined using real life recorded COPD IPs. 
Therefore, simulated IPs were used to assess the effect of each inspiratory parameters on the 
dose emission of 150µg indacaterol Breezhaler®. The results showed that all inhalation 
parameters have shown an impact on the dose emission. However, the impact of the MIF was 
more pronounced than the Vin and ACIM by affecting all the aerodynamic dose emission 
characteristics (i.e., TED, FPD, and MMAD). By combining high MIF, Vin and ACIM, the 
quality of the inhaled particles was improved. The use of ex-vivo methodology provides more 
realistic representation to the way patient use their inhaler and the dose they would receive in 
real life. 
To sum up, depending on the intrinsic resistance of the inhaler devices, a minimum MIF and 
Vin was required to operate the device and aerosolise the dose to the patient’s lungs. The 
present work highlighted the minimum MIF and Vin to operate Easyhaler® (30 L/min – 750 
mL) while higher MIF and Vin were founded for low resistance Aerolizer® and Breezhaler® 
(60 L/min – 1L). Furthermore, patients using DPIs should inhale forcefully from the start of 
the inhalation manoeuvre for as long as they can, however, patients who cannot meet these 
conditions should be encouraged to inhale twice to ensure dose emptying for each single dose. 
The use of simulated inhalation profiles along with real life recorded COPD patients’ IP 
enable better understanding and evaluation to the extent of each inspiratory parameter MIF, 
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Vin and ACIM on the overall dose emission aerodynamic characteristics of 150µg indacaterol 
Breezhaler® when ex-vivo methodology was used.   
  The in-vitro and ex-vivo dose emission of indacaterol and formoterol from three marketed 
DPIs have been investigated in the present work. The in-vitro studies highlight the importance 
of using a wide range of MIF and Vin to study the dose emission using DUSA, while COPD 
patients’ IPs were used to study the performance of indacaterol Breezhaler®.  To study the 
effect of the inspiratory parameters individually simulated profiles were used (i.e., changing 
one parameter at a time). The present work can be extended in future to cover all the 
possibilities and conditions for the use of DPIs as follows: 
 The range of MIFs and Vins for DUSA and ACI work could be extended.  
 The threshold MIF and Vin required for dose de-aggregation is missing in the PIL 
and it is worth to determine these values for all marketed DPIs.  
 The use of both children and adult asthmatic and COPD patients’ IPs with different 
throat geometries (i.e., USP throat, Alberta throats for both adult and children) 
 Dose emission using DUSA for all the profiles after one and two inhalations.  
 Comparison of the results with the pharmacopeial conditions of MIF (corresponding 
to 4kPa, with a Vin of 4 L) for in-vitro testing of DPIs. 
 The use of a wide range of ACIM and Vin IPs depending on the inhaler device. 
 The ex-vivo methodology used in this thesis can be extended to other DPIs with 
different intrinsic resistances and engineered formulations.  
 Investigate if there is any possible correlation between the in-vitro, ex-vivo and in-
vivo data.  
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Appendix  
Appendix (A) 
The robustness data of indacaterol and formoterol HPLC method 
The two methods were found to be robust, as slight but deliberate changes in chromatographic 
conditions, parameters have shown no significance change in the method performance. The 
acceptance criteria for tailing factor (tf ≤ 2.0) and for resolution Rs >1.5 (ICH, 2005) 
 
Table 1. Robustness results of indacaterol HPLC method  
 
 
a). Indacaterol method 
Parameter Variation  Resolution  Tailing factor 
Flow rate (mL/min 0.8  5.41 1.5 
1.2 5.97 1.4 
Buffer pH 2.3 5.13 1.4 
2.7 6.89 1.6 
Column oven 
Temperature(oC ) 
35 5.33 1.5 
45 5.84 1.4 
Methanol (%) 58% 6.92 1.4 
62% 5.38 1.4 
 
 
Table 2. Robustness results of formoterol HPLC method  
  
 
 
 
 
 
 
 
 
b). Formoterol method 
Parameter Variation  Resolution  Tailing factor 
Flow rate (mL/min 0.5  8.86 1.8 
0.9 6.94 1.7 
Buffer pH 2.8 7.01 1.7 
3.2 6.41 1.7 
Column oven 
Temperature (oC ) 
25 6.56 1.7 
35 5.84 1.6 
Acetonitrile (%) 58% 5.12 1.7 
62% 4.55 1.7 
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Appendix (B) 
 Results of formoterol dose emission using two separate inhalations at different 
MIFs and Vins [n=16] 
 
Mean (SD) of the emitted dose after first (ED1) second(ED2) inhalations, Capsule, Total 
residual amount and total recovered dose from Foradil Aerolizer® using different Vins at  MIF 
of 28.3 L/min. [ Results presented as % of the nominal dose]. 
 
Total recovered dose (µg) of Formoterol emitted from Foradil Aerolizer for 16 separate 
capsules at different Vins and MIF of 28.3 L/min. 
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Mean (SD) of the emitted dose after first (ED1) second(ED2) inhalations, Capsule, Total 
residual amount and total recovered dose from Foradil Aerolizer® using different Vins at  
MIF of 60 L/min. [ Results presented as % of the nominal dose].  
 
Total recovered dose (µg) of Formoterol emitted from Foradil Aerolizer for 16 separate 
capsules at different Vins and MIF of 60 L/min.  
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Mean (SD) of the emitted dose after first (ED1), second (ED2) inhalation, Capsule, Total 
residual amount and total recovered dose from Foradil Aerolizer® using Vins at  MIF of 90 
L/min. [ Results presented as % of the nominal dose]. 
 
 
Total recovered dose (µg) of Formoterol emitted from Foradil Aerolizer for 16 separate 
capsules at different Vins and MIF of 90 L/min.  
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Mean (SD) of the emitted dose after first (ED1) second(ED2) inhalations, Capsule, Total 
residual amount and total recovered dose from Foradil Aerolizer® using Vins at  MIF of 120 
L/min. [ Results presented as % of the nominal dose]. 
 
Total recovered dose (µg) of Formoterol emitted from Foradil Aerolizer® for 16 separate 
capsules at Vins and MIF of 120 L/min 
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 Results of indacaterol dose emission using two separate inhalations at different 
MIFs and Vins. [n=16] 
 
 
Mean (SD) of the emitted dose after first (ED1) second(ED2) inhalations, Capsule, Total 
residual amount and total recovered dose from Onbrez Breezhaler® using Vins at  MIF of 
28.3 L/min. [ Results presented as % of the nominal dose]. 
 
Total recovered dose (µg) of indacaterol emitted from Onbrez Breezhaler® for 16 separate 
capsules at Vins and MIF of 28.3 L/min. 
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Mean (SD) of the emitted dose after first (ED1) second(ED2) inhalations, Capsule, Total 
residual amount and total recovered dose from Onbrez Breezhaler® using Vins at  MIF of 60 
L/min. [ Results presented as % of the nominal dose]. 
 
Total recovered dose (µg) of indacaterol emitted from Onbrez Breezhaler® for 16 separate 
capsules at different Vins and MIF of 60 L/min. 
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Mean (SD) of the emitted dose after first (ED1), second (ED2) inhalations, Capsule, Total 
residual amount and total recovered dose from Onbrez Breezhaler® using Vins at  MIF of 90 
L/min. [% of the nominal dose]. 
 
Total recovered dose (µg) of indacaterol emitted from Onbrez Breezhaler® for 16 separate 
capsules at different Vins and MIF of 90 L/min. 
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Mean (SD) of the emitted dose after first (ED1), second (ED2) inhalations, Capsule, Total 
residual amount and total recovered dose from Onbrez Breezhaler® using Vins at  MIF of 120 
L/min. [% of the nominal dose. 
 
Total recovered dose (µg) of indacaterol emitted from Onbrez Breezhaler® for 16 separate 
capsules at different Vins and MIF of 120 L/min. 
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Appendix (C) 
 
 COPD patients’ inhalation profiles generated when patients inhale through an empty 
Onbrez Breezhaler® (Azouz et al., 2015). [ used with permission] 
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 Simulated COPD patients’ inhalation profiles, where one parameter was changed at a 
time to study the effect of each parameter of the inhalation manoeuvre (MIF, Vin and 
ACIM) separately. The profiles MIF was chosen from the raw inhalation profiles, 
while Vin was increased or decreased by altering the points beyond the peak 
inspiratory flow of the profiles. Furthermore, the ACIM was altered accordingly by 
increasing or decreasing the initial slope of the inhalation profile [ ACIM value with 
higher R2 was chosen as the profile main ACIM]. 
  
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